US20230213525A1 - Detecting microbial infection in wounds - Google Patents
Detecting microbial infection in wounds Download PDFInfo
- Publication number
- US20230213525A1 US20230213525A1 US16/090,091 US201716090091A US2023213525A1 US 20230213525 A1 US20230213525 A1 US 20230213525A1 US 201716090091 A US201716090091 A US 201716090091A US 2023213525 A1 US2023213525 A1 US 2023213525A1
- Authority
- US
- United States
- Prior art keywords
- reactive
- wound
- cbm
- chitosan
- anchor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000027418 Wounds and injury Diseases 0.000 title abstract description 265
- 206010052428 Wound Diseases 0.000 title abstract description 264
- 208000015181 infectious disease Diseases 0.000 title description 30
- 230000000813 microbial effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 106
- 150000001875 compounds Chemical class 0.000 claims abstract description 100
- 150000005829 chemical entities Chemical class 0.000 claims abstract description 93
- 239000000758 substrate Substances 0.000 claims abstract description 73
- 239000000975 dye Substances 0.000 claims description 186
- 229920001661 Chitosan Polymers 0.000 claims description 132
- 102000004190 Enzymes Human genes 0.000 claims description 86
- 108090000790 Enzymes Proteins 0.000 claims description 86
- 229940088598 enzyme Drugs 0.000 claims description 86
- -1 reactive green 19 Chemical compound 0.000 claims description 51
- 239000012634 fragment Substances 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 108010014251 Muramidase Proteins 0.000 claims description 38
- 102000016943 Muramidase Human genes 0.000 claims description 38
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 38
- 239000004325 lysozyme Substances 0.000 claims description 38
- 229960000274 lysozyme Drugs 0.000 claims description 38
- 235000010335 lysozyme Nutrition 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 108010013639 Peptidoglycan Proteins 0.000 claims description 34
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 33
- HFIYIRIMGZMCPC-YOLJWEMLSA-J remazole black-GR Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC2=CC(S([O-])(=O)=O)=C(\N=N\C=3C=CC(=CC=3)S(=O)(=O)CCOS([O-])(=O)=O)C(O)=C2C(N)=C1\N=N\C1=CC=C(S(=O)(=O)CCOS([O-])(=O)=O)C=C1 HFIYIRIMGZMCPC-YOLJWEMLSA-J 0.000 claims description 32
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 31
- 229920002678 cellulose Polymers 0.000 claims description 27
- 239000001913 cellulose Substances 0.000 claims description 25
- 230000008859 change Effects 0.000 claims description 23
- 230000036961 partial effect Effects 0.000 claims description 23
- 230000003993 interaction Effects 0.000 claims description 22
- KUIXZSYWBHSYCN-UHFFFAOYSA-L remazol brilliant blue r Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=C2C(=O)C3=CC=CC=C3C(=O)C2=C1NC1=CC=CC(S(=O)(=O)CCOS([O-])(=O)=O)=C1 KUIXZSYWBHSYCN-UHFFFAOYSA-L 0.000 claims description 22
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 20
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 19
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 19
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 16
- DHHGSXPASZBLGC-VPMNAVQSSA-L remazole orange-3R Chemical compound [Na+].[Na+].OC=1C2=CC(NC(=O)C)=CC=C2C=C(S([O-])(=O)=O)C=1\N=N\C1=CC=C(S(=O)(=O)CCOS([O-])(=O)=O)C=C1 DHHGSXPASZBLGC-VPMNAVQSSA-L 0.000 claims description 16
- 239000000178 monomer Substances 0.000 claims description 15
- BLFZMXOCPASACY-UHFFFAOYSA-N 1,4-bis(propan-2-ylamino)anthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(NC(C)C)=CC=C2NC(C)C BLFZMXOCPASACY-UHFFFAOYSA-N 0.000 claims description 11
- OVSNDJXCFPSPDZ-UHFFFAOYSA-N Reactive red 120 Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=CC(NC=3N=C(NC=4C=CC(NC=5N=C(NC=6C7=C(O)C(N=NC=8C(=CC=CC=8)S(O)(=O)=O)=C(C=C7C=C(C=6)S(O)(=O)=O)S(O)(=O)=O)N=C(Cl)N=5)=CC=4)N=C(Cl)N=3)=C2C(O)=C1N=NC1=CC=CC=C1S(O)(=O)=O OVSNDJXCFPSPDZ-UHFFFAOYSA-N 0.000 claims description 11
- GRQJWISCNBOZMB-UHFFFAOYSA-I disodium;chromium(3+);2-[[6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-1-oxido-3-sulfonatonaphthalen-2-yl]diazenyl]benzoate;hydron Chemical compound [H+].[Na+].[Na+].[Cr+3].[O-]C(=O)C1=CC=CC=C1N=NC(C(=CC1=C2)S([O-])(=O)=O)=C([O-])C1=CC=C2NC1=NC(Cl)=NC(Cl)=N1.[O-]C(=O)C1=CC=CC=C1N=NC(C(=CC1=C2)S([O-])(=O)=O)=C([O-])C1=CC=C2NC1=NC(Cl)=NC(Cl)=N1 GRQJWISCNBOZMB-UHFFFAOYSA-I 0.000 claims description 11
- 229920001282 polysaccharide Polymers 0.000 claims description 11
- 239000005017 polysaccharide Substances 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000011324 bead Substances 0.000 claims description 10
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 10
- 229920002401 polyacrylamide Polymers 0.000 claims description 9
- IHDBZCJYSHDCKF-UHFFFAOYSA-N 4,6-dichlorotriazine Chemical compound ClC1=CC(Cl)=NN=N1 IHDBZCJYSHDCKF-UHFFFAOYSA-N 0.000 claims description 8
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 claims description 8
- 229920000058 polyacrylate Polymers 0.000 claims description 8
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 229920002873 Polyethylenimine Polymers 0.000 claims description 6
- XBLIFEQTVVSTIM-UHFFFAOYSA-L chembl2105392 Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC2=CC(S([O-])(=O)=O)=CC=C2C(O)=C1N=NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O XBLIFEQTVVSTIM-UHFFFAOYSA-L 0.000 claims description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- ADIGAFWLDDSRAG-UHFFFAOYSA-N [ClH]1[ClH]N=NN=C1 Chemical compound [ClH]1[ClH]N=NN=C1 ADIGAFWLDDSRAG-UHFFFAOYSA-N 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 108090001008 Avidin Proteins 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 108010090804 Streptavidin Proteins 0.000 claims description 3
- 101710120037 Toxin CcdB Proteins 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 229920002704 polyhistidine Polymers 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 238000010791 quenching Methods 0.000 claims description 3
- 230000000171 quenching effect Effects 0.000 claims description 3
- OYCLSQDXZMROJK-UHFFFAOYSA-N 2-bromo-4-[3-(3-bromo-4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]phenol Chemical compound C1=C(Br)C(O)=CC=C1C1(C=2C=C(Br)C(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 OYCLSQDXZMROJK-UHFFFAOYSA-N 0.000 claims description 2
- ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 claims description 2
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 claims description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 2
- WWAABJGNHFGXSJ-UHFFFAOYSA-N chlorophenol red Chemical compound C1=C(Cl)C(O)=CC=C1C1(C=2C=C(Cl)C(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 WWAABJGNHFGXSJ-UHFFFAOYSA-N 0.000 claims description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 2
- PRZSXZWFJHEZBJ-UHFFFAOYSA-N thymol blue Chemical compound C1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=CC(O)=C(C(C)C)C=2)C)=C1C PRZSXZWFJHEZBJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 3
- JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 75
- 238000000034 method Methods 0.000 abstract description 75
- 238000006243 chemical reaction Methods 0.000 abstract description 37
- 230000001684 chronic effect Effects 0.000 abstract description 36
- 238000001514 detection method Methods 0.000 abstract description 30
- 238000003745 diagnosis Methods 0.000 abstract description 25
- 238000005516 engineering process Methods 0.000 abstract description 25
- 238000003556 assay Methods 0.000 abstract description 14
- 230000002255 enzymatic effect Effects 0.000 abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 120
- 235000001014 amino acid Nutrition 0.000 description 88
- 229940024606 amino acid Drugs 0.000 description 87
- 150000001413 amino acids Chemical class 0.000 description 87
- 102000004196 processed proteins & peptides Human genes 0.000 description 79
- 108090000617 Cathepsin G Proteins 0.000 description 73
- 102000004173 Cathepsin G Human genes 0.000 description 73
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 72
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 68
- 108010081808 poly(3-hydroxyalkanoic acid) depolymerase Proteins 0.000 description 61
- 229920001184 polypeptide Polymers 0.000 description 61
- 102100033174 Neutrophil elastase Human genes 0.000 description 58
- 238000003776 cleavage reaction Methods 0.000 description 57
- 230000007017 scission Effects 0.000 description 57
- 230000027455 binding Effects 0.000 description 53
- 239000000243 solution Substances 0.000 description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- 102000035195 Peptidases Human genes 0.000 description 47
- 108091005804 Peptidases Proteins 0.000 description 47
- 150000007523 nucleic acids Chemical class 0.000 description 47
- 239000004365 Protease Substances 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 44
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 42
- 230000000694 effects Effects 0.000 description 40
- 235000019419 proteases Nutrition 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 102000016387 Pancreatic elastase Human genes 0.000 description 36
- 108010067372 Pancreatic elastase Proteins 0.000 description 36
- 108010013369 Enteropeptidase Proteins 0.000 description 34
- 102100029727 Enteropeptidase Human genes 0.000 description 34
- 239000010410 layer Substances 0.000 description 33
- 102000039446 nucleic acids Human genes 0.000 description 33
- 125000003396 thiol group Chemical group [H]S* 0.000 description 33
- 239000012530 fluid Substances 0.000 description 32
- 108020004707 nucleic acids Proteins 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 32
- 239000000985 reactive dye Substances 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 30
- 125000003275 alpha amino acid group Chemical group 0.000 description 29
- 235000018417 cysteine Nutrition 0.000 description 28
- 125000006850 spacer group Chemical group 0.000 description 27
- 239000006228 supernatant Substances 0.000 description 26
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 25
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 25
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 23
- 235000004279 alanine Nutrition 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 22
- 102000003896 Myeloperoxidases Human genes 0.000 description 22
- 108090000235 Myeloperoxidases Proteins 0.000 description 22
- 239000002773 nucleotide Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 102000040430 polynucleotide Human genes 0.000 description 22
- 108091033319 polynucleotide Proteins 0.000 description 22
- 239000002157 polynucleotide Substances 0.000 description 22
- 108091006116 chimeric peptides Proteins 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 20
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 20
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 20
- 239000004472 Lysine Substances 0.000 description 19
- 102000007079 Peptide Fragments Human genes 0.000 description 19
- 108010033276 Peptide Fragments Proteins 0.000 description 19
- 235000018977 lysine Nutrition 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 102000002933 Thioredoxin Human genes 0.000 description 18
- 238000006640 acetylation reaction Methods 0.000 description 18
- 238000006911 enzymatic reaction Methods 0.000 description 18
- 230000035876 healing Effects 0.000 description 18
- 235000004400 serine Nutrition 0.000 description 18
- 108060008226 thioredoxin Proteins 0.000 description 18
- 229940094937 thioredoxin Drugs 0.000 description 18
- 101150118060 trxA gene Proteins 0.000 description 18
- PCKPVGOLPKLUHR-UHFFFAOYSA-N indoxyl Chemical group C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 17
- 239000004471 Glycine Substances 0.000 description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 16
- 239000002253 acid Substances 0.000 description 16
- 108010087049 alanyl-alanyl-prolyl-valine Proteins 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- 238000005406 washing Methods 0.000 description 16
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 15
- 102000004157 Hydrolases Human genes 0.000 description 15
- 108090000604 Hydrolases Proteins 0.000 description 15
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 102000003992 Peroxidases Human genes 0.000 description 15
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 15
- 230000003301 hydrolyzing effect Effects 0.000 description 15
- 125000005647 linker group Chemical group 0.000 description 15
- 235000013930 proline Nutrition 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 230000002209 hydrophobic effect Effects 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- VPSHHQXIWLGVDD-ZLUOBGJFSA-N Asp-Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VPSHHQXIWLGVDD-ZLUOBGJFSA-N 0.000 description 13
- 125000003047 N-acetyl group Chemical group 0.000 description 13
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 13
- 230000009471 action Effects 0.000 description 13
- 238000007792 addition Methods 0.000 description 13
- 108010092854 aspartyllysine Proteins 0.000 description 13
- 230000003115 biocidal effect Effects 0.000 description 13
- 238000011065 in-situ storage Methods 0.000 description 13
- 108040007629 peroxidase activity proteins Proteins 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 241000588813 Alcaligenes faecalis Species 0.000 description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 12
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- 206010048038 Wound infection Diseases 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229910052731 fluorine Inorganic materials 0.000 description 12
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000004475 Arginine Substances 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 11
- 229940005347 alcaligenes faecalis Drugs 0.000 description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 11
- 235000009697 arginine Nutrition 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 229960002442 glucosamine Drugs 0.000 description 11
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 11
- 235000004554 glutamine Nutrition 0.000 description 11
- 239000002105 nanoparticle Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 239000012099 Alexa Fluor family Substances 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 102000052502 human ELANE Human genes 0.000 description 10
- 230000002163 immunogen Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 229920000139 polyethylene terephthalate Polymers 0.000 description 10
- 239000005020 polyethylene terephthalate Substances 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 108010038196 saccharide-binding proteins Proteins 0.000 description 10
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 10
- VZPXDCIISFTYOM-UHFFFAOYSA-K trisodium;1-amino-4-[4-[[4-chloro-6-(3-sulfonatoanilino)-1,3,5-triazin-2-yl]amino]-3-sulfonatoanilino]-9,10-dioxoanthracene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S([O-])(=O)=O)C=C1NC(C=C1S([O-])(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S([O-])(=O)=O)=C1 VZPXDCIISFTYOM-UHFFFAOYSA-K 0.000 description 10
- 230000029663 wound healing Effects 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 239000012491 analyte Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 210000004207 dermis Anatomy 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000004474 valine Substances 0.000 description 9
- 229920002101 Chitin Polymers 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 238000005520 cutting process Methods 0.000 description 8
- 150000001945 cysteines Chemical class 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 8
- 235000005772 leucine Nutrition 0.000 description 8
- 229930182817 methionine Natural products 0.000 description 8
- 235000006109 methionine Nutrition 0.000 description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 8
- 235000008729 phenylalanine Nutrition 0.000 description 8
- 150000004804 polysaccharides Chemical class 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 239000002250 absorbent Substances 0.000 description 7
- 230000002745 absorbent Effects 0.000 description 7
- 230000021736 acetylation Effects 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical group NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 6
- 108010008885 Cellulose 1,4-beta-Cellobiosidase Proteins 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 208000004210 Pressure Ulcer Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000499912 Trichoderma reesei Species 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- JUYKRZRMNHWQCD-SKSLZCFZSA-N [(2r,3s,4r,5r,6r)-5-acetamido-3-[(2s,3r,4r,5s,6r)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-4,6-diacetyloxyoxan-2-yl]methyl acetate Chemical compound O1[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](NC(=O)C)[C@@H]1O[C@H]1[C@H](OC(C)=O)[C@@H](NC(C)=O)[C@@H](OC(C)=O)O[C@@H]1COC(C)=O JUYKRZRMNHWQCD-SKSLZCFZSA-N 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 150000004982 aromatic amines Chemical class 0.000 description 6
- JUYKRZRMNHWQCD-UHFFFAOYSA-N betaAc3GlcNAc-alphaAc2GlcNAc-OAc Natural products O1C(COC(C)=O)C(OC(C)=O)C(OC(C)=O)C(NC(=O)C)C1OC1C(OC(C)=O)C(NC(C)=O)C(OC(C)=O)OC1COC(C)=O JUYKRZRMNHWQCD-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000003349 gelling agent Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 229950003937 tolonium Drugs 0.000 description 6
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 6
- 229910052720 vanadium Inorganic materials 0.000 description 6
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 6
- HEMGYNNCNNODNX-UHFFFAOYSA-N 3,4-diaminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1N HEMGYNNCNNODNX-UHFFFAOYSA-N 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 108010029541 Laccase Proteins 0.000 description 5
- CDOJPCSDOXYJJF-CBTAGEKQSA-N N,N'-diacetylchitobiose Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CDOJPCSDOXYJJF-CBTAGEKQSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 150000002301 glucosamine derivatives Chemical class 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 230000003252 repetitive effect Effects 0.000 description 5
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical group N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 4
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 4
- VTRKJVRJTVKUIA-UHFFFAOYSA-N 3-amino-2-methoxyphenol Chemical compound COC1=C(N)C=CC=C1O VTRKJVRJTVKUIA-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229940126062 Compound A Drugs 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 206010011985 Decubitus ulcer Diseases 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229940126575 aminoglycoside Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- 238000000224 chemical solution deposition Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 150000002373 hemiacetals Chemical class 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 150000002475 indoles Chemical class 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical class O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- DDRCIGNRLHTTIW-UHFFFAOYSA-N n-(4-amino-2,5-dimethoxyphenyl)benzamide Chemical compound C1=C(N)C(OC)=CC(NC(=O)C=2C=CC=CC=2)=C1OC DDRCIGNRLHTTIW-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- 229920001059 synthetic polymer Polymers 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 235000008521 threonine Nutrition 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 4
- 150000003952 β-lactams Chemical class 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- GOJFAKBEASOYNM-UHFFFAOYSA-N 2-(2-aminophenoxy)aniline Chemical compound NC1=CC=CC=C1OC1=CC=CC=C1N GOJFAKBEASOYNM-UHFFFAOYSA-N 0.000 description 3
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 3
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 3
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 3
- IGHBXJSNZCFXNK-UHFFFAOYSA-N 4-chloro-7-nitrobenzofurazan Chemical compound [O-][N+](=O)C1=CC=C(Cl)C2=NON=C12 IGHBXJSNZCFXNK-UHFFFAOYSA-N 0.000 description 3
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 3
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 3
- LEOJISUPFSWNMA-UHFFFAOYSA-N ABEI Chemical compound O=C1NNC(=O)C=2C1=CC(N(CCCCN)CC)=CC=2 LEOJISUPFSWNMA-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- BZORFPDSXLZWJF-UHFFFAOYSA-N N,N-dimethyl-1,4-phenylenediamine Chemical compound CN(C)C1=CC=C(N)C=C1 BZORFPDSXLZWJF-UHFFFAOYSA-N 0.000 description 3
- FBWADIKARMIWNM-UHFFFAOYSA-N N-3,5-dichloro-4-hydroxyphenyl-1,4-benzoquinone imine Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1N=C1C=CC(=O)C=C1 FBWADIKARMIWNM-UHFFFAOYSA-N 0.000 description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000001268 conjugating effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000009881 electrostatic interaction Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000011066 ex-situ storage Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229940124307 fluoroquinolone Drugs 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229940097275 indigo Drugs 0.000 description 3
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 150000002960 penicillins Chemical class 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940040944 tetracyclines Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical class C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 3
- 229960004089 tigecycline Drugs 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 235000002374 tyrosine Nutrition 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 2
- KKTUQAYCCLMNOA-UHFFFAOYSA-N 2,3-diaminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1N KKTUQAYCCLMNOA-UHFFFAOYSA-N 0.000 description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 2
- SXOPCLUOUFQBJV-UHFFFAOYSA-N 3-methoxyanthranilic acid Chemical compound COC1=CC=CC(C(O)=O)=C1N SXOPCLUOUFQBJV-UHFFFAOYSA-N 0.000 description 2
- NFPYJDZQOKCYIE-UHFFFAOYSA-N 4-amino-3-hydroxybenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1O NFPYJDZQOKCYIE-UHFFFAOYSA-N 0.000 description 2
- ZQBCJNIOJOGZPT-UHFFFAOYSA-N 4-nitro-3-octanoylbenzoic acid Chemical compound CCCCCCCC(=O)C1=CC(C(O)=O)=CC=C1[N+]([O-])=O ZQBCJNIOJOGZPT-UHFFFAOYSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BWKDAAFSXYPQOS-UHFFFAOYSA-N Benzaldehyde glyceryl acetal Chemical compound O1CC(O)COC1C1=CC=CC=C1 BWKDAAFSXYPQOS-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 108010022172 Chitinases Proteins 0.000 description 2
- 102000012286 Chitinases Human genes 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 108010078777 Colistin Proteins 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 2
- 239000005058 Isophorone diisocyanate Substances 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- 208000005230 Leg Ulcer Diseases 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 239000002879 Lewis base Substances 0.000 description 2
- 102100037611 Lysophospholipase Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 102100030411 Neutrophil collagenase Human genes 0.000 description 2
- 229920002201 Oxidized cellulose Polymers 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 229930195708 Penicillin V Natural products 0.000 description 2
- 108700020962 Peroxidase Proteins 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- 229920005830 Polyurethane Foam Polymers 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- NAYYKQAWUWXLPD-KSTCHIGDSA-N [(2r,3s,4r,5r,6r)-5-acetamido-3,4-diacetyloxy-6-chlorooxan-2-yl]methyl acetate Chemical compound CC(=O)N[C@H]1[C@@H](Cl)O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O NAYYKQAWUWXLPD-KSTCHIGDSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229960001570 ademetionine Drugs 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000987 azo dye Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003781 beta lactamase inhibitor Substances 0.000 description 2
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 2
- 229960000603 cefalotin Drugs 0.000 description 2
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 2
- 229960003012 cefamandole Drugs 0.000 description 2
- 229960002100 cefepime Drugs 0.000 description 2
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 2
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 2
- 229960005495 cefotetan Drugs 0.000 description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 2
- 229960002682 cefoxitin Drugs 0.000 description 2
- 229960000466 cefpirome Drugs 0.000 description 2
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 2
- 229960001668 cefuroxime Drugs 0.000 description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 229940106164 cephalexin Drugs 0.000 description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 108010089807 chitosanase Proteins 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229960002770 ertapenem Drugs 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- UHRBTBZOWWGKMK-DOMZBBRYSA-N flomoxef Chemical compound O([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC(F)F)OC)CC=1CSC1=NN=NN1CCO UHRBTBZOWWGKMK-DOMZBBRYSA-N 0.000 description 2
- 229960002878 flomoxef Drugs 0.000 description 2
- 229920002313 fluoropolymer Polymers 0.000 description 2
- 239000004811 fluoropolymer Substances 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229920000550 glycopolymer Polymers 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000012052 hydrophilic carrier Substances 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 2
- 229960002182 imipenem Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000011872 intimate mixture Substances 0.000 description 2
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 150000007527 lewis bases Chemical class 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- GHRXPKBLHFSXTB-UHFFFAOYSA-N methyl 3-hydroxy-1h-indole-2-carboxylate Chemical compound C1=CC=C2C(O)=C(C(=O)OC)NC2=C1 GHRXPKBLHFSXTB-UHFFFAOYSA-N 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 229960004023 minocycline Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- PGBHMTALBVVCIT-VZXHOKRSSA-N neomycin C Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VZXHOKRSSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229940107304 oxidized cellulose Drugs 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 229940056367 penicillin v Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 2
- 229940041153 polymyxins Drugs 0.000 description 2
- 239000011496 polyurethane foam Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical group [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 150000004992 toluidines Chemical class 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- DSHQTSIXXYZXGR-UHFFFAOYSA-N (1-acetyl-5-bromo-4-chloroindol-3-yl) acetate Chemical compound C1=C(Br)C(Cl)=C2C(OC(=O)C)=CN(C(C)=O)C2=C1 DSHQTSIXXYZXGR-UHFFFAOYSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SXGMVGOVILIERA-UHFFFAOYSA-N (2R,3S)-2,3-diaminobutanoic acid Natural products CC(N)C(N)C(O)=O SXGMVGOVILIERA-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- HUHVJSXYULHZJW-ZDUSSCGKSA-N (4s)-4-benzyl-2-thiophen-3-yl-4,5-dihydro-1,3-oxazole Chemical compound C([C@@H](N=1)CC=2C=CC=CC=2)OC=1C=1C=CSC=1 HUHVJSXYULHZJW-ZDUSSCGKSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- RNIADBXQDMCFEN-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=C(Cl)C=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O RNIADBXQDMCFEN-IWVLMIASSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- QOSTVEDABRQTSU-UHFFFAOYSA-N 1,4-bis(methylamino)anthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(NC)=CC=C2NC QOSTVEDABRQTSU-UHFFFAOYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- QEQDLKUMPUDNPG-UHFFFAOYSA-N 2-(7-amino-4-methyl-2-oxochromen-3-yl)acetic acid Chemical compound C1=C(N)C=CC2=C1OC(=O)C(CC(O)=O)=C2C QEQDLKUMPUDNPG-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- ZAPTZHDIVAYRQU-UHFFFAOYSA-N 2-(dimethylaminodiazenyl)benzenesulfonic acid Chemical compound CN(C)N=NC1=CC=CC=C1S(O)(=O)=O ZAPTZHDIVAYRQU-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- MQFYRUGXOJAUQK-UHFFFAOYSA-N 2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC MQFYRUGXOJAUQK-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TUADYTFWZPZZTP-UHFFFAOYSA-N 2-amino-4-methoxyphenol Chemical compound COC1=CC=C(O)C(N)=C1 TUADYTFWZPZZTP-UHFFFAOYSA-N 0.000 description 1
- ZMXYNJXDULEQCK-UHFFFAOYSA-N 2-amino-p-cresol Chemical compound CC1=CC=C(O)C(N)=C1 ZMXYNJXDULEQCK-UHFFFAOYSA-N 0.000 description 1
- BNGPVKSKKYIJCR-UHFFFAOYSA-N 2-chloro-1,3-dimethylimidazolidine;hydrochloride Chemical compound [Cl-].CN1CC[NH+](C)C1Cl BNGPVKSKKYIJCR-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical group OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 101001012262 Bos taurus Enteropeptidase Proteins 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241001509299 Brucella canis Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 229930182476 C-glycoside Natural products 0.000 description 1
- 150000000700 C-glycosides Chemical class 0.000 description 1
- QOGQKIKPYQUKMV-PUSAOEICSA-N CC(=O)N1C=C(C2=CC=CC=C21)OC3C[C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C Chemical compound CC(=O)N1C=C(C2=CC=CC=C21)OC3C[C@H]([C@@H]([C@H](O3)COC(=O)C)OC(=O)C)OC(=O)C QOGQKIKPYQUKMV-PUSAOEICSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011026 Corneal lesion Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108010000540 Hexosaminidases Proteins 0.000 description 1
- 102000002268 Hexosaminidases Human genes 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000933179 Homo sapiens Cathepsin G Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- CDOJPCSDOXYJJF-KSKNGZLJSA-N N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CDOJPCSDOXYJJF-KSKNGZLJSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 108030001564 Neutrophil collagenases Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
- AWZJFZMWSUBJAJ-UHFFFAOYSA-N OG-514 dye Chemical compound OC(=O)CSC1=C(F)C(F)=C(C(O)=O)C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=C1F AWZJFZMWSUBJAJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000199911 Peridinium Species 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- 241000606695 Rickettsia rickettsii Species 0.000 description 1
- 229930182475 S-glycoside Natural products 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229930192786 Sisomicin Natural products 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- BFSBNVPBVGFFCF-UHFFFAOYSA-N Tabtoxin Natural products CC(O)C(C(O)=O)NC(=O)C(N)CCC1(O)CNC1=O BFSBNVPBVGFFCF-UHFFFAOYSA-N 0.000 description 1
- 241001295025 Thermobifida cellulosilytica Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- OVPIZHVSWNOZMN-OXGONZEZSA-N [(2r,3s,4r,5r,6s)-5-acetamido-3,4,6-triacetyloxyoxan-2-yl]methyl acetate Chemical compound CC(=O)N[C@H]1[C@H](OC(C)=O)O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O OVPIZHVSWNOZMN-OXGONZEZSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- OCKWAZCWKSMKNC-UHFFFAOYSA-N [3-octadecanoyloxy-2,2-bis(octadecanoyloxymethyl)propyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC OCKWAZCWKSMKNC-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 1
- 229960003169 biapenem Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229940038698 brucella melitensis Drugs 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 108010005400 cutinase Proteins 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- 229960003807 dibekacin Drugs 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- OKZIUSOJQLYFSE-UHFFFAOYSA-N difluoroboron Chemical compound F[B]F OKZIUSOJQLYFSE-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- OVTCUIZCVUGJHS-UHFFFAOYSA-N dipyrrin Chemical compound C=1C=CNC=1C=C1C=CC=N1 OVTCUIZCVUGJHS-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 208000015355 drug-resistant tuberculosis Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000002901 elastaselike Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 150000002118 epoxides Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960003704 framycetin Drugs 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- NJDRXTDGYFKORP-LLVKDONJSA-N garenoxacin Chemical compound N([C@@H](C1=CC=2)C)CC1=CC=2C(C=1OC(F)F)=CC=C(C(C(C(O)=O)=C2)=O)C=1N2C1CC1 NJDRXTDGYFKORP-LLVKDONJSA-N 0.000 description 1
- 229960001430 garenoxacin Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 1
- 229960003170 gemifloxacin Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000052896 human CTSG Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229940054190 hydroxypropyl chitosan Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 229960000433 latamoxef Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- AHEVKYYGXVEWNO-UEPZRUIBSA-N lymecycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCNCCCC[C@H](N)C(O)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O AHEVKYYGXVEWNO-UEPZRUIBSA-N 0.000 description 1
- 229960004196 lymecycline Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229960000826 meclocycline Drugs 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000004784 molecular pathogenesis Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- WIDKTXGNSOORHA-CJHXQPGBSA-N n,n'-dibenzylethane-1,2-diamine;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate Chemical compound O.O.O.O.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 WIDKTXGNSOORHA-CJHXQPGBSA-N 0.000 description 1
- YKQOSKADJPQZHB-YNWHQGOSSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1s)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-YNWHQGOSSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- CTNZOGJNVIFEBA-UPSUJEDGSA-N nocardicin A Chemical compound C1=CC(OCC[C@@H](N)C(O)=O)=CC=C1C(=N\O)\C(=O)N[C@@H]1C(=O)N([C@@H](C(O)=O)C=2C=CC(O)=CC=2)C1 CTNZOGJNVIFEBA-UPSUJEDGSA-N 0.000 description 1
- CTNZOGJNVIFEBA-SCTDSRPQSA-N nocardicin A Natural products N[C@@H](CCOc1ccc(cc1)C(=NO)C(=O)N[C@@H]2CN([C@H](C(=O)O)c3ccc(O)cc3)C2=O)C(=O)O CTNZOGJNVIFEBA-SCTDSRPQSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- NAIXASFEPQPICN-UHFFFAOYSA-O p-nitrophenylphosphocholine Chemical compound C[N+](C)(C)CCOP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 NAIXASFEPQPICN-UHFFFAOYSA-O 0.000 description 1
- 229950011346 panipenem Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940086560 pentaerythrityl tetrastearate Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- CTRLRINCMYICJO-UHFFFAOYSA-N phenyl azide Chemical compound [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 description 1
- 108060006184 phycobiliprotein Proteins 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- WQVJHHACXVLGBL-GOVYWFKWSA-N polymyxin B1 Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCC[C@H](C)CC)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 WQVJHHACXVLGBL-GOVYWFKWSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- XFGOMLIRJYURLQ-GOKYHWASSA-N razupenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)SC(SC=1)=NC=1C1=C[C@H](C)NC1 XFGOMLIRJYURLQ-GOKYHWASSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 229940075118 rickettsia rickettsii Drugs 0.000 description 1
- HMEYVGGHISAPJR-IAHYZSEUSA-N rolitetracycline Chemical compound O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCCC1 HMEYVGGHISAPJR-IAHYZSEUSA-N 0.000 description 1
- 229960005009 rolitetracycline Drugs 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 150000003347 selenoglycosides Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical class [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 229960005456 sisomicin Drugs 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- BFSBNVPBVGFFCF-WDOVLDDZSA-N tabtoxin Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC[C@]1(O)CNC1=O BFSBNVPBVGFFCF-WDOVLDDZSA-N 0.000 description 1
- 108010055631 tabtoxin Proteins 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229920002997 teichuronic acid Polymers 0.000 description 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
- 229960001114 temocillin Drugs 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 150000003569 thioglycosides Chemical class 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- VAMSVIZLXJOLHZ-QWFSEIHXSA-N tigemonam Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 VAMSVIZLXJOLHZ-QWFSEIHXSA-N 0.000 description 1
- 229950010206 tigemonam Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/528—Atypical element structures, e.g. gloves, rods, tampons, toilet paper
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/548—Carbohydrates, e.g. dextran
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G01N2333/936—Hydrolases (3) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetyl-amino 2-deoxy-D-glucose, e.g. lysozyme
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/966—Elastase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Definitions
- the Sequence Listing associated with this application includes the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.821 - 1.825.
- the Sequence Listing is hereby incorporated by reference in its entirety.
- the Sequence Listing includes no new matter.
- the name of the ASCII text file which includes the Sequence Listing is Sequence_Listing_CVT05_40137 - Sequence Listing.
- the date of creation is Oct. 29, 2020.
- the size of the file is 3 KB.
- Embodiments described herein generally relate to wound healing, and in particular to compositions and methods for the detection and treatment of wounds.
- Wound healing is a complex dynamic process that results in the restoration of anatomic continuity and function: an ideally healed wound is one that has returned to normal anatomic structure, function, and appearance.
- the inflammatory phase is particularly important to the wound healing process, wherein biochemical reactions at the wound situs facilitate healing but also cause tissue breakdown due to production of excess proteases.
- pathogens in a wound can produce toxins (e.g., Clostridium species), generate noxious metabolites like ammonia that raise pH (e.g., Proteus species), activate or produce tissue lytic enzymes like proteases, or promote tissue invasion, thereby leading to an increase in the size or seriousness of the wound. In a worst case, pathogens can leave the wound and cause sepsis.
- toxins e.g., Clostridium species
- generate noxious metabolites like ammonia that raise pH e.g., Proteus species
- activate or produce tissue lytic enzymes like proteases
- promote tissue invasion thereby leading to an increase in the size or seriousness of the wound.
- pathogens can leave the wound and cause sepsis.
- a variety of assessment techniques and/or tools are employed in the clinical and veterinary setting.
- Current methods of assessing an infected wound are based primarily on assaying for a variety of parameters associated with the wound. For instance, a wound may be assessed visually, length and depth measurements may be taken, digital photography may be used where available to track the visual condition and size of a wound (Krasner et al., supra).
- diagnosis of infection is based on measurement of secondary parameters, such as, odor, presence of local pain, heat, swelling, discharge, and redness Many of these clinical indicators, such as inflammation and discharge have a low predictive value of infection in wounds.
- the number(s) and type(s) of pathogenic flora at the wound situs may be determined using laboratory and/or clinical diagnostic procedures. Swabbing of a wound followed by microbiology testing in the hospital laboratory is an option for confirmation of bacterial colonization and identification of the strains associated with infection, thus allowing for the prescription of correct antibiotic course.
- this process is time consuming and labor intensive. Delay in diagnosis of infection can delay the administration of antibiotics and may increase the risk of developing sepsis.
- the technology disclosed herein provides for compositions and methods of detecting infected and/or chronic wounds.
- the disclosed technology improves upon exiting assays by: increasing the sensitivity, precision and specificity of detection of infected wounds; providing for the ability of qualitative and quantitative measurements; and, increasing the speed of detection of infected wounds in situ and in real-time.
- the assays and methods described herein are partly based on the use of specific reagents that detect biomarkers and/or probes which are present in infected or chronic wounds.
- the detection process may involve use of reagents that are specific to the markers present in infected wounds but not non-infected or non-chronic wounds and the detection step may involve qualitative or quantitative measurements of the signal(s) that are generated when the probe is acted upon by the marker.
- the probes comprise modified enzyme substrates that are specific to the enzyme, which generate signals that may be optionally amplified. This greatly improves efficiency and specificity of detection.
- a plurality of detection probes, each specific for one or more targets, e.g., enzymes that are specific to the wounds, may be employed.
- the experimental results disclosed herein confirm that the novel probes and the assay techniques based thereon are capable of detecting and characterizing various types of wounds.
- the reagents of the disclosed technology may be used together with therapeutic molecules such as antibiotics, antifungal agents, etc. to monitor and evaluate treatment and management of chronic wounds.
- Embodiments described herein are based, in part, on the discovery that cells of the immune system, including enzymes generated thereby, may serve as markers in the early diagnosis of wounds. These cells, e.g., neutrophils, are recruited at the wound situs to combat infection, do so by engulfing bacteria (and other pathogens) and/or neutralizing them with enzymes.
- Some enzymes are specific towards proteins (e.g., elastase, cathepsin G), others are specific towards cell wall components (e.g., lysozyme) and yet others mediate protein denaturation (e.g., NADPH oxidase, xanthine oxidase, myeloperoxidase (MPO) and other peroxidases).
- proteins e.g., elastase, cathepsin G
- cell wall components e.g., lysozyme
- mediate protein denaturation e.g., NADPH oxidase, xanthine oxidase, myeloperoxidase (MPO) and other peroxidases.
- MPO myeloperoxidase
- neutrophils are generally only short-lived and when they lyse in the area of the infection, they release the contents of their lysosomes including the enzymes, which can then be
- various embodiments described herein utilize the detection of enzyme markers, which are indicative of the presence of myeloid cells, and neutrophils in particular, in a biological sample of interest, for example, wound tissue. Increased level or activity of such enzymes in the wound fluid, therefore, corresponds to a heightened bacterial challenge and a manifestation of disturbed host/bacteria equilibrium in favor of the invasive bacteria.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor; and I is an indicator region.
- a chemical entity comprising a compound with the structure A-I (Formula I), wherein the anchor A is covalently associated with the indicator I via a covalent interaction to form a recognition site S.
- a chemical entity comprising a compound with the structure A-I (Formula I), wherein the anchor A is covalently associated with the indicator I via a covalent interaction to form a recognition site S, and wherein the recognition site (S) is specific for a wound-specific hydrolase.
- the hydrolase is a glycosidase or a protease.
- the protease is elastase, cathepsin G or myeloperoxidase.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor; and I is an indicator region, wherein the anchor A comprises a polysaccharide, a cellulose, a polyacrylate, a polyethyleneimine, a polyacrylamide, a peptidoglycan, or a chitosan, or a monomer thereof, an oligomer thereof, a derivative thereof, a mixture or a combination thereof.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor; and I is an indicator region, wherein the anchor A comprises chitosan or a monomer thereof, an oligomer thereof, a derivative thereof, a mixture or a combination thereof.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor; and I is an indicator region, wherein the anchor A comprises a monomer of chitosan comprising D-glucosamine or N-acetyl-D-glucosamine, an oligomer thereof, or a combination thereof.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor; and I is an indicator region, wherein the anchor A comprises at least two units of D-glucosamine, N-acetyl -D-glucosamine or a combination thereof.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor; and I is an indicator region, wherein the anchor A comprises a randomly substituted partial N-, partial O-acetylated chitosan, chitosan oligosaccharide, carboxymethyl chitosan, or hydroxyalkyl chitosan or a derivative thereof.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor; and I is an indicator region, wherein the anchor A comprises a randomly substituted partial N-, partial O-acetylated chitosan.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor; and I is an indicator region, wherein the anchor A comprises a randomly substituted partial N-, partial O-acetylated chitosan, wherein the acetylated chitosan comprises a degree of acetylation (DA) between about 40% to about 90%.
- A is an anchor
- I is an indicator region
- the anchor A comprises a randomly substituted partial N-, partial O-acetylated chitosan
- the acetylated chitosan comprises a degree of acetylation (DA) between about 40% to about 90%.
- DA degree of acetylation
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor; and I is an indicator region, wherein the anchor A comprises a randomly substituted partial N-, partial O-acetylated chitosan, wherein the acetylated chitosan comprises a degree of acetylation (DA) of greater than 50%.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor; and I is an indicator region, wherein the anchor A comprises a randomly substituted partial N-, partial O-acetylated chitosan, wherein the chitosan is halogenated.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor; and I is an indicator region, wherein the anchor A comprises chitosan or a monomer thereof, an oligomer thereof, a derivative thereof, a mixture or a combination thereof.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator (I) or a motif therein is conjugated to the anchor and the conjugate is a substrate for a glycosidase.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator (I) or a motif therein is conjugated to the anchor and the conjugate is a substrate for a glycosidase.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator (I) or a motif therein is conjugated to the anchor and the conjugate is a substrate for lysozyme.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator (I) or a motif therein is conjugated to the anchor via a glycosidic bond at the la- carbon of chitosan or a monomer thereof, an oligomer thereof, or a derivative thereof.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator (I) further comprises a dye containing a sulfonylethyl-hydrogensulphate-reactive-group or a dye containing a dichlortriazine reactive-group.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator (I) further comprises a dye which is reactive black 5, remazol brilliant blue, reactive violet 5 or reactive orange 16 or a combination thereof.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator (I) further comprises a dye which is reactive blue 4, reactive red 120, reactive blue 2, reactive green 19, or reactive brown 10, or a combination thereof.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator (I) comprises a detectable label selected from the group consisting of a luminescent molecule, a chemiluminescent molecule, a fluorochrome, a fluorescent quenching agent, a lipid, a colored molecule, a radioisotope, a scintillant, biotin, avidin, streptavidin, protein A, protein G, an antibody or a fragment thereof, a polyhistidine, Ni2+, a Flag tag, a myc tag, a heavy metal, and an enzyme.
- A is an anchor and I is an indicator region
- the indicator (I) comprises a detectable label selected from the group consisting of a luminescent molecule, a chemiluminescent molecule, a fluorochrome, a fluorescent quenching agent, a lipid, a colored molecule, a radiois
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region and the anchor is directly conjugated to the indicator via a glycosidic linkage.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region and the anchor is directly conjugated to the indicator via a glycosidic linkage, wherein the indicator is selected from the group consisting of reactive black 5, remazol brilliant blue, reactive violet 5 or reactive orange 16, reactive blue 4, reactive red 120, reactive blue 2, reactive green 19 and reactive brown 10, or a combination thereof.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator comprises a hydrophilic binding module (CBM) from Cellobiohydrolase I (Trichoderma reesei) or the hydrophobic binding module (PDB) from Polyhydroxyalkanoate depolymerase ⁇ Alcaligenes faecalis) or a chimeric variant thereof.
- CBM hydrophilic binding module
- PDB hydrophobic binding module
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator comprises a hydrophilic binding module (CBM) from Cellobiohydrolase I ⁇ Trichoderma reesei) or the hydrophobic binding module (PDB) from Polyhydroxyalkanoate depolymerase ⁇ Alcaligenes faecalis) or a chimeric variant thereof, wherein the anchor comprises cellulose or a derivative thereof or polyethylene terephthalate or a derivative thereof.
- CBM hydrophilic binding module
- PDB hydrophobic binding module
- the anchor comprises cellulose or a derivative thereof or polyethylene terephthalate or a derivative thereof.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator comprises a hydrophilic binding module (CBM) from Cellobiohydrolase I ⁇ Trichoderma reesei) or the hydrophobic binding module (PDB) from Polyhydroxyalkanoate depolymerase ⁇ Alcaligenes faecalis) or a chimeric variant thereof, wherein the anchor comprises cellulose or a derivative thereof or polyethylene terephthalate or a derivative thereof.
- CBM hydrophilic binding module
- PDB hydrophobic binding module
- the anchor comprises cellulose or a derivative thereof or polyethylene terephthalate or a derivative thereof.
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator comprises a hydrophilic binding module (CBM) from Cellobiohydrolase I ⁇ Trichoderma reesei) or a chimeric variant thereof and the anchor comprises cellulose or a derivative thereof, wherein the indicator is hydrophilically associated with the anchor.
- A is an anchor and I is an indicator region
- the indicator comprises a hydrophilic binding module (CBM) from Cellobiohydrolase I ⁇ Trichoderma reesei) or a chimeric variant thereof and the anchor comprises cellulose or a derivative thereof, wherein the indicator is hydrophilically associated with the anchor.
- CBM hydrophilic binding module
- a chemical entity comprising a compound with the structure A-I (Formula I) wherein, A is an anchor and I is an indicator region, wherein the indicator comprises Polyhydroxyalkanoate depolymerase ⁇ Alcaligenes faecalis) and the anchor comprises polyethylene terephthalate or a derivative thereof, wherein the indicator is hydrophobically associated with the anchor.
- a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a histidine-tag and an enterokinase cleavage site, or a portion thereof.
- a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) gene, a spacer sequence encoding a histidine-tag and an enterokinase cleavage site, or a portion thereof.
- trxA thioredoxin
- a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof.
- the spacer sequence encodes a hexahistidine (His6) tag [SEQ ID NO: 11.
- a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 21.
- a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 21 and an elasubl sequence.
- the elasubl sequence is located subsequent to the enterokinase cleavage site.
- the elasubl sequence encodes for functional amino acids selected from the group consisting of cysteine, lysine, arginine, glutamine, asparagine, glutamic acid, aspartic acid, serine, threonine or tyrosine.
- a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 21 and an elasubl sequence and a hydrophilic binding module (CBM) directly downstream to the elasubl sequence.
- trxA thioredoxin
- spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site
- CBM hydrophilic binding module
- a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 21 and an elasubl sequence and a Alcaligenes faecalis Polyhydroxyalkanoate depolymerase (PDM) sequence directly downstream to the elasubl sequence.
- PDM Polyhydroxyalkanoate depolymerase
- a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 21 and an elasubl sequence and a hydrophilic binding module (CBM) directly downstream to the elasubl sequence, wherein the elasubl sequence comprises nucleic acids encoding an HLE recognition site (Ala- Ala-Pro- Val) [SEQ ID NO: 31 or CatG recognition site (Ala-Ala-Pro-Phe) [SEQ ID NO: 41 or both HLE and CatG recognition sites.
- HLE recognition site Ala-Pro- Val
- CatG recognition site Al-Ala-Pro-Phe
- a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 21 and an elasubl sequence and & Alcaligenes faecalis Polyhydroxyalkanoate depolymerase (PDM) sequence directly downstream to the elasubl sequence, wherein the elasubl sequence comprises nucleic acids encoding an HLE recognition site (Ala-Ala-Pro- Val) [SEQ ID NO: 31 or CatG recognition site (Ala-Ala-Pro-Phe) [SEQ ID NO: 41 or both HLE and CatG recognition sites.
- HLE recognition site Al-Ala-Pro- Val
- CatG recognition site Al-Ala
- a vector comprising an expression control sequence and a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 21 and an elasubl sequence and a hydrophilic binding module (CBM) directly downstream to the elasubl sequence, wherein the elasubl sequence comprises nucleic acids encoding an HLE recognition site (Ala-Ala-Pro- Val) [SEQ ID NO: 31 or CatG recognition site (Ala-Ala-Pro-Phe) [SEQ ID NO: 41 or both HLE and CatG recognition sites.
- a vector comprising an expression control sequence and a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 21 and an elasubl sequence and & Alcaligenes faecalis Polyhydroxyalkanoate depolymerase (PDM) sequence directly downstream to the elasubl sequence, wherein the elasubl sequence comprises nucleic acids encoding an HLE recognition site (Ala-Ala-Pro-Val) [SEQ ID NO: 31 or CatG recognition site (Ala-Ala-Pro-Phe) [SEQ ID NO: 31 or both HLE and CatG recognition sites.
- PDM Polyhydroxyalkanoate depolyme
- a host cell comprising a vector comprising an expression control sequence and a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 21 and an elasubl sequence and a hydrophilic binding module (CBM) directly downstream to the elasubl sequence, wherein the elasubl sequence comprises nucleic acids encoding an HLE recognition site (Ala-Ala-Pro-Val) [SEQ ID NO: 31 or CatG recognition site (Ala-Ala-Pro-Phe) [SEQ ID NO: 41 or both HLE and CatG recognition sites.
- the host cell is a bacterial cell or an insect cell
- a host cell comprising a vector comprising an expression control sequence and a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 21 and an elasubl sequence and a Alcaligenes faecalis Polyhydroxyalkanoate depolymerase (PDM) sequence directly downstream to the elasubl sequence, wherein the elasubl sequence comprises nucleic acids encoding an HLE recognition site (Ala-Ala-Pro-Val) [SEQ ID NO: 31 or CatG recognition site (Ala-Ala-Pro-Phe) [SEQ ID NO: 41 or both HLE and CatG recognition sites.
- a vector comprising an
- a method of making the protein encoded by a chimeric construct comprising polynucleotide sequences encoding (a) a trxA (thioredoxin) or a portion thereof; (b) a spacer sequence encoding a histidine-tag; (c) an enterokinase cleavage site or a portion thereof; (d) an elasubl sequence subsequent to the enterokinase cleavage site; (e) a hydrophilic binding module (CBM) directly downstream to the elasubl sequence; and (f) an HLE recognition site (Ala-Ala-Pro-Val) [SEQ ID NO: 31 or CatG recognition site (Ala-Ala-Pro-Phe) [SEQ ID NO: 41 or both HLE and CatG recognition sites in the elasubl sequence; comprising culturing a host cell comprising the chimeric construct under conditions sufficient to induce expression of the chimeric construct and obtaining the chi
- a method of making the protein encoded by a chimeric construct comprising polynucleotide sequences encoding (a) a trxA (thioredoxin) or a portion thereof; (b) a spacer sequence encoding a histidine-tag; (c) an enterokinase cleavage site or a portion thereof; (d) an elasubl sequence subsequent to the enterokinase cleavage site; (e) a hydrophobic Alcaligenes faecalis Polyhydroxyalkanoate depolymerase (PDM) sequence directly downstream to the elasubl sequence; and (f) an HLE recognition site (Ala-Ala-Pro-Val) [SEQ ID NO: 31 or CatG recognition site (Ala-Ala-Pro-Phe) [SEQ ID NO: 41 or both HLE and CatG recognition sites in the elasub 1 sequence; comprising culturing a host cell comprising the
- a polypeptide encoded by a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 21 and an elasubl sequence and a hydrophilic binding module (CBM) directly downstream to the elasubl sequence, wherein the elasubl sequence comprises nucleic acids encoding an HLE recognition site (Ala-Ala-Pro-Val) [SEQ ID NO: 31 or CatG recognition site (Ala-Ala-Pro-Phe) [SEQ ID NO: 31 or both HLE and CatG recognition sites.
- composition comprising the CBM sequence containing polypeptide (“CBM polypeptide”) and a dye or a label.
- CBM polypeptide CBM sequence containing polypeptide
- a chemical entity comprising an anchor and an indicator region comprising the composition comprising the CBM polypeptide and the dye/label.
- a chemical entity comprising an anchor which is cellulose or a derivative thereof and the indicator region comprising the composition comprising the CBM polypeptide and the dye/label.
- a polypeptide encoded by a chimeric construct comprising polynucleotide sequences encoding a trxA (thioredoxin) or a portion thereof, a spacer sequence encoding a poly-histidine-tag and an enterokinase cleavage site, or a portion thereof and an enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 21 and an elasubl sequence and a Alcatigenes faecalis Polyhydroxyalkanoate depolymerase (PDM) sequence directly downstream to the elasubl sequence, wherein the elasubl sequence comprises nucleic acids encoding an HLE recognition site (Ala-Ala-Pro-Val) [SEQ ID NO: 31 or CatG recognition site (Ala-Ala-Pro-Phe) [SEQ ID NO: 41 or both HLE and CatG recognition sites.
- a trxA thioredoxin
- a composition comprising the PDM sequence containing polypeptide (“PDM polypeptide”) and a dye or a label.
- PDM polypeptide PDM sequence containing polypeptide
- a chemical entity comprising an anchor and an indicator region comprising the composition comprising the PDM polypeptide and the dye/label.
- a chemical entity comprising an anchor which is polyethylene terephthalate or a derivative thereof and the indicator region comprising the composition comprising the PDM polypeptide and the dye/label.
- a method for the determining the presence or absence of an enzyme selected from the group consisting of HLE and CatG in a biological sample comprising contacting the biological sample with the composition containing the CBM polypeptide and the dye/label or a chemical entity comprising the anchor and the indicator comprising the CBM polypeptide and the dye/label; and detecting the label.
- a method for the determining the presence or absence of an enzyme selected from the group consisting of HLE and CatG in a biological sample comprising contacting the biological sample with the composition containing the PDM polypeptide and the dye/label or a chemical entity comprising the anchor and the indicator comprising the PDM polypeptide and the dye/label; and detecting the label.
- a method for diagnosing an infected or a chronic wound comprising, contacting the wound with the composition containing the CBM polypeptide and the dye/label or a chemical entity comprising the anchor and the indicator comprising the CBM polypeptide and the dye/label; and detecting the label.
- the wound is present in a tissue, e.g., skin tissue, of a subject in need of such diagnosis, e.g., a human subject.
- the detection is made in situ.
- the diagnosis can be at multiple time points, based on visual and/or electronic valuation of the dye.
- a method for diagnosing an infected or a chronic wound comprising, contacting the wound with the composition containing the PDM polypeptide and the dye/label or a chemical entity comprising the anchor and the indicator comprising the CBM polypeptide and the dye/label; and detecting the label.
- the wound is present in a tissue, e.g., skin tissue, of a subject in need of such diagnosis, e.g., a human subject.
- the detection is made in situ.
- the diagnosis can be at multiple time points, based on visual and/or electronic valuation of the dye.
- a method for treating an infected or a chronic wound comprising, contacting the wound with any of the foregoing compositions, wherein the composition comprises at least one antibiotic and optionally together with a healing agent.
- the wound to be treated is present in a tissue, e.g., skin tissue, of a subject in need of such diagnosis, e.g., a human subject.
- the wound is treated in situ and may be accompanied by pre-treatment or post-treatment diagnosis.
- a polypeptide comprising the sequence set forth in (a) X y AAPX y -Z , (b) X y AAPX y -L-Z , (c) X y AAP(V/F/A)X y - Z , or (d) X y AAP(V/F/A)X y -L-Z , wherein each X is independently any amino acid, y is each, independently, an integer between 0 and 200, L is a linking moiety, and Z comprises a detectable label.
- a polypeptide comprising the sequence set forth in (a) X y AAPX y -Z , (b) X y AAPX y -L-Z , (c) X y AAP(V/F/A)X y - Z , or (d) X y AAP(V/F/A)X y -L-Z , wherein each X is independently any amino acid, y is each, independently, an integer between 1 and 50, L is a linking moiety, and Z comprises a detectable label.
- a polypeptide comprising the sequence set forth in (a) X y AAPX y -Z , (b) X y AAPX y -L-Z , (c) X y AAP(V/F/A)X y - Z , or (d) X y AAP(V/F/A)X y -L-Z , wherein each X is independently any amino acid, y is each, independently, an integer between 1 and 10, L is a linking moiety, and Z comprises a detectable label.
- a polypeptide comprising the sequence set forth in (a) X y AAPX y -Z , (b) X y AAPX y -L-Z , (c) X y AAP(V/F/A)X y - Z , or (d) X y AAP(V/F/A)X y -L-Z , wherein each X is independently any amino acid, y is each, independently, an integer between 1 and 6, L is a linking moiety, and Z comprises a detectable label.
- a polypeptide comprising the sequence set forth in (a) X y AAPX y -Z , (b) X y AAPX y -L-Z , (c) X y AAP(V/F/A)X y - Z , or (d) X y AAP(V/F/A)X y -L-Z , wherein each X is independently any amino acid, y is each, independently, an integer between 0 and 200, L is a linking moiety, and Z comprises a detectable label, wherein each of the peptides comprising the sequence X y AAPX y -Z , X y AAPX y -L-Z , X y AAP(V/F/A)X y -Z or X y AAP(V F/A)X y -L-Z , are each, individually, labile to elastase.
- composition comprising a polypeptide comprising the sequence set forth in (a) X y AAPX y -Z , (b) X y AAPX y -L-Z , (c) X y AAP(V/F/A)X y - Z , or (d) X y AAP(V/F/A)X y -L-Z , wherein each X is independently any amino acid, y is each, independently, an integer between 0 and 200, L is a linking moiety, and Z comprises a detectable label, and a carrier.
- a chemical entity comprising an anchor region (A) and an indicator region (I) comprising a polypeptide comprising the sequence set forth in (a) X y AAPX y -Z , (b) X y AAPX y -L-Z , (c) X y AAP(V/F/A)X Z , or (d) X y AAP(V/F/A)X y -L-Z , wherein each X is independently any amino acid, y is each, independently, an integer between 0 and 200, L is a linking moiety, and Z comprises a detectable label.
- a polypeptide comprising the amino acid sequence set forth in (a) X N 4 N 3 N 2 N -Z , or (b) X N 4 N 3 N 2 N -E-Z , wherein X is each, independently any amino acid; y is each, independently, a number selected from 0 to 6; N 4 is selected from alanine, glycine, valine, and glutamine; N 3 is selected from alanine, glycine, proline, lysine, and serine ; N 2 is selected from proline, alanine, and glycine; N 1 is selected from serine, lysine, phenylalanine, arginine, leucine, and methionine; L is a linking moiety; and Z comprises a detectable label.
- a polypeptide comprising the amino acid sequence set forth in (a) X N 4 N 3 N 2 N3 ⁇ 4-Z, or (b) X y N 4 N 3 N 2 N 1 X Y -L-Z , wherein X is each, independently any amino acid; y is each, independently, a number selected from 1 to 3; N 4 is selected from alanine, glycine, valine, and glutamine; N 3 is selected from alanine, glycine, proline, lysine, and serine ; N 2 is selected from proline, alanine, and glycine; N 1 is selected from serine, lysine, phenylalanine, arginine, leucine, and methionine; L is a linking moiety; and Z comprises a detectable label.
- a polypeptide comprising the amino acid sequence set forth in (a) X y N 4 N 3 N 2 N 1 X y -Z , or (b) X y N 4 N 3 N 2 N 1 X Y -L-Z , wherein X is each, independently any amino acid; y is each, independently, a number selected from 0 to 6; N 4 is selected from alanine, glycine, valine, and glutamine; N 3 is selected from alanine, glycine, proline, lysine, and serine ; N 2 is selected from proline, alanine, and glycine; N 1 is selected from serine, lysine, phenylalanine, arginine, leucine, and methionine; L is a linking moiety; and Z comprises a detectable label, wherein the polypeptides comprising the sequence (a) X y N 4 N 3 N 2 N 1 X y -
- composition comprising a polypeptide comprising the amino acid sequence set forth in (a) X y N ⁇ N ⁇ X y -Z , or (b) X y N ⁇ N ⁇ X y -L-Z , wherein X is each, independently any amino acid; y is each, independently, a number selected from 0 to 6; N 4 is selected from alanine, glycine, valine, and glutamine; N 3 is selected from alanine, glycine, proline, lysine, and serine ; N 2 is selected from proline, alanine, and glycine; N 1 is selected from serine, lysine, phenylalanine, arginine, leucine, and methionine; L is a linking moiety; and Z comprises a detectable label and a carrier.
- a chemical entity comprising an anchor region (A) and an indicator region (I) comprising a polypeptide comprising the amino acid sequence set forth in (a) X y N 4 N 3 N 2 N 1 X y -Z, or (b) X y N 4 N 3 N 2 N 1 X y -L-Z , wherein X is each, independently any amino acid; y is each, independently, a number selected from 0 to 6; N 4 is selected from alanine, glycine, valine, and glutamine; N 3 is selected from alanine, glycine, proline, lysine, and serine; N 2 is selected from proline, alanine, and glycine; N 1 is selected from serine, lysine, phenylalanine, arginine, leucine, and methionine; L is a linking moiety; and Z comprises a detectable label.
- FIG. 1 Infrared spectrum of Example 2. Chitosan derivatives with varying degree of acetylation (DA) were produced, but only material with a DA of 48% was further used.
- DA acetylation
- FIG. 2 Infrared spectrum and NMR spectrum of Example 2. Chitosan derivatives with varying DA were produced, but only material with a DA of 48% was further used.
- FIG. 3 Infrared spectrum of chitooligosaccharides of Example 5.
- FIG. 4 Infrared spectrum of chitooligosaccharides of Example 6.
- FIG. 5 Time course of dye release from dye conjugated acetyl chitosan when incubated with 5000 units per mL lysozyme.
- FIG. 6 (A) Time course of dye release from dye conjugated acetyl chitosan when incubated with 5000 units per mL lysozyme in phosphate buffer when the chitosan has varying concentrations of dye conjugated; (B) Time course of dye release from dye conjugated acetyl chitosan when incubated with 5000 units per mL lysozyme in either phosphate buffer of artificial wound fluid containing 2% protein as BSA.
- FIG. 7 Color response of immobilized nitrazine yellow and bromocresol purple of Example 11 varies depending on the pH at which the preparation is dried.
- FIG. 8 Comparison of different lysozyme responsive dye releases of different staining degrees.
- FIG. 9 Influence of the proportion between reactive dye and PG.
- FIG. 10 Elastase responsive dye release.
- FIG. 11 Multiple Sequence Alignment of the Various Constructs.
- Asterisk (*) indicates identity; semi -colon (:) indicates conservative substitution; and period (.) indicates semi-conservative substitution.
- “Substantially” or “essentially” means nearly totally or completely, for instance, 80%-95% or greater of some given quantity, e.g., at least 85%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.9%, or more % by weight or volume or any other parameter being measured.
- “Substantially free” means nearly totally or completely absent of some given quantity such as being present at a level of less than about 1% to about 20% of some given quantity, e.g., less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%), less than 0.1%, or less % by weight or volume or any other parameter being measured.
- “substantially free” means presence at a level of less than or equal to 1 -5% by weight of the pharmaceutical composition.
- compositions and systems for the therapy and diagnosis of wounds and wound management wherein the compositions, when in use, indicate the presence of elevated enzyme levels in a wound in situ.
- wound refers to physical disruption of the continuity or integrity of tissue structure.
- Wild healing refers to the restoration of tissue integrity. It will be understood that this can refer to a partial or a full restoration of tissue integrity. Treatment of a wound thus refers to the promotion, improvement, progression, acceleration, or otherwise advancement of one or more stages or processes associated with the wound healing process.
- the wound may be acute or chronic.
- Chronic wounds including pressure sores, venous leg ulcers and diabetic foot ulcers, can simply be described as wounds that fail to heal. Whilst the exact molecular pathogenesis of chronic wounds is not fully understood, it is acknowledged to be multi -factorial. As the normal responses of resident and migratory cells during acute injury become impaired, these wounds are characterized by a prolonged inflammatory response, defective wound extracellular matrix (ECM) remodeling and a failure of re-epithelialization.
- ECM extracellular matrix
- the wound may be any internal wound, e.g., where the external structural integrity of the skin is maintained, such as in bruising or internal ulceration, or external wounds, particularly cutaneous wounds, and consequently the tissue may be any internal or external bodily tissue.
- the tissue is skin (such as human skin), i.e. the wound is a cutaneous wound, such as a dermal or epidermal wound.
- the human skin is composed of two distinct layers, the epidermis and the dermis, below which lies the subcutaneous tissue.
- the primary functions of the skin are to provide protection to the internal organs and tissues from external trauma and pathogenic infection, sensation and thermoregulation.
- the skin tissue of most mammals is structured similarly.
- the outermost layer of skin, the epidermis is approximately 0.04 mm thick, is avascular, is comprised of four cell types (keratinocytes, melanocytes, Langerhans cells, and Merkel cells), and is stratified into several epithelial cell layers.
- the inner-most epithelial layer of the epidermis is the basement membrane, which is in direct contact with, and anchors the epidermis to, the dermis. All epithelial cell division occurring in skin takes place at the basement membrane. After cell division, the epithelial cells migrate towards the outer surface of the epidermis. During this migration, the cells undergo a process known as keratinization, whereby nuclei are lost and the cells are transformed into tough, flat, resistant non-living cells.
- Migration is completed when the cells reach the outermost epidermal structure, the stratum corneum, a dry, waterproof squamous cell layer which helps to prevent desiccation of the underlying tissue.
- This layer of dead epithelial cells is continuously being sloughed off and replaced by keratinized cells moving to the surface from the basement membrane. Because the epidermal epithelium is avascular, the basement membrane is dependent upon the dermis for its nutrient supply.
- the dermis is a highly vascularized tissue layer supplying nutrients to the epidermis.
- the dermis contains nerve endings, lymphatics, collagen protein, and connective tissue.
- the dermis is approximately 0.5 mm thick and is composed predominantly of fibroblasts and macrophages. These cell types are largely responsible for the production and maintenance of collagen, the protein found in all animal connective tissue, including the skin. Collagen is primarily responsible for the skin’s resilient, elastic nature.
- the subcutaneous tissue, found beneath the collagen-rich dermis provides for skin mobility, insulation, calorie storage, and blood to the tissues above it.
- Wounds can be classified in one of two general categories, partial thickness wounds or full thickness wounds.
- a partial thickness wound is limited to the epidermis and superficial dermis with no damage to the dermal blood vessels.
- a full thickness wound involves disruption of the dermis and extends to deeper tissue layers, involving disruption of the dermal blood vessels.
- the healing of the partial thickness wound occurs by simple regeneration of epithelial tissue. Wound healing in full thickness wounds is more complex. Cutaneous wounds contemplated herein may be either partial thickness or full thickness wounds.
- Wounds contemplated herein include cuts and lacerations, surgical incisions or wounds, punctures, grazes, scratches, compression wounds, abrasions, friction wounds (e.g., nappy rash, friction blisters), decubitus ulcers (e.g., pressure or bed sores); thermal effect wounds (burns from cold and heat sources, either directly or through conduction, convection, or radiation, and electrical sources), chemical wounds (e.g.
- pathogenic infections e.g., viral, bacterial or fungal
- pathogenic infections including open or intact boils, skin eruptions, blemishes and acne, ulcers, chronic wounds, (including diabetic-associated wounds such as lower leg and foot ulcers, venous leg ulcers and pressure sores), skin graft/transplant donor and recipient sites, immune response conditions, e.g., psoriasis and eczema, stomach or intestinal ulcers, oral wounds, including a ulcers of the mouth, damaged cartilage or bone, amputation wounds and corneal lesions.
- Embodiments described herein provide chemical entities, which may be used to diagnose and/or treat chronic wounds.
- the chemical entities and compositions thereof, as described herein are used in methods to detect the level of one or more enzymes in a mammalian wound.
- the chemical entities and compositions thereof, as described herein are used in methods to diagnose a chronic wound in a mammal.
- the chemical entities and compositions thereof described herein are used in methods to diagnose an infected wound in a mammal.
- the chemical entities and compositions thereof described herein are used in methods to treat a wound in a mammal.
- the chemical entities and compositions thereof described herein are used in methods to treat an infected or a chronic wound in a mammal.
- a chemical entity capable of detecting enzyme activity from a body fluid, the chemical entity comprising: an anchor region (A) and an indicator region (I).
- the chemical entity has a basic chemical structure A-I (Formula I), wherein A is an anchor region and I is an indicator region.
- the anchor region (A) is associated with the indicator region (I) via an enzyme recognition site (S).
- the enzyme recognition site is a structure or a motif that allows binding to an enzyme.
- the enzyme recognition site (S) is naturally present in the anchor region. In another embodiment, the enzyme recognition site (S) is introduced in the anchor region via chemical modification. Alternately, the enzyme recognition site (S) may be naturally present in the indicator region (I) or synthetically introduced in the indicator region (I) via one or more chemical modifications.
- the chemical entity of Formula I comprises an anchor (A) which is associated with the indicator (I), either covalently or non-covalently.
- the association between the anchor region (A) and the indicator region (I) is mediated via a covalent interaction.
- covalent bonds involve sharing of electrons between the bonded atoms.
- non-covalent bonds may include, for example, ionic interactions, electrostatic interactions, hydrogen bonding interactions, physiochemical interactions, van der Waal forces, Lewis-acid/Lewis-base interactions, or combinations thereof.
- the anchor A is associated with the indicator I via a covalent interaction to form the recognition site S. In another embodiment, the anchor A is associated with the indicator I via a covalent interaction that is not a part of the recognition site S.
- the chemical entity further comprises an enzyme-labile or enzyme-reactive region (R).
- the reactive region (R) is a part of the anchor region.
- the reactive region (R) is a part of the indicator region (I).
- the reactive region (R) is a part of the enzyme recognition site (S).
- the reactive region (R) interacts with one or more target enzymes selected from the group consisting of elastase, lysozyme, cathepsin G, and myeloperoxidase, or a combination thereof.
- the anchor region comprises a compound which is a polysaccharide, cellulose, polyacrylate, polyethyleneimine, polyacrylamide, peptidoglycan, or chitosan, or a monomer thereof, a derivative thereof, a mixture or a combination thereof.
- the anchor A comprises a compound which is a chitosan or a monomer thereof, a derivative thereof, a mixture or a combination thereof.
- Non-covalent bonds may include, for example, ionic interactions, electrostatic interactions, hydrogen bonding inetyl-D-glucosamine (acetylated unit).
- chitosan monomer may comprise D-glucosamine and N-acetyl-D-glucosamine.
- the chitosan may comprise at least 2, at least 3, at least 4, at least 5, or more units of D-glucosamine or N-acetyl-D-glucosamine or a combination thereof.
- Chitosan, including, shorter fragments thereof is generally manufactured by treating chitin with an alkaline substance, e.g., sodium hydroxide, and optionally hydrolyzing the glycosidic linkages between the individual monomer units.
- the anchor A comprises a chitosan derivative.
- Example chitosan or chitosan derivatives include chitosan salts, water-soluble chitosan, water-soluble, randomly substituted partial N-, partial O-acetylated chitosan, chitosan oligosaccharide, carboxymethyl chitosan, and hydroxyalkyl chitosan.
- the hydroxyalkyl substituents of the hydroxyalkyl, chitosans and the carboxym ethyl substituents of the carboxy methyl chitosans could be attached to any of the pendant nitrogen or oxygen groups on the chitin or chitosan ring subunit.
- hydroxyalkyl chitosans include but are not limited to, hydroxyethyl chitosan (also known as glycol chitosan), hydroxypropyl chitosan, dihydroxypropyl chitosan, hydroxybutyl chitosan and dihydroxybutyl chitosan.
- the chitosan derivative is a randomly substituted partial N-, partial O-acetylated chitosan.
- the acetylated chitosan derivatives are generally defined by a degree of acetylation or degree of acetylation.
- the degree of acetylation represents the proportion of N-acetyl-d-glucosamine units with respect to the total number of units in the chitosan molecule. See, Chatelet et al., Biomaterials , 22(3):261-8, 2001.
- degree of deacetylation is meant the percentage of free amino groups on the water soluble, chitosan or chitosan derivative.
- the percent of N-acetylation can be calculated from the deacetylation value.
- N-acetylation or O-acetylation are also referred to as the degree of substitution with C(0)CH 3 on either N or O.
- a chitosan derivative having a DA value greater than 50% N-acetylation is sometimes described as a chitin.
- the term “chitosan” is used throughout the disclosure herein to include chitosans and, if the N-acetylation is greater than 50%, to include chitins. See, U.S. Pat. No. 7,683,039.
- the chitosan derivative has a DA of at least about 40%, about 41%, about 42%, about 43%, about 44%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about
- chitosan derivative as used herein includes salts, amides, esters, enol ethers, enol esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, acids, bases, solvates, hydrates or prodrugs of the chitosan.
- Such derivatives may be readily prepared by those of skill in this art using known methods for such derivatization.
- the derivatives may be administered to animals or humans without substantial toxic effects and either are pharmaceutically active or are prodrugs. Representative types of chitosan derivatives are described in U.S. Pat. Nos. 9,012,429; 5,773,608; and 3,911,116.
- the derivative is a salt of the polymeric compound, e.g., salts of Li + , Na + , K + , Rb + , Mg 2+ , Ca 2+ , Sr 2+ , or Ba 2+ , preferably Na + , K + , Mg 2+ , Ca + .
- Salts of chitin and chitosan, such as sodium or calcium salts, are known in the art. See, U.S. Pat. No. 5,599,916.
- the derivative anchor compound is a halogenated anchor compound, e.g., halogenated polysaccharide, halogenated cellulose, halogenated polyacrylate, halogenated polyethyleneimine, halogenated polyacrylamide, halogenated peptidoglycan, or halogenated chitosan, or a monomer thereof, e.g., halogenated D-glucosamine and/or halogenated N-acetyl -D-glucosamine.
- the halogen is selected from the group consisting of CI, Br, I; particularly, the halogen is CI.
- the derivative compound is an isomer of the anchor compound
- term “isomer” includes compounds with the same formula but a different arrangement of atoms in the molecule.
- isomers of the compounds are “tautomers” or “stereoisomers” of the compounds.
- stereoisomer refers to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers.
- tautomer refers to alternate forms of a compound that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of the anchor compound.
- the anchor compound may contain a combination or mixture of one or more of the aforementioned compounds.
- the term “combination” includes compounds containing more than one component, which may be conjugated or non-conjugated to one another.
- the anchor compound comprises a combination of one or more of the aforementioned compounds which are conjugated to each other, e.g., via covalent or non-covalent interaction.
- the anchor may comprise a combination of chitosan and oxidized cellulose. See, U.S. Pat. Application Publication No. 2014/0045761.
- the compounds include mixtures of the aforementioned polymeric compounds.
- the term “mixture” refers to a mingling together of two or more substances without the occurrence of a reaction by which they would lose their individual properties.
- a mixture of compound A and compound B may contain any weight ratio of compound A and compound B, such that the total weight of the mixture would amount to 100%, e.g., 99: 1 weight ratio of compound A/compound B or 1 :99 weight ratio of compound A/compound B.
- a typical mixture may contain about 2, 3, 4, 5, or more of the aforementioned polymer compounds.
- the anchor A further comprises an ionic chemical group, a material with a hydrophilic moiety, or a material with a hydrophobic moiety, e.g., an aliphatic chain or an aliphatic alcohol.
- the anchor comprises an ionic chemical group
- the ionic chemical group may be positively or negatively charged.
- the anchor region comprises a reactive moiety for covalent attachment to a support material such as a photoactive phenylazide or an epoxide group. See, U.S. Pat. Application Publication No. 2016/0159777.
- the chemical entities comprise one or more indicators, e.g., at least 1, at least 2, at least 3, at least 4, or more of indicators.
- Such compositions may include, for example, a plurality of substrates conjugated to the same gel polymer or different gel polymers.
- the indicators are labeled.
- label refers to any substance attached to an epitope binding agent, or other substrate material, in which the substance is detectable by a detection method.
- suitable labels include luminescent molecules, chemiluminescent molecules, fluorochromes, fluorescent quenching agents, colored molecules, radioisotopes, scintillants, biotin, avidin, streptavidin, protein A, protein G, antibodies or fragments thereof, polyhistidine, Ni2+, Flag tags, myc tags, heavy metals, and enzymes (including alkaline phosphatase, peroxidase, and luciferase). Methods for attaching the labels to the anchor compounds are described in the Examples.
- the indicators are labeled with a label which is a detectable label.
- a detectable label is a moiety, the presence of which can be ascertained directly or indirectly.
- detection of the label involves the creation of a detectable signal such as for example an emission of energy.
- the label may be of a chemical, peptide or nucleic acid nature although it is not so limited. The nature of label used will depend on a variety of factors, including the nature of the analysis being conducted, the type of the energy source and detector used and the type of polymer, analyte, probe and primary and secondary analyte-specific binding partners.
- the label is sterically and chemically compatible with the constituents to which it is bound, e.g., the anchor region.
- the label is of the shape and size that it does not hinder enzyme recognition site (S) and/or enzyme-reactive region (R).
- the indicator or a motif therein attached to the anchor is a substrate for a glycosidase.
- the indicator or motif therein attached to the anchor is a substrate for lysozyme.
- the indicator or a motif therein attached to the anchor is a substrate for a protease selected from the group consisting of elastase, cathepsin G or myeloperoxidase (MAO), or a combination thereof.
- a protease selected from the group consisting of elastase, cathepsin G or myeloperoxidase (MAO), or a combination thereof.
- the indicator or a motif therein attached to the anchor is a substrate for a glycosidase which is lysozyme and a protease selected from the group consisting of elastase, cathepsin G or myeloperoxidase (MAO), or a combination thereof.
- a glycosidase which is lysozyme and a protease selected from the group consisting of elastase, cathepsin G or myeloperoxidase (MAO), or a combination thereof.
- the indicator (I) or a motif therein attached to the anchor is a peroxidase substrate, an arylamine, an amino phenol, an aminophenyl ether, an indoxyl, a neutral dye, a charged dye, a nanoparticle, or a colloidal gold particle.
- the indicator (I) or a motif therein attached to the anchor is a peroxidase substrate.
- the peroxidase substrate is selected from p-aminophenol, ABTS (2,2inophenol, ABTS (strate.
- acid) diammonium salt 3,3′-diaminobenzidine, 3,4 diaminobenzoic acid, DCPIP, N,N dimethyl-p-phenylenediamine, o-dianisidine, /?-phenylenediamine, 4-chloro-l-naphthol, o-phenylenediamine N-(4-aminobutyl)-N-ethylisoluminol, 3-amino-9-ethylcarbazole, 4-aminophthalhydrazide, 5-aminosalicylic acid, 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid), indoxyl, indigo, Fast Blue RR, 4-chloro-7-nitrobenzofurazan.
- the indicator (I) or a label attached thereto is an arylamine. In some embodiments, the indicator (I) or a label attached thereto is an amino phenol. In some embodiments, the indicator (I) or a label attached thereto is an aminophenol ether. In some embodiments, the indicator (I) or a label attached thereto is an indoxyl. In some embodiments, the indicator (I) or a label attached thereto is a neutral dye. In some embodiments, the indicator (I) or a label attached thereto is a charged dye.
- the charged dye is selected from remazole brilliant blue, toluidine blue, reactive black 5, remazol brilliant blue, reactive violet 5, and reactive orange 16, or a hydrolytic or ammonolytic derivatives thereof.
- the charged dye is remazole brilliant blue, or a hydrolytic or ammonolytic derivatives thereof.
- the charged dye is toluidine blue.
- the charged dye is reactive black 5, or ahydrolytic or ammonolytic derivatives thereof.
- the charged dye is reactive violet 5, or hydrolytic or ammonolytic derivatives thereof.
- the charged dye is reactive orange 16, or hydrolytic or ammonolytic derivatives thereof.
- the indicator (I) or a label attached thereto is a dichlorotriazine-based reactive dye such as reactive blue 4, reactive red 120, reactive blue 2, reactive green 19 and reactive brown 10. In some embodiments, the dichlorotriazine-based reactive dye appears black.
- the indicator (I) or a label attached thereto is a reactive dye containing a sulfonyl ethyl -hydrogensulphate-reactive-group.
- the reactive dye is reactive black 5, remazol brilliant blue, reactive violet 5 or reactive orange 16.
- the reactive dye is reactive black 5.
- the reactive dye is remazol brilliant blue.
- the reactive dye is reactive violet 5.
- the reactive dye is reactive orange 16.
- the reactive dye is reactive black 5, remazol brilliant blue, or reactive violet 5.
- the reactive dye is reactive black 5 or remazol brilliant blue.
- the indicator (I) or a label attached thereto is a nanoparticle. In some embodiments, the indicator (I) or a label attached thereto is a colloidal gold particle. In some embodiments, the indicator (I) or a label attached thereto is a charged dye, an indole derivative, or a luminol derivative.
- the indicator or a motif therein attached to the anchor comprises a dye containing a sulfonyl ethyl -hydrogensulphate-reactive-group, e.g., reactive black 5, remazol brilliant blue, reactive violet 5 or reactive orange 16, or a combination thereof; or a dye containing a dichlortriazine reactive-group, e.g., reactive blue 4, reactive red 120, reactive blue 2, reactive green 19 and reactive brown 10, or a combination thereof.
- a dye containing a sulfonyl ethyl -hydrogensulphate-reactive-group e.g., reactive black 5, remazol brilliant blue, reactive violet 5 or reactive orange 16, or a combination thereof
- a dye containing a dichlortriazine reactive-group e.g., reactive blue 4, reactive red 120, reactive blue 2, reactive green 19 and reactive brown 10, or a combination thereof.
- an anchor A is conjugated with the indicator I directly, e.g., via an glycosidic linkage.
- the indicator is selected from the group consisting of reactive black 5, remazol brilliant blue, reactive violet 5 or reactive orange 16, reactive blue 4, reactive red 120, reactive blue 2, reactive green 19 and reactive brown 10, or a combination thereof.
- a glycosidic linkage is formed between a hydroxyl group of the anchor compound with a reactive group in the indicator compound.
- the la-carbon in the sugar backbone of the anchor molecule is involved in the glycosidic linkage.
- Embodiments described herein may utilize chemical moieties that assay for various biological markers present in a chronic or infected wound.
- the marker is a wound- specific marker, which is an enzyme selected from the group consisting of hydrolases, proteases, esterases, and peroxidases.
- a “wound specific enzyme” is an enzyme that is differentially expressed in a wound.
- differential expression it is meant that the level or the activity of the enzyme is higher or lower in the wound microenvironment compared to other sites, e.g., normal tissue or surrounding tissue. Particularly, differential expression implies higher level of expression or activity of the enzyme in the wound microenvironment compared to normal or unwounded tissue.
- Differential expression of enzyme may be analyzed by routine means. For example, levels of enzyme in a sample may be analyzed by ELISA assays or other immunoassays. Activities of the enzyme may be analyzed by measuring rates of loss of a substrate and/or rates of formation of the product, e.g., using mass spectroscopy or HPLC. Such techniques are known in the art and are described in the Examples section.
- the marker is a hydrolase.
- a “hydrolase” or “hydrolytic enzyme” is an enzyme that catalyzes the hydrolysis of a chemical bond, e.g., esterases and nucleases (break ester bonds); glycolases (break glycosidic linkers); peptidases (break peptide bonds), etc.
- the wound-specific glycoside hydrolase is lysozyme.
- Lysozyme (UNIPROT accession Nos. P61626 [human] and P08905 [mouse]) is a glycoside hydrolase and its main function is to destroy the cell walls of bacteria. It hydrolyses the (1 ⁇ 4)- ⁇ -linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and also between N-acetyl-D glucosamine residues in chitodextrin.
- the natural substrate for lysozyme is the peptidoglycan layer of bacterial cell walls.
- the individual components of the chemical moiety have been adapted for recognition by wound-specific hydrolase, e.g., a wound-specific lysozyme.
- the individual components of the chemical moiety can be modified for recognition by other wound specific enzymes.
- the additional wound specific enzyme is a protease.
- a “wound specific protease” is a protease that is differentially expressed in a wound.
- differential expression it is meant that the level or the activity of the protease is higher or lower in the wound microenvironment compared to other sites, e.g., normal tissue or surrounding tissue.
- differential expression implies higher level of expression or activity of the protease in the wound microenvironment compared to unwounded tissue. Differential expression of proteases may be analyzed by routine means.
- levels of proteases in a sample may be analyzed by ELISA assays or other immunoassays. Activities of the proteases may be analyzed by measuring rates of loss of a peptide substrate and/or rates of formation of the product, e.g., using mass spectroscopy or HPLC. Such techniques are known in the art and are described in the Examples section.
- the wound-specific protease is cathepsin G (UNIPROT accession Nos. P08311 [human] and P28293 [mouse]), which is one of the three serine proteases of the chymotrypsin family that are stored in the azurophil granules.
- Cathepsin G-specific substrates have the sequence Ala-Ala-Pro-Phe [SEQ ID NO: 41 or Ala-Ala-Pro-Met [SEQ ID NO: 51 (Sigma Aldrich Catalog Nos. S7388 and M7771).
- the wound specific protease is elastase (e.g., human neutrophil elastase or HNE) (UNIPROT accession Nos. P08246 [human] and Q3UP87 [mouse]).
- HNE is a serine proteinase in the same family as chymotrypsin and has broad substrate specificity. Secreted by neutrophils and macrophages during inflammation, it destroys bacteria and host tissue.
- the substrate for detecting HNE has a core sequence Alanine-Alanine-Proline- Valine (AAPV) [SEQ ID NO: 31.
- the substrate for HNE is Ala- Pro-Glu-Glu-Ile/[ SEQ ID NO: 6]Met-Arg-Arg-Gln [SEQ ID NO: 7](APEEI MRRQ) (Kasperkiewicz et al., PNAS USA, 111(7): 2518-2523, 2014; Korkmaz et al., Methods Mol Biol , 844: 125-138, 2012).
- the wound-specific enzyme is peroxidase, more specifically, a myeloperoxidase (MPO).
- MPO myeloperoxidase
- H202 hydrogen peroxide
- a halide most commonly chloride
- hypochlorite singlet oxygen
- chlorine C12
- hydroxyl radicals OH ⁇
- MPO can be detected using tetramethylbenzidine or 4-Benzoylamino-2,5-dimethoxyaniline. See, Andrews et al, Anal Biochem , 127(2):346-50, 1982; Klebanoff et al., J. Leukocyte Biol , 11, 598-625, 2005.
- the chemical moiety comprises an anchor region A or an indicator (I) comprising a recognition site for a wound-specific enzyme, e.g., an enzyme cleavage site.
- the enzyme recognition site comprises glycosidic bonds.
- a “glycosidic bond” is formed between the hemiacetal or hemiketal group of a saccharide (or a molecule derived from a saccharide) and the hydroxyl group of some compound such as an alcohol.
- a substance containing a glycosidic bond is a glycoside.
- glycoside is now extended to also cover compounds with bonds formed between hemiacetal (or hemiketal) groups of sugars and several chemical groups other than hydroxyls, such as -SR (thioglycosides), -SeR (selenoglycosides), -NR1R2 (N-glycosides), or even -CR1R2R3 (C-glycosides).
- the chemical moieties disclosed herein contain one or more glycosidic bonds which are cleaved by glycolases.
- the chemical moieties comprise a glycosidic bond linking anchor A and the indicator I, either directly or via another group.
- the anchor A and the indicator I are directly linked via one or more glycosidic bonds, in which case, the chemical entity is cleaved by the glycolase and therefore can be used in detecting the glycolase.
- the indicator molecule comprises an enzymatically-cleavable peptide comprising a peptide bond.
- a “peptide bond” is formed by the condensation reaction between two amino acids, wherein the acid moiety of one reacts with the amino moiety of the other to produce a peptide bond (—CO—NH—) between the two amino acids.
- the individual peptides provide a motif for the recognition by a sequence-specific protease.
- sequence-specific protease means a protease recognizing a specific sequence of a peptide for its digesting (for example, caspase), and is distinguished from a generic protease (for example, trypsin) that sequentially decomposes a peptide from one end thereof or digest a peptide in a sequence-nonspecific manner.
- the amino acid sequence of the peptide substrate may comprise four or more amino acid (a.a.) residues.
- peptide includes a natural peptide comprising a linear chain or branched amino acids, peptidomimetics, as well as pharmaceutically acceptable salts thereof.
- a peptide comprises a plurality of amino acid residues, e.g., 2, 3, 4, 5, 6, 8, 10, or more amino acid residues which are bonded to each other via covalent bonds, e.g., a peptide bond.
- Amino acid residue means the individual amino acid units incorporated into the peptides of the disclosure.
- amino acid means a naturally occurring or synthetic amino acid, as well as amino acid analogs, stereoisomers, and amino acid mimetics that function similarly to the naturally occurring amino acids.
- amino acids such as: (1) histidine (His) (2) isoleucine (He) (3) leucine (Leu) (4) ysine (Lys) (5) methionine (Met) (6) phenylalanine (Phe) (7) threonine (Thr) (8) tryptophan (Trp) (9) valine (Val) (10) arginine (Arg) (11) cysteine (Cys) (12) glutamine (Gin) (13) glycine (Gly) (14) proline (Pro) (15) serine (Ser) (16) tyrosine (Tyr) (17) alanine (Ala) (18) asparagine (Asn) (19) aspartic acid (Asp) (20) glutamic acid (Glu) (21) selenocysteine (Sec); including unnatural amino acids: (a) citrulline; (b) cystine; (c) gama-amino butyric acid (GAB A); (d)
- amino acids containing reactive side chains e.g., cysteine, serine, threonine, lysine, arginine, aspartate/asparagine, glutamate/glutamine, glycine, alanine, etc. are particularly employed for modification of the substrate.
- the chemical entities contain one or more enzyme-labile or enzyme-reactive regions (R) for the detection of wound-specific enzymes.
- the enzyme-labile or enzyme-reactive region comprises an acyl chitosan of at least 3 glucosamine or N-acetylglucosamine or peptidoglycan units, which are optionally acetylated.
- the enzyme reactive site may contain, for example, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20 or more units of glucosamine or N-acetylglucosamine or peptidoglycan units.
- the R comprises at least 3 glucosamine or N-acetylglucosamine or a combination thereof, wherein the glucosamine and/or N-acetylglucosamine are optionally acetylated.
- the enzyme-labile or enzyme-reactive region comprises peptidoglycan, wherein the peptidoglycan is optionally acetylated.
- the chemical moieties comprise enzyme reactive sites (R) for one or more wound-specific protease disclosed above, e.g., cathepsin G, and myeloperoxidase, elastase or a combination thereof.
- R enzyme reactive sites
- the term “reactive site for a protease” means a peptide comprising an amino acid sequence of a protein, which is recognized by the protease as a substrate for its protease activity, e.g., as a substrate that can be cleaved into one or more products.
- the chemical entities comprise a peptide region comprising a peptide sequence comprising a plurality of amino acids.
- the indicator region (I) of the chemical entity comprises the peptide which serves as the enzyme reactive site for the wound-specific protease.
- the enzyme-labile or enzyme-reactive region comprises a peptide that is labile to elastase, cathepsin G, myeloperoxidase or a combination thereof.
- the enzyme-labile region comprises a peptide that is liable to elastase.
- the chromogenic indicator for elastase would be high contrast and thus serve as a clear indicator when used in situ in medicinal products.
- the ideal substrate would make a blue, violet or deep green colour. It would also be fixed in a sterically permissible position with high turnover.
- the state of the art is the opposite.
- Available substrates contain a p-nitrophenol group, which is low molecular weight but gives rise to a yellow soluble chromophore.
- Most skilled investigators regard that the substrate should be soluble in water, reasoning that this is the most likely way that the substrate will find its way to the active site.
- embodiments described herein contemplate use of a low water soluble, elastase substrates that give rise to Blue, violet or Green colors.
- the enzyme-labile or enzyme-reactive region comprises a peptide comprising an amino acid sequence of:
- the enzyme-labile or enzyme-reactive region comprises a peptide comprising an amino acid sequence of:
- the enzyme-labile or enzyme-reactive region comprises a peptide comprising an amino acid sequence of:
- the enzyme-labile or enzyme-reactive region comprises a peptide comprising an amino acid sequence of:
- the reactive region R comprises the peptide sequence X y AAPX y -Z , X y AAPX y -L-Z , X y AAP(V/F/A)X y -Z or X y AAP(V/F/A)X y -L-Z , wherein X, L and Z are each, as described above, and y is, each, independently an integer from 1 to 50.
- the reactive region R comprises the peptide sequence X y AAPX Z , X y AAPX y -L-Z , X y AAP(V/F/A)X y -Z or X y AAP(V/F/A)X y -L-Z , wherein X, L and Z are each, as described above, and y is, each, independently an integer from 1 to 10.
- the reactive region R comprises the peptide sequence X y AAPX y -Z , X y AAPX y -L-Z , X y AAP(V/F/A)X y -Z or X y AAP(V/F/A)X y -L-Z , wherein X, L and Z are each, as described above, and y is, each, independently an integer from 1 to 6.
- each of the aforementioned peptides comprising the sequence X y AAPX y -Z , X y AAPX y -L-Z , X y AAP(V/F/A)X y -Z or X y AAP(V/F/A)X y -L-Z , are each, individually, labile to elastase.
- one or more of the amino acids in the amino acid sequence X y AAPX y -Z , X y AAPX y -L-Z , X y AAP(V/F/A)X y -Z or X y AAP(V/F/A)X y -L-Z is protected, e . g . , with an amine protection group, for example, fluorenylmethyloxycarbonyl (Fmoc).
- an amine protection group for example, fluorenylmethyloxycarbonyl (Fmoc).
- the elastase substrates have the formula a-b-c-d-e-f, wherein
- elastase substrates have the formula a-b-c-d-e-f, wherein
- elastase substrates have the formula a-b-c-d-e-f, wherein
- elastase substrates have the formula a-b-c-d-e-f, wherein
- elastase substrates have the formula a-b-c-d-e-f, wherein
- elastase substrates have the formula a-b-c-d-e-f, wherein
- the enzyme-labile or enzyme-reactive region comprises a peptide that is labile to cathepsin G.
- the enzyme-labile or enzyme-reactive region comprises a peptide comprising an amino acid sequence of:
- one or more of the amino acids in the amino acid sequence is protected. In some embodiments, one or more of the amino acids in the amino acid sequence is protected with an fmoc group. In some embodiments, one of the amino acid in the amino acid sequence is protected with an fmoc group.
- the enzyme-labile or enzyme-reactive region comprises a peptide comprising an amino acid sequence of
- each of the aforementioned peptides comprising the sequence X y N 4 N 3 N 2 N 1 -Z and X y N 4 N 3 N 2 N 1 X y -L-Z , are each, individually, labile to cathepsin G.
- one or more of the amino acids in the amino acid sequence X y N 4 N 3 N 2 N 1 X y -Z and X y N 4 N 3 N 2 N 1 X y -L-Z is protected, e.g., with an amine protection group, for example, fluorenylmethyloxycarbonyl (Fmoc).
- an amine protection group for example, fluorenylmethyloxycarbonyl (Fmoc).
- Z is a peroxidase substrate, an arylamine, an amino phenol, an aminophenyl ether, an indoxyl, a neutral dye, a charged dye, a nanoparticle, or a colloidal gold particle.
- Z is a peroxidase substrate selected from p-aminophenol, ABTS (2,2inophenol, ABTS (s, the peroxidase substrate acid) diammonium salt), 3,3′-diaminobenzidine, 3,4 diaminobenzoic acid, DCPIP, N,N-dimethyl-p-phenylenediamine, o-dianisidine, >-phenylenediamine, 4-chloro-l-naphthol, o-phenylenedi amine N-(4-aminobutyl)-N-ethylisoluminol, 3-amino-9-ethylcarbazole, 4-aminophthalhydrazide, 5-aminosalicylic acid, 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid), indoxyl, indigo, Fast Blue RR, 4-chloro-7-nitrobenzofurazan.
- Z is an arylamine, an amino phenol, an aminophenol ether, an indoxyl, a neutral dye, a charged dye selected from remazole brilliant blue, toluidine blue, reactive black 5, remazol brilliant blue, reactive violet 5, and reactive orange 16, or a hydrolytic or ammonolytic derivatives thereof.
- Z is a charged dye selected from remazole brilliant blue; toluidine blue; reactive black 5 or a hydrolytic or an ammonolytic derivative thereof.
- Z is a dichlorotriazine-based reactive dye such as reactive blue 4, reactive red 120, reactive blue 2, reactive green 19 and reactive brown 10. In some embodiments, the dichlorotriazine-based reactive dye appears black. In some embodiments, Z is a reactive dye containing a sulfonylethyl-hydrogensulphate-reactive-group.
- Z is a nanoparticle. In some embodiments, Z is a colloidal gold particle.
- Z is a charged dye, an indole derivative, or a luminol derivative.
- the enzyme-labile or enzyme-reactive region comprises a phenol, an amino phenol, an aminophenyl ether, an indoxyl, or a quinone. In some embodiments, the enzyme-labile or enzyme-reactive region comprises a phenol. In some embodiments, the enzyme-labile or enzyme-reactive region comprises an amino phenol. In some embodiments, the enzyme-labile or enzyme-reactive region comprises an amino phenol ether. In some embodiments, the enzyme-label or enzyme-reactive region comprises an indoxyl. In some embodiments, the enzyme-labile or enzyme-reactive region comprises a quinone. In some embodiments, the enzyme-labile or enzyme-reactive region reacts with myeloperoxidase but does not react with heme.
- the enzyme-labile or enzyme-reactive region comprises a peroxidase substrate, an arylamine, an amino phenol, a neutral dye, a charged dye, a nanoparticle, or a colloidal gold particle. In some embodiments, the enzyme-labile or enzyme-reactive region comprises a peroxidase substrate.
- the peroxidase substrate is selected from p-aminophenol, ABTS (2,2-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt), 3,3′-diaminobenzidine, 3,4 diaminobenzoic acid, DCPIP, N,N-dimethyl-p-phenylenediamine, o-dianisidine, p-phenylenediamine, 4-chloro-l-naphthol, o- phenylenediamine N-(4-aminobutyl)-N-ethylisoluminol, 3-amino-9-ethylcarbazole, 4- aminophthalhydrazide, 5-aminosalicylic acid, 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid), and 4-chloro-7-nitrobenzofurazan, Fast Blue RR, N-(2-hydroxy)
- the enzyme-labile or enzyme-reactive region comprises an arylamine. In some embodiments, the enzyme-labile or enzyme-reactive region comprises an amino phenol. In some embodiments, the enzyme-labile or enzyme-reactive region comprises a neutral dye. In some embodiments, the enzyme-labile or enzyme-reactive region comprises a charged dye. In some embodiments, the charged dye is selected from remazole brilliant blue, toluidine blue, reactive black 5, remazol brilliant blue, reactive violet 5, and reactive orange 16, or hydrolytic or ammonolytic derivatives of each of these. In some embodiments, the charged dye is remazole brilliant blue, or hydrolytic or ammonolytic derivatives thereof. In some embodiments, the charged dye is toluidine blue.
- the charged dye is reactive black 5, or hydrolytic or ammonolytic derivatives thereof. In some embodiments, the charged dye is reactive violet 5, or hydrolytic or ammonolytic derivatives thereof. In some embodiments, the charged dye is reactive orange 16, or hydrolytic or ammonolytic derivatives thereof.
- the enzyme-labile or enzyme-reactive region comprises a dichlorotriazine-based reactive dye such as reactive blue 4, reactive red 120, reactive blue 2, reactive green 19 and reactive brown 10.
- the enzyme-labile or enzyme-reactive region comprises a nanoparticle.
- Z is a colloidal gold particle.
- the enzyme-labile or enzyme-reactive region comprises a charged dye, an indole derivative, or a luminol derivative. In some embodiments, the enzyme-labile or enzyme-reactive region comprises an indole derivative. In some embodiments, the enzyme-labile or enzyme-reactive region comprises a luminol derivative.
- the indicator region comprises a dye that presents a visible color change in normal ambient lighting.
- the dye has a contrasting color to wound products, which are commonly red, yellow, or brown.
- the dye is violet, blue or dark green.
- the dye is violet.
- the dye is blue.
- the dye is dark green.
- the dye has low molecular weight, is charged, contains reactive or linkable groups, is stable to gamma irradiation, and is deeply colored.
- the dye is selected from cibracron series dyes, azo dyes, and remazol dyes, or hydrolytic or ammonolytic derivatives thereof.
- the dye is selected from cibracron series dyes. In some embodiments, the dye is selected from azo dyes. In some embodiments, the dye is selected from remazol dyes, or hydrolytic or ammonolytic derivatives thereof.
- the dye is selected from rhodamine, coumarin, cyanine, xanthene, polymethine, pyrene, dipyrromethene borondifluoride, napthalimide, a phycobiliprotein, peridinium chlorophyll proteins, fluorescein, 6-FAM, rhodamine, Texas Red, California Red, iFluor594, tetramethylrhodamine, a carboxyrhodamine, carboxyrhodamine 6F, carboxyrhodol, carboxyrhodamine 110, Cascade Blue, Cascade Yellow, coumarin, Cy2®, Cy3®, Cy3.5®, Cy5®, Cy5.5®, Cy7®, Cy-Chrome, DyLight 350, DyLight 405, DyLight 488, DyLight 549, DyLight 594, DyLight 633, DyLight 649, DyLight 680, DyLight 750, DyL
- the indicator region comprises a dichlorotriazine-based reactive dye such as reactive blue 4, reactive red 120, reactive blue 2, reactive green 19 and reactive brown 10. In some embodiments, the dichlorotriazine-based reactive dye appears black.
- the indicator region comprises the reaction product of a reactive dye containing a sulfonylethyl-hydrogensulphate-reactive-group.
- the reactive dye is reactive black 5, remazol brilliant blue, reactive violet 5 or reactive orange 16.
- the reactive dye is reactive black 5.
- the reactive dye is remazol brilliant blue.
- the reactive dye is reactive violet 5.
- the reactive dye is reactive orange 16.
- the reactive dye is reactive black 5, remazol brilliant blue, or reactive violet 5.
- the reactive dye is reactive black 5 or remazol brilliant blue.
- the indicator region comprises a particle ⁇ e.g., colloidal metal or quantum dots) that present color changes in normal ambient lighting.
- the indicator region comprises a nanoparticle.
- the indicator region comprises a colloidal gold particle.
- the indicator region comprises a dye that presents a visible color change under UV light. In some embodiments, the indicator region comprises a dye that is fluorescent. In some embodiments, the indicator region comprises a dye that is luminescent.
- the indicator region comprises an enzyme-reactive moiety.
- the enzyme-reactive moiety interacts with an accessory enzyme to produce a product that is visible to the naked eye or detectable by electronic means.
- the enzyme-reactive moiety interacts with an accessory enzyme to produce a product that is visible to the naked eye.
- the enzyme -reactive moiety interacts with an accessory enzyme to produce a product that is detectable by electronic means.
- the indicator region comprises an indoxyl glycoside that is cleaved by hexaminidase, glucuronidase, glucosidase or galactosidase depending on the terminal sugar used, to produce indigo.
- the indicator region comprises a phenol that is oxidized by an accessory enzyme to produce a visible product. In some embodiments, the indicator region comprises a phenol that is oxidized by laccase to produce a visible product. In some embodiments, the indicator region comprises a metallo motif that is detectable by electronic means. In some embodiments, the indicator region comprises a ferrocene or ferrocene analog that is detectable by electronic means.
- the accessory enzyme is selected from lipase, esterase, hexosaminidase, peroxidase, oxidase, glycosidase, glucosidase, and laccase. In some embodiments, the accessory enzyme is not present in the wound fluid. In some embodiments, the accessory enzyme is present in the wound fluid. In some embodiments, the enzyme-reactive moiety interacts with an accessory enzyme to produce a product that is visible under UV light.
- chemical entities containing the anchor A, the indicator I which individually or together comprise a plurality of enzyme recognition sites (S) and enzyme reaction group (R).
- S enzyme recognition sites
- R enzyme reaction group
- such chemical entities are employed to assay for a plurality of enzymes, e.g., a combination comprising at least one protease and at least one glycosidase.
- chemical entities containing the anchor A, the indicator I which individually or together comprise a plurality of enzyme recognition sites (S) and enzyme reaction sites (R), wherein at least one reactive site is specific for a glycosidase, e.g., lysozyme; and at least one enzyme reaction site is specific for a protease selected from the group consisting of elastase, cathepsin G, myeloperoxidase or a combination thereof.
- S enzyme recognition sites
- R enzyme reaction sites
- chemical entities containing the anchor A, the indicator I which individually or together comprise a plurality of enzyme recognition sites (S) and enzyme reaction sites (R), wherein at least one reactive site is specific for a glycosidase, e.g., lysozyme; and at least one enzyme reaction site is specific for a protease selected from the group consisting of elastase.
- S enzyme recognition sites
- R enzyme reaction sites
- chemical entities containing the anchor A, the indicator I which individually or together comprise a plurality of enzyme recognition sites (S) and enzyme reaction sites (R), wherein at least one reactive site is specific for a glycosidase, e.g., lysozyme; and at least one enzyme reaction site is specific for a protease selected from the group consisting of cathepsin G.
- S enzyme recognition sites
- R enzyme reaction sites
- chemical entities containing the anchor A, the indicator I which individually or together comprise a plurality of enzyme recognition sites (S) and enzyme reaction sites (R), wherein at least one reactive site is specific for a glycosidase, e.g., lysozyme; and at least one enzyme reaction site is specific for a protease selected from the group consisting of myeloperoxidase (MPO).
- S enzyme recognition sites
- R enzyme reaction sites
- MPO myeloperoxidase
- the diagnostic utility of chemical entities comprising a plurality of reaction and recognition sites will be greatly enhanced compared to entities comprising unitary (e.g., single type) of reaction and recognition sites.
- entities comprising a plurality of reaction/recognition sites will permit diagnosis of at least 2, at least 3, at least 4 or more markers simultaneously.
- lysosomal and protease activity at the wound situs may be detected and monitored simultaneously using the multiplex chemical entities disclosed herein.
- the anchor region (A) of the chemical entity binds the chemical entity to a support material, e.g., via covalent interaction, ionic interaction, hydrophobic interaction, electrostatic interactions, hydrogen bonding interactions, physiochemical interactions, van der Waal forces, Lewis-acid/Lewis-base interactions, or combinations thereof.
- the support matrix comprises dextran, agarose, silica, synthetic polymer, or dextran, agarose, silica, or synthetic polymer covalently coupled to an antibody, ligand, or epitope tag.
- the anchor region is a polystyrene bead, silica gel bead, polysaccharide bead, polyacrylamide bead, cellulose bead, polysaccharide, derivatized cellulose, polyacrylate, polyethyleneimine, polyacrylamide, UV-activatable reactive group, peptidoglycan, or chitosan derivative, or a combination thereof.
- the anchor region binds to a support material after a short period of UV irradiation.
- the chemical entity is printed on or in a support material such as filter paper or a woven or non-woven material that is capable of being wet by a wound fluid and which displays capillary action.
- the reporting entity or chemical entity is chemically bonded onto or into a support material such as filter paper or a woven or non-woven material that is capable of being wet by a wound fluid and which displays capillary action that is similar in all dimensions.
- the chemical entity is ionically bound onto or into a support material such as filter paper or a woven or non-woven material that is capable of being wet by a wound fluid and which displays capillary action.
- the chemical entity is covalently bound onto or into a support material such as filter paper or a woven or non-woven material that is capable of being wet by a wound fluid and which displays capillary action.
- Support material includes, but is not limited to, cellulose, polyamide, polyester, polyacrylate and other similar polymers that are useful as fibers.
- the support material is cellulose.
- the support material is polyamide.
- the support material is polyester.
- the support material is polyacrylate.
- the pH of a wound can influence many factors of wound healing, such as angiogenesis, protease activity, oxygen release, and bacterial toxicity.
- Chronic nonhealing wounds may have an elevated alkaline environment. As the wound progresses towards healing, the pH of the wound moves to neutral and then becomes acidic. Monitoring of the pH of the wound may provide a method to assess the condition of the wound (e.g., infection or no infection) and aid in determining a wound’s response to treatment.
- the chemical entity for the detection of infection in a wound comprises an indicator region comprising a pH-sensitive moiety that presents a visible color change.
- the pH-sensitive moiety is selected from the group consisting of bromothymol blue, phenol red, bromophenol red, chlorophenol red, thymol blue, bromocresol green, bromocresol purple; nitrazine yellow; and sulfophthalein dyes or a combination thereof.
- compositions are Compositions:
- Embodiments described herein further relate to compositions containing the compounds of Formula I. Such compositions may be prepared using conventional methods.
- the resulting stock composition of compounds of Formula I may be further modified into desired form, e.g., gels, balms, lotions, cream, paste, ointments, etc. using conventional methods, e.g., using carriers, gelling agents, emollients, surfactants, humectants, viscosity enhancers, emulsifiers, etc. See, e.g., WO 2013/004953.
- Carriers for use in the composition may include, but are not limited to, water, glycerin, diglycerin, glycerin derivatives, glycols, glycol derivatives, sugars, ethoxylated and/or propoxylated esters and ethers, urea, sodium PCA, alcohols, ethanol, isopropyl alcohol, and combinations thereof.
- the carrier is propylene glycol.
- the composition contains a carrier in an amount from about 1% by weight of the composition to about 99.9% by weight of the composition, more typically from about 2% by weight of the composition to about 95% by weight of the composition, and more typically from about 5% by weight of the composition to about 90% by weight of the composition.
- Thermo-reversible gelling agents are defined as ingredients that are soluble, partially soluble, or miscible in a hydrophilic carrier at elevated temperatures, such as 50° C., wherein the agents have the ability to thicken the carrier when cooled to 25° C., but will be less viscous at 50° C. when application to a substrate is necessary.
- Suitable hydrophilic carriers include water, glycols, e.g., propylene glycol.
- Thermo-reversible gelling agents for use in the composition may include salts of fatty acids such as sodium stearate, sodium palmitate, potassium stearate. These salts can be added to the composition or can be created in-situ by addition of the fatty acid and neutralizing with appropriate base.
- compositions are to provide stearic acid and sodium hydroxide to produce sodium stearate.
- Other common hermos-reversible gelling agents could include, e.g., polyethylene glycols and derivatives such as PEG-20, PEG-150 distearate, PEG-150 pentaerythrityl tetrastearate, disteareth-75 IPDI, disteareth-100 IPDI, fatty alcohols, e.g., cetyl alcohol, fatty acids such as stearic acid, hydroxystearic acid and its derivatives, and combinations thereof.
- the composition can contain various other ingredients and components.
- other ingredients that may be included within the composition are emollients, sterols or sterol derivatives, natural and synthetic fats or oils, viscosity enhancers, rheology modifiers, polyols, surfactants, alcohols, esters, silicones, clays, starch, cellulose, particulates, moisturizers, film formers, slip modifiers, surface modifiers, skin protectants, humectants, sunscreens, and the like.
- Embodiments described herein further relate to pharmaceutical compositions and/or preparations comprising one or more of the aforementioned compounds of Formula I and a carrier.
- pharmaceutically acceptable is employed herein to refer to those compounds, salts, compositions, dosage forms, etc., which are—within the scope of sound medical judgment—suitable for use in contact with the tissues of human beings and/or other mammals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- “pharmaceutically acceptable” means approved by a regulatory agency of the federal or a state government, or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals (e.g., animals), and more particularly, in humans.
- compositions may be prepared by any suitable means known in the art.
- suitable means known in the art.
- examples of such compositions include those adapted for: (a) topical application, e.g., articles (e.g., gauzes, pads, swabs, dressings), creams, ointments, gels, lotions, etc.; (b) parenteral administration, e.g., subcutaneous, intramuscular or intravenous injection as a sterile solution or suspension; (c) oral administration, external application (e.g. drenches including aqueous and non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pellets for admixture with feedstuffs, pastes for application to the tongue, etc.
- the pharmaceutical compositions may comprise one or more antibiotic agents.
- antibiotic or “antimicrobial agent” refers to a substance that inhibits the growth of or destroys microorganisms.
- the antibiotic is useful in curbing the virulence of an infectious agent and/or treating an infectious disease.
- Antibiotic also refers to semi-synthetic substances wherein a natural form produced by a microorganism, e.g., yeast or fungus is structurally modified.
- the antibiotic is selected from the group consisting of ⁇ -lactams (including, ⁇ -lactamase inhibitors and cephalosporins), fluoroquinolones, aminoglycosides, tetracyclines and/or glycylcyclines and/or polymyxins.
- ⁇ -lactams including, ⁇ -lactamase inhibitors and cephalosporins
- fluoroquinolones aminoglycosides
- tetracyclines and/or glycylcyclines and/or polymyxins Any combination of antimicrobial agents may also be employed, e.g., at least one ⁇ -lactam and at least one fluoroquinolone; at least one aminoglycoside and one cephalosporin; at least one ⁇ -lactam and one ⁇ -lactamase inhibitor, optionally together with an aminoglycoside, etc.
- ⁇ -lactam includes natural and semi-synthetic penicillins and penicillin derivatives, e.g., benzathine penicillin, benzylpenicillin (penicillin G), phenoxymethylpenicillin (penicillin V), procaine penicillin and oxacillin; methicillin, dicloxacillin and flucloxacillin; temocillin; amoxicillin and ampicillin; azlocillin, carbenicillin, ticarcillin, mezlocillin and piperacillin; biapenem, doripenem, ertapenem, imipenem, meropenem, panipenem and PZ-601 ; cephalexin, cephalothin, cefazolin, cefaclor, cefuroxime, cefamandole, cefotetan, cefoxitin, cefotaxime, and cefpodoxime; cefepime and cefpirome; cefadrox
- Fluoroquinolones include, ciprofloxacin, garenoxacin, gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
- Aminoglycosides include, for e.g., kanamycin, amikacin, tobramycin, dibekacin, gentamicin, sisomicin, netilmicin, neomycin B, neomycin C, neomycin E (paromomycin) and streptomycin, including, synthetic derivatives clarithromycin and azithromycin.
- Tetracyclines include naturally-occurring compounds (e.g., tetracycline, chlortetracycline, oxytetracycline, demeclocycline) or semisynthetic agents (e.g., lymecycline, meclocycline, methacycline, minocycline, roli tetracycline).
- Glycylcyclines e.g., minocycline/tigecycline
- Polymyxins include, e.g., polymyxin B and polymyxin E (colistin).
- the compositions may contain an antibiotic at a concentration of 0.1 mg/mL, 0.5 mg/L, 1 mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, 10 mg/mL, 11 mg/mL, 12 mg/mL, 13 mg/mL, 14 mg/mL, 15 mg/mL, 16 mg/mL, 17 mg mL, 18 mg/mL, 19 mg/mL, 20 mg/mL, 21 mg/mL, 22 mg/mL, 23 mg/mL, 24 mg/mL, 25 mg mL, 26 mg mL, 27 mg/mL, 28 mg/mL, 29 mg/mL, 30 mg/mL, 31 mg/mL, 32 mg/mL, 33 mg/mL, 34 mg mL, 35 mg/mL, 36 mg/mL, 37 mg/mL, 38 mg/mL, 10
- wound dressings comprising wound dressing materials as described herein, e.g., compounds of Formula I.
- the wound dressings consist essentially of the wound dressing materials as described herein, e.g., a compound of Formula I.
- wound dressing disclosed herein are biocompatible, biodegradable, non-immunogenic and readily commercially available.
- the compounds of Formula I are provided in the form of particles, such as fiber particles or powder particles, optionally containing a medicament.
- the materials preferably contain CMC fibers.
- compositions may preferably comprise an intimate mixture of the dressing material and other compounds.
- the intimate mixture comprises a mixed solution or dispersion of the dressing material and a suitable vehicle, such as a solvent, or a solid composition produced by removing solvent from such a solution or dispersion.
- the dressing material makes up at least 5%, more preferably at least 10%, 20%, 30%, 50%, 75%, 90% or greater % by weight of the material.
- the material consists essentially of the dressing material.
- Other components of the material may include 0-25% by weight, for example from about 1 to about 20% by weight, of one or more other biocompatible polysaccharides, for example alginates such as sodium alginate or calcium alginate, starch derivatives such as sodium starch glycolate, cellulose derivatives such as methyl cellulose or carboxymethyl cellulose, or glycosaminoglycans such as hyaluronic acid or its salts, chondroitin sulfate or heparan sulfate.
- the materials may also comprise up to about 25% by weight, for example from about 1 to about 20%) by weight, of one or more structural proteins selected from the group consisting of fibronectin, fibrin, laminin, elastin, collagen and mixtures thereof.
- the protein comprises collagen, and more preferably it consists essentially of collagen.
- the materials may also comprise up to about 20% by weight, preferably from about 2% to about 10% by weight of water.
- the materials may also contain 0-40% by weight, for example from about 5 to about 25% by weight, of a plasticizer, preferably a polyhydric alcohol such as glycerol or sorbitol.
- the materials may also comprise up to about 10% by weight, for example from about 0.01 to about 5% by weight, typically from about 0.1 to about 2% by weight of one or more therapeutic wound healing agents, such as non-steroidal anti-inflammatory drugs (e.g., acetaminophen), steroids, local anesthetics, antimicrobial agents, or growth factors (e.g., fibroblast growth factor or platelet derived growth factor).
- therapeutic wound healing agents such as non-steroidal anti-inflammatory drugs (e.g., acetaminophen), steroids, local anesthetics, antimicrobial agents, or growth factors (e.g., fibroblast growth factor or platelet derived growth factor).
- the antimicrobial agent may, for example, comprise an antiseptic, an antibiotic, or mixtures thereof.
- Preferred antibiotics include tetracycline, penicillins, terramycins, erythromycin, bacitracin, neomycin, polymycin B, mupirocin, clindamycin and mixtures thereof.
- Preferred antiseptics include silver, including colloidal silver, silver salts including salts of one or more of the anionic polymers making up the material, silver sulfadiazine, chlorhexidine, povidone iodine, triclosan, sucralfate, quaternary ammonium salts and mixtures thereof.
- the weight ratio of the wound dressing material to other auxiliary agents and materials is from about 1 :99 to about 99: 1. More preferably, the weight ratio is in the range about 1 :9 to about 9: 1, more preferably it is in the range about 4: 1 to about 1 :4, still more preferably in the range about 2: 1 to about 1 :2.
- the material may be in any convenient form, such as a powder, microspheres, flakes, a mat or a film.
- the material is in the form of a semisolid or gel ointment for topical application.
- the material is in the form of a freeze-dried or solvent-dried bioabsorbable sponge for application to a chronic wound.
- the average pore size of the sponge is in the region of 10-500 ⁇ m, more preferably about 100-300 ⁇ m.
- a suitable sponge has been made by freeze-drying or solvent drying an aqueous dispersion comprising compounds of Formula I, together with suitable therapeutic agents.
- the material is in the form of a flexible film, which may be continuous or interrupted (e.g. perforated).
- the flexible film preferably comprises a plasticizer to render it flexible, such as glycerol.
- both gel forming polymers e.g., cellulose derivatives
- having a range of controllable properties means that the properties of the compositions the disclosed technology can be controlled to an exceptional degree.
- the rate of biological absorption, porosity and density of the materials can be controlled.
- wound dressing materials in sheet form comprising an active layer of a composition comprising compounds of Formula I.
- the active layer would normally be the wound contacting layer in use, but in some embodiments it could be separated from the wound by a liquid-permeable top sheet.
- the area of the active layer is from about 1 cm 2 to about 400 cm 2 , particularly from about 4 cm 2 to about 100 cm 2 .
- the wound dressing material further comprises a backing sheet extending over the active layer opposite to the wound facing side of the active layer.
- the backing sheet is larger than the active layer such that a marginal region of width 1 mm to 50 mm, preferably 5 mm to 20 mm extends around the active layer to form a so-called island dressing.
- the backing sheet is preferably coated with a pressure sensitive medical grade adhesive in at least its marginal region.
- the back sheet is substantially liquid-impermeable.
- the backing sheet is semipermeable, e.g., the backing sheet is preferably permeable to water vapor, but not permeable to liquid water or wound exudate.
- the backing sheet is also microorganism-impermeable.
- Suitable continuous conformable backing sheets will preferably have a moisture vapor transmission rate (MVTR) of the backing sheet alone of 300 to 5000 g/m 2 /24 hrs, preferably 500 to 2000 g/m 2 /24 hrs at 37.5° C. at 100% to 10% relative humidity difference.
- the backing sheet thickness is preferably in the range of 10 to 1000 micrometers, more preferably 100 to 500 micrometers.
- Suitable polymers for forming the backing sheet include polyurethanes and poly alkoxyalkyl acrylates and methacrylates.
- the backing sheet comprises a continuous layer of a high density blocked polyurethane foam that is predominantly closed-cell.
- a suitable backing sheet material is a polyurethane film.
- the adhesive layer should be moisture vapor transmitting and/or patterned to allow passage of water vapor.
- the adhesive layer is preferably a continuous moisture vapor transmitting, pressure-sensitive adhesive layer of the type conventionally used for island-type wound dressings, for example, a pressure sensitive adhesive based on acrylate ester copolymers, polyvinyl ethyl ether and polyurethane. Polyurethane-based pressure sensitive adhesives may be selectively used.
- the dressing may comprise further layers of a multilayer absorbent article may be built up between the active layer and the protective sheet.
- these layers may comprise an apertured plastic film to provide support for the active layer in use, in which case the apertures in the film are preferably aligned in register with the apertures in the hydrogel layer.
- the dressing may comprise an absorbent layer between the active layer and the protective sheet, especially if the dressing is for use on exuding wounds.
- the optional absorbent layer may be any of the layers conventionally used for absorbing wound fluids, serum or blood in the wound healing art, including gauzes, nonwoven fabrics, superabsorbents, hydrogels and mixtures thereof.
- the absorbent layer comprises a layer of absorbent foam, such as an open celled hydrophilic polyurethane foam.
- the absorbent layer may be a nonwoven fibrous web, for example a carded web of viscose staple fibers.
- the wound dressing may be protected by a removable cover sheet.
- the cover sheet is normally formed from flexible thermoplastic material. Suitable materials include polyesters and polyolefins.
- the adhesive-facing surface of the cover sheet is a release surface. That is to say, a surface that is only weakly adherent to the active layer and the adhesive on the backing sheet to assist peeling of the hydrogel layer from the cover sheet.
- the cover sheet may be formed from a non-adherent plastic such as a fluoropolymer, or it may be provided with a release coating such as a silicone or fluoropolymer release coating.
- the wound dressing is sterile and packaged in a microorganism-impermeable container.
- kits comprising, in one or separate compartments, the compounds of Formula I, optionally together with an excipient, carrier or oil.
- the kits may further comprise additional ingredients, e.g., gelling agents, emollients, surfactants, humectants, viscosity enhancers, emulsifiers, etc., in one or more compartments.
- additional ingredients e.g., gelling agents, emollients, surfactants, humectants, viscosity enhancers, emulsifiers, etc.
- the kits may optionally comprise instructions for formulating an article for diagnosing, detecting or treating wounds, e.g., chronic or infected wounds.
- the kits may also comprise instructions for using the components, either individually or together, in the treatment of wounds.
- kits comprising a package and at least one absorbent article (described above) comprising the aforementioned compositions.
- the kits may comprise the individual components separately, optionally together with secondary information, useable in or with the package.
- the wound is a chronic wound, for example a wound selected from the group consisting of venous ulcers, decubitis ulcers and diabetic ulcers.
- Embodiments of the disclosed technology further provide for surfaces comprising the aforementioned compounds of Formula I, wherein the reporter or peptide is oriented to permit binding to a partner, e.g., an enzyme.
- a partner e.g., an enzyme.
- the surface is a surface of a solid support. Numerous and varied solid supports are known to those in the art.
- Useful solid supports include natural polymeric carbohydrates and their synthetically modified, cross-linked or substituted derivatives, such as agar, agarose, cross-linked alginic acid, substituted and cross-linked guar gums, cellulose esters, especially with nitric acid and carboxylic acids, mixed cellulose esters, and cellulose ethers; natural polymers containing nitrogen, such as proteins and derivatives, including cross-linked or modified gelatins; natural hydrocarbon polymers, such as latex and rubber; synthetic polymers which may be prepared with suitably porous structures, such as vinyl polymers, including polyethylene, polypropylene, polystyrene, polyvinylchloride, polyvinylacetate and its partially hydrolyzed derivatives, polyacrylamides, polymethacrylates, copolymers and terpolymers of the above polycondensates, such as polyesters, polyamides, and other polymers, such as polyurethanes or polyepoxides; porous inorganic materials such as sulfates
- the support is a well of an array plate, e.g., a microarray.
- array plate e.g., a microarray.
- Methods for constructing such arrays are known in the art, e.g., Cao et al., Appl Environ Microbiol , 77(23): 8219-8225, 201 1.
- Each compound of Formula I (or the peptide indicators alone) may be spotted in triplicate to eliminate irregular data due to physical defects in the array.
- Embodiments of the disclosed technology further provide for diagnostic systems comprising the aforementioned compositions and/or kits.
- the various components of the diagnostic systems may be provided in a variety of forms.
- the compounds of Formula I e.g., compounds containing peptide reporters
- these lyophilized reagents may be pre-mixed before lyophilization so that when reconstituted they form a complete mixture with the proper ratio of each of the components ready for use in the assay.
- the diagnostic systems of the disclosed technology may contain a reconstitution reagent for reconstituting the lyophilized reagents of the kit.
- nucleic acids encoding the following peptides:
- nucleic acids encoding the polypeptide sequences for ElaSubl CBM, CatGSubl CBM, ElaSubl CBM His, CatGSubl CBM His, ElaSub2_CBM, CatGSub2_CBM, ElaSub2_CBM His, CatGSub2_CBM His, ElaSubl PDM, CatGSubl_PDM, ElaSubl PDM His, CatGSubl PDM His, ElaSub2_PDM, CatGSub2 _PDM, ElaSub2_PDM His, CatGSub2_PDM or an enzyme-cleavable fragment thereof and/or an immunogenic fragment thereof.
- nucleic acids encoding the polypeptide sequences set forth in Table 4 (for ElaSubl CBM, CatGSubl CBM, ElaSubl CBM His, CatGSubl CBM His, ElaSub2_CBM, CatGSub2_CBM, ElaSub2_CBM _His, CatGSub2_CBM_His) or an enzyme-cleavable fragment thereof and/or an immunogenic fragment thereof.
- nucleic acid or “nucleic acid sequence,” as used herein, refer to an oligonucleotide, nucleotide, polynucleotide, or any fragment thereof, to DNA or RNA of genomic or synthetic origin which may be single- stranded or double- stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.
- fragments refers to those nucleic acid sequences which are greater than about 10 nucleotides in length, and most preferably are at least about 40 nucleotides, at least about 100 nucleotides, or at least about 300 nucleotides in length.
- Embodiments disclosed herein further relate to variants of the aforementioned polynucleotides.
- nucleic acids which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%, or greater % identity to, for example, the nucleic acids encoding the following peptides: X y AAPX y -Z , X y AAPX y -L-Z , X y AAP(V/F/A)X y -Z or X y AAP(V/F/A)X L-Z ; X N 4 N 3 N 2 Z 1 -Z or X N 4 N 3 N 2 Z 1 -L-Z , wherein X, N1, N2, N3, N4, L and Z are each, as described above.
- nucleic acids which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%, or greater % identity to, for example, the nucleotide coding sequence in ElaSubl CBM, CatGSub 1 CBM, ElaSubl CBM His, CatGSubl CBM His, ElaSub2_CBM, CatGSub2_CBM, ElaSub2_CBM His, CatGSub2_CBM His, ElaSub 1_PDM, CatGSub 1 PDM, ElaSubl PDM His, CatGSub 1 PDM His, ElaSub2 _PDM, CatGSub2 _PDM, ElaSub2_PDM His, CatGSub2_PDM His, or the complementary strand thereto, or the RNA equivalent thereof, or a complementary RNA equivalent thereof.
- nucleotide sequence variants of aforementioned nucleic acids which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%, or greater % identity to, for example, the nucleotide encoding the polypeptide sequences set forth in Table 4 (for ElaSub 1 CBM, CatGSubl CBM, ElaSub 1 CBM His, CatGSubl CBM His, ElaSub2_CBM, CatGSub2_CBM, ElaSub2_CBM_His, CatGSub2_CBM _His) , or the complementary strand thereto, or the RNA equivalent thereof, or a complementary RNA equivalent thereof.
- Three-to-One Sequence Manipulation Suite which generates three potential nucleic acid sequences for each inputted polypeptide sequence
- the Three-to-One software is available freely from bioinformatics(dot)org.
- Percent identity refers to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MEGALIGN program (LASERGENE software package, DNASTAR).
- the MEGALIGN program can create alignments between two or more sequences according to different methods, e.g., the Clustal Method. (Higgins, D. G. and P. M. Sharp (1988) Gene 73 :237-244.)
- the Clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups.
- the percentage similarity between two amino acid sequences is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of low or of no homology between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be calculated by the Clustal Method, or by other methods known in the art, such as the Jotun Hein Method. (See, e.g., Hein, J. (1990) Mehtods Enzymol. 183:626-645.) Identity between sequences can also be determined by other methods known in the art, e.g., by varying hybridization conditions.
- hybridization refers to any process by which a strand of nucleic acid bonds with a complementary strand through base pairing.
- hybridization under high stringency conditions could occur in about 50% formamide at about 37° C. to 42° C.
- Hybridization could occur under reduced stringency conditions in about 35% to 25% formamide at about 30° C. to 35° C.
- hybridization could occur under high stringency conditions at 42° C.
- Hybridization could occur under reduced stringency conditions as described above, but in 35% formamide at a reduced temperature of 35° C.
- the temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions are well known in the art.
- hybridization complex refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases.
- a hybridization complex may be formed in solution or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).
- variants which are polynucleotide fragments of the aforementioned nucleic acids.
- oligonucleotides e.g., PCR primers, which hybridize to one or more nucleic acids.
- oligonucleotide refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or microarray.
- the term “oligonucleotide” is substantially equivalent to the terms “amplimers,” “primers,” “oligomers,” and “probes,” as these terms are commonly defined in the art.
- PNA protein nucleic acid
- PNA protein nucleic acid
- PNA refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition.
- PNAs preferentially bind complementary single stranded DNA and RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell. (See, e.g., Nielsen, P. E. et al. (1993) Anticancer Drug Des. 8:53-63.)
- the vector comprises at least one protein encoding nucleic acid, e.g., nucleic acids encoding the polypeptide sequences for ElaSubl_CBM [SEQ ID NO: 20], CatGSub 1_CBM [SEQ ID NO: 201, ElaSubl _CBM His [SEQ ID NO: 211, CatGSubl __CBM His [SEQ ID NO: 221, ElaSub2_CBM [SEQ ID NO: 231, CatGSub2___CBM [SEQ ID NO: 241, ElaSub2_CBM His [SEQ ID NO: 251, CatGSub2__CBM His [SEQ ID NO: 261, ElaSubl _PDM, CatGSub 1_PDM, ElaSubl _PDM _His, CatGSubl PDM His, ElaSub2 _PDM, CatGSub2 _PDM, ElaSub2_PDM, ElaSub2_PDM
- operably associated or “operably linked,” as used herein, refer to functionally related nucleic acid sequences.
- a promoter is operably associated or operably linked with a coding sequence if the promoter controls the transcription of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be contiguous and in reading frame, certain genetic elements, e.g., repressor genes, are not contiguously linked to the encoded polypeptide but still bind to operator sequences that control expression of the polypeptide.
- Codon optimization for expression in a host cell e.g., bacteria such as E. coli or insect Hi5 cells
- Codon Optimization Tool may be routinely performed using Codon Optimization Tool (CodonOpt), available freely from Integrated DNA Technologies, Inc., Coralville, Iowa.
- the host cell is capable of recombinantly expressing the gene sequence contained in the vector under standard culture conditions to generate the polypeptide product, e.g., polypeptide sequences for ElaSub 1 CBM, CatGSubl CBM, ElaSub 1 CBM His, CatGSub 1 CBM His, ElaSub2_CBM, CatGSub2_CBM, ElaSub2_CBM His, CatGSub2_CBM His, ElaSub 1_PDM, CatGSub 1_PDM, ElaSub 1 PDM His, CatGSubl PDM His, ElaSub2_PDM, CatGSub2_PDM, ElaSub2_PDM His, CatGSub2_PDM or an enzyme-cleavable fragment thereof and/or an immunogenic fragment thereof.
- the host cell is E. coli .
- polypeptides comprising the following amino acid sequences: X y AAPX y -Z , X y AAPX y -L-Z , X y AAP(V/F/A)X y -Z or X y AAP(V F/A)X y -L-Z ; X y N 4 N 3 N 2 N 1 X y -Z or X y N 4 N 3 N 2 N 1 X y -L-Z , wherein X, N1, N2, N3, N4, L and Z are each, as described above.
- polypeptide sequences set forth in Table 4 for ElaSubl CBM [SEQ ID NO: 111, CatGSub 1 CBM [SEQ ID NO: 121, ElaSub l_CBM_His [SEQ ID NO: 131, CatGSub l CBM His [SEQ ID NO: 14], ElaSub2_CBM [SEQ ID NO: 151] CatGSub2_CBM [SEQ ID NO: 161, ElaSub2_CBM His [SEQ ID NO: 171, CatGSub2_CBM_His [SEQ ID NO: 181] or an enzyme- cleavable fragment thereof and/or an immunogenic fragment thereof.
- variants of aforementioned polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%, or greater % identity to, for example, the following polypeptide sequences: X y AAPX y -Z , X y AAPX y -L-Z , X y AAP(V/F/A)X y -Z or X y AAP(V F/A)X y -L-Z ; X y N 4 N 3 N 2 N 1 X y -Z or X y N 4 N 3 N 2 N 1 X y -L-Z , wherein X, N1, N2, N3, N4, L and Z are each, as described above.
- variant polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%o, 99%, or greater % identity to, for example, the polypeptide sequences for ElaSub 1 CBM, CatGSub 1 CBM, ElaSub 1 CBM His, CatGSub 1 CBM His, ElaSub2 CBM, CatGSub2_CBM, ElaSub2_CBM His, CatGSub2_CBM His, ElaSub 1 PDM, CatGSub 1 PDM, ElaSub 1 PDM His, CatGSub 1 PDM His, ElaSub2 _PDM, CatGSub2 _PDM, ElaSub2 _PDM His, CatGSub2_PDM or an enzyme-cleavable fragment thereof.
- the fragment comprises a minimal structural motif for the enzyme recognition site (S) or enzyme-reactive site (R) for the hydrolase enzymes described herein, e.g., lysozyme, elastase, cathepsin G, MAO, or a combination thereof.
- the fragment peptides are immunogenic molecules that can be recognized by antibodies or antigen-binding domains thereof.
- homologs to the aforementioned peptides and polynucleotides.
- a partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as “substantially homologous.” The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency.
- a substantially homologous sequence or hybridization probe will compete for and inhibit the binding of a completely homologous sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that nonspecific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i .e., a selective) interaction.
- the absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% homology or identity). In the absence of nonspecific binding, the substantially homologous sequence or probe will not hybridize to the second non-complementary target sequence.
- variant peptides comprising a mutation in the core polypeptide sequence for ElaSub 1 CBM, CatGSub 1 CBM, ElaSubl CBM His, CatGSub 1_CBM His, ElaSub2_CBM, CatGSub2_CBM, ElaSub2_CBM His, CatGSub2_CBM His, ElaSub 1 PDM, CatGSub 1 PDM, ElaSubl PDM His, CatGSub1 PDM His, ElaSub2 PDM, CatGSub2 PDM, ElaSub2 PDM His, CatGSub2 PDM or an enzyme-cleavable fragment thereof.
- the mutation is a substitution, deletion, addition of 1-3 amino acids.
- the mutation does not change the enzyme recognition sites in the mutant peptides so formed. If the mutation results in a change in the composition of the recognition site or cleavage site, then it is contemplated that the mutation is due to a conserved amino acid substitution,
- substitution refers to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.
- substitution refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.
- Embodiments disclosed herein further include antibodies which bind specifically to one or more of the aforementioned immunogenic peptides.
- the antibodies bind to polypeptides comprising the following amino acid sequences: X y AAPX y -Z , X y AAPX y -L-Z , X y AAP(V/F/A)X y -Z or X y AAP(V F/A)X y -L-Z ; X y N 4 N 3 N 2 N 1 X y -Z or X y N 4 N 3 N 2 N 1 X y -L-Z , wherein X, N1, N2, N3, N4, L and Z are each, as described above.
- the antibodies bind to fragment of these polypeptides.
- Antigen-binding fragments of such antibodies e.g., F(ab) domain, F(ab) 2 domains, scFv domains, including synthetically generated antibodies (using, e.g., phase display technology).
- the antibodies bind to polypeptide sequences for ElaSub1_CBM, CatGSub1_CBM, ElaSub1_CBM His, CatGSub1_CBM His, ElaSub2_CBM, CatGSub2_CBM, ElaSub2_CBM His, CatGSub2_CBM His, ElaSub1_PDM, CatGSub1_PDM, ElaSub1_PDM His, CatGSub1_PDM His, ElaSub2_PDM, CatGSub2_PDM, ElaSub2_PDM His, CatGSub2_PDM or an enzyme-cleavable fragment thereof and/or an immunogenic fragment thereof.
- Antigen-binding fragments of such antibodies e.g., F(ab) domain, F(ab) 2 domains, scFv domains, including synthetically generated antibodies (using, e.g., phase display technology).
- nucleic acids e.g., nucleic acids, proteins, peptides, and/or antibody molecules, including, conjugates thereof.
- substantially purified refers to nucleic acids, amino acids or antibodies that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.
- the biomolecules may be altered by combining with various components of the chemical entities, e.g., anchor region and/or indicator region, such that their form and/or functionality is significantly changed compared to any natural counterparts.
- Embodiments provided herein further relate to methods of making compounds of Formula I, including precursors thereof.
- precursor includes any compound which is employed as a reactant to generate an intermediary or a final product.
- a method of making a compound of Formula I comprising the structure A-I, wherein, A is an anchor as described above and I is an indicator as described above, comprising, conjugating the anchor with the indicator molecule, e.g., via covalent bond.
- the anchor or the indicator may comprise a recognition site (S) or a reaction/labile site (R) for a wound-specific marker, e.g., a wound-specific enzyme such as a hydrolase, and more specifically a protease or glycosidase, as described before.
- the substrate for the wound-specific marker comprises, for example, a hydrolysable substrate, e.g., an amino acid, a sugar, a peptide, a polysaccharide, a nucleic acid, a lipid, or a combination thereof.
- a hydrolysable substrate e.g., an amino acid, a sugar, a peptide, a polysaccharide, a nucleic acid, a lipid, or a combination thereof.
- the anchor is conjugated to the reporter molecule via a peptide linkage, a glycosidic linkage, an amide linkage, an ester linkage, an ether linkage, an anhydride linkage or a similar linkage.
- a “peptide bond” is formed by the condensation reaction between two amino acids, wherein the acid moiety of one reacts with the amino moiety of the other to produce a peptide bond (—CO—NH—) between the two amino acids.
- the peptide bond is cleaved with a wound-specific protease, e.g., elastase, cathepsin G or MAO, or a combination thereof.
- a “glycosidic bond” is formed between the hemiacetal or hemiketal group of a saccharide (or a molecule derived from a saccharide) and the hydroxyl group of some compound such as an alcohol.
- the peptide bond is cleaved with a wound-specific glycosidase, e.g., lysozyme.
- a method of making a compound of Formula I comprising the structure A-I, wherein, A and I are each, as described previously.
- the A is conjugated to the I via a glycosidic linkage.
- the A is conjugated to the I via a hydrophilic or hydrophobic linkage.
- the compound of Formula I having the structure A-I is synthesized by first conjugating the anchor region A with the indicator region I to generate the compound of Formula I.
- the indicator is first synthesized via genetic recombinant technology, e.g., expressing a nucleic acid encoding the indicator region in a suitable host cell, and combining the indicator with the anchor region.
- the indicator region is designed to contain nucleic acid sequences which bind to the anchor region, e.g., hydrophilically or hydrophobically.
- hydrophilic interaction comprises use of an anchor containing polar groups, e.g., partially deacetylated (e.g., DA of ⁇ 30%) chitosan, cellulose or carboxym ethyl cellulose (or a derivative thereof), which interacts with a hydrophilic carbohydrate binding module (CBM) from Cellobiohydrolase I ⁇ Trichoderma reesei).
- an anchor containing polar groups e.g., partially deacetylated (e.g., DA of ⁇ 30%) chitosan, cellulose or carboxym ethyl cellulose (or a derivative thereof)
- CBM hydrophilic carbohydrate binding module
- hydrophobic interaction comprises use of an anchor containing non-polar groups, e.g., polyethylene terephthalate (or a derivative thereof), which interacts with a or the hydrophobic binding module from Alcaligenes faecalis Polyhydroxyalkanoate depolym erase (PDB).
- an anchor containing non-polar groups e.g., polyethylene terephthalate (or a derivative thereof)
- PDB Polyhydroxyalkanoate depolym erase
- peptide indicators e.g., polypeptides comprising the following amino acid sequences: X y AAPX y -Z , X y AAPX y -L-Z , X y AAP(V/F/A)X y -Z or X y AAP(V/F/A)X y -L-Z ; X y N 4 N 3 N 2 N 1 X y -Z or X y N 4 N 3 N 2 N 1 X y -L-Z , wherein X, N1, N2, N3, N4, Land Z are each, as described above, (including variant polypeptides) may be synthesized via host-cell expression systems.
- Such a method may comprise, for example, generating a construct encoding one or more of the aforementioned polypeptides or variants, placing said construct in a suitable vector, e.g., plasmid vector or baculovirus vector, transfecting a host cell, e.g., E coli or insect Hi5 cells, with the vector; culturing the host cells under suitable conditions to allow expression of said vector; and optionally purifying the expressed polypeptide from the culture.
- a suitable vector e.g., plasmid vector or baculovirus vector
- peptide indicators e.g., polypeptides comprising the following amino acid sequences: X y AAPX y -Z , X y AAPX y -L-Z , X y AAP(V/F/A)X y -Z or X y AAP(V/F/A)X y -L-Z ; X y N 4 N 3 N 2 N 1 X y -Z or X y N 4 N 3 N 2 N 1 X y -L-Z , wherein X, N1, N2, N3, N4, Land Z are each, as described above (including variant polypeptides) may be synthesized using solid-phase peptide synthesis (see, Merrifield et al., J. Am. Chem. Soc. 85 (14): 2149-2154).
- the compound of Formula I having the structure A-I may be synthesized in a single reaction chamber or multiple reaction chambers.
- the compositions, dressing materials, articles, kits and systems described herein are useful in diagnosing or treating wounds, particularly chronic or infected wounds.
- any type of wound may be diagnosed and/or treated, the embodiments are particularly suitable for diagnosing and treating wounds that exude wound fluid.
- the wound may be a chronic or acute wound.
- Representative examples of chronic wounds include, e.g., venous ulcers, pressure sores, decubitis ulcers, diabetic ulcers and chronic ulcers of unknown aetiology.
- Representative examples of acute wounds include, e.g., acute traumatic laceration, perhaps resulting from an intentional operative incision.
- a wound fluid refers to any wound exudate or other fluid (suitably substantially not including blood) that is present at the surface of the wound, or that is removed from the wound surface by aspiration, absorption or washing.
- the determining, measuring or quantifying is suitably carried out on wound fluid that has been removed from the body of the patient, but can also be performed on wound fluid in situ.
- wound fluid does not normally refer to blood or tissue plasma remote from the wound site.
- the wound fluid is mammalian wound fluid, suitably human wound fluid.
- the diagnostic method comprises contacting a wound with at least one composition comprising a compound of Formula I or Formula II, a dressing material comprising such compounds, article comprising such materials or compounds, kits comprising such materials or compounds, or a system comprising such materials or compounds described herein; and measuring a parameter associated with the wound.
- the parameter being measured is a level or activity of a wound-specific hydrolase.
- the parameter being measured is the activity of the hydrolase.
- the measurement may either be made in situ or ex situ.
- in situ refers to processes, events, objects, or components that are present or take place within the context of the system or device, including, the surrounding environment, for example, the biological material with which the composition, article, system or device is in contact with.
- an in situ reaction may refer to the reaction of the various components present in the device (e.g., compound of Formula I or Formula II), including, components provided by the human skin tissue (e.g., wound exudate containing the enzyme).
- ex situ refers to outside of the environment.
- the measurement is performed ex situ, e.g., removing the fluid from the wound for analysis in the apparatus or device of the disclosed technology.
- the measurement is made in situ.
- the method comprising determining a level of a reporter, e.g., a product of a substrate acted upon by a wound-specific enzyme. More specifically, the method comprises determining a level of a hydrolase enzyme product.
- determining includes measuring a numerical value of the activity or level of said hydrolase; establishing if the activity or level falls above or below a predetermined range; and/or comparing the numerical value of activity or level with a control standard.
- the control standard may comprise determining a level or activity of the hydrolase in a biopsy material obtained from an unwounded site or from a healthy subject.
- the term “determining” comprises measuring the parameter (e.g., activity or level) of at least one wound specific protease is selected from the group consisting of MMP-1 (collagenase), MMP-2 (gelatinase A), MMP-3 (stomelysin 1), MMP-8 (neutrophil collagenase), MMP-9 (gelatinase B), human neutrophil elastase (HNE), cathepsin G, urokinase-type plasminogen activator (uPA), and lysozyme, or a combination thereof; establishing if said parameter exceeds a first predetermined threshold; and/or comparing the numerical value of parameter with a control standard.
- MMP-1 collagenase
- MMP-2 gelatinase A
- MMP-3 stomelysin 1
- MMP-8 neutral collagenase
- MMP-9 gelatinase B
- HNE human neutrophil elastase
- cathepsin G cathe
- the control standard may comprise determining a parameter of the protease in a biopsy material obtained from an unwounded site or from a healthy subject.
- the term “determining” comprises establishing whether a weighted average (weighted sum) of the parameters associated with a plurality of the aforementioned proteases exceeds a predetermined threshold value for said weighted average.
- the parameter is activity level of the analyte (e.g. a protease) in a wound fluid.
- the activity of an individual analyte is expressed in terms units/mL.
- the parameter is the level of the analyte (e.g., protease) in a wound fluid.
- the term amount is also indicative of the activity of a particular analyte.
- the term “combined amount” or “combined activity” refers to a single numerical value that results from the application of a mathematical function to a plurality of values, for example those amounts obtained for a number of individual analytes.
- the term “combined amount” or “combined activity” may refer to the sum or product of a group of individual values.
- the term “combined amount” or “combined activity” relates to the sum of a group of individual values.
- the amount of elastase refers to elastase-like activity (e.g., U/mL) and the amount of metalloproteinase (MMP) refers to total concentration of the respective analyte (e.g., in ng/mL).
- MMP metalloproteinase
- the term “quantifying” refers to measuring an absolute numerical quantity of a particular analyte(s) or substrate(s) in a sample, within the margins of experimental error.
- markers refers to any chemical entity that is identified or determined using the apparatus, devices, kits or methods defined herein.
- the markers or analytes determined or identified by the apparatus, devices, kits or methods of the disclosed technology are cleaved products of the aforementioned enzymes.
- the term “predetermined range” refers to a data range or profile that the skilled person would understand is indicative of a particular sub-class of patient.
- the predetermined range may be a data range or profile that is typical of a wound that would respond well to a particular wound treatment, such as antibiotic therapy.
- the predetermined range may suitably refer to a data range that is typical of a wound that would not respond well to a particular wound treatment, such as antibiotic therapy.
- the term “predetermined threshold” refers to a minimum level that the skilled person would determine is indicative of a non-healing wound based on statistical analysis of levels determined for known healing and non-healing wounds, for example as explained further above.
- the threshold should be set at an appropriate level so that non-healing wounds with high protease activity are correctly identified. Increasing the threshold will increase the chance of only non-healing wounds being over the threshold. However, if the threshold is too high, wounds that are non-healing due to a high level of proteases would not be identified and clinically this would mean they would not receive the required protease modulating treatment.
- control standard refers to a data set or profile that can be used as a reference or comparison in order to define or normalize another data point or set of data.
- control or “control standard” may be data set or profile that is indicative of a particular sub-class of patient.
- control standard may be a data set or profile indicative of healing or non-healing wound status.
- control or “control standard” can be a data set or profile that can be used as a comparative tool to allow a skilled person to determine whether a wound is likely to be responsive or non-responsive to a wound treatment, such as antibiotic therapy.
- control standard is a data set or profile indicative of a patient that does not respond well to wound treatment.
- control standard is a data set or profile indicative of a patient that responds well to wound treatment.
- Patients that tend to respond well to wound treatment as disclosed herein exhibit lower combined amount or activity of hydrolases than patients that tend not to respond well to the treatment. For example, patients that tend to respond well to wound treatment as disclosed herein exhibit lower combined amounts of at least one wound-specific hydrolase.
- the threshold human neutrophil elastase activity is about 5 U/mL to about 30 U/mL, including all values in between, e.g., about 6 U/mL, about 7 U/mL, about 8 U/mL, about 9 U/mL, about 10 U/mL, about 11 U/mL, about 12 U/mL, about 13 U/mL, about 14 U/mL, about 15 U/mL, about 16 U/mL, about 17 U/mL, about 18 U/mL, about 19 U/mL, about 20 U/mL, about 21 U/mL, about 22 U/mL, about 23 U/mL, about 24 U/mL, about 25 U/mL, or more, indicate chronic wound infection.
- the threshold human neutrophil elastase activity levels of at least 9.6 indicate chronic wound infection. In some embodiments, human neutrophil elastase activity levels of at least 22.9 U/mL indicate chronic wound infection.
- the threshold cathepsin G activity levels of about 10 U/mL to about 100 U/mL including all values in between, e.g., about 15 U/mL, about 20 U/mL, about 25 U/mL, about 30 U/mL, about 35 U/mL, about 40 U/mL, about 45 U/mL, about 50 U/mL, about 55 U/mL, about 60 U/mL, about 65 U/mL, about 70 U/mL, about 75 U/mL, about 80 U/mL, about 85 U/mL, about 90 U/mL, about 95 U/mL, about 100 U/mL, about 1 10 U/mL, about 120 U/mL, or more, indicate chronic wound infection.
- cathepsin G activity levels of at least 50 U/mL, at least 40 U/mL, at least 30 U/mL, at least 20 U/mL, at least 15 U/mL or at least 10 U/mL indicates chronic wound infection.
- Embodiments disclosed herein further relate to treatment of chronic or infected wounds using the compositions, materials, articles, dressings, kits and/or systems described herein.
- the therapeutic embodiment includes, contacting a composition, material, article, dressing, kit, system or devices of the disclosed technology with a subject in need thereof.
- the method may include determination of whether the subject is responding to the treatment.
- wounds are “responsive to treatment” or not.
- the skilled person will readily be able to determine the levels of the proteases identified in the present claims that are predictive or indicative of a good response or poor response to wound treatment, particularly to treatment with wound dressings comprising oxidized cellulose.
- responsive and responder(s) refer to wounds that are considered to respond well to wound treatment, particularly to treatment with a pharmacological agent, e.g., antibiotics.
- non-responsive and non-responder(s) refers to wounds that are not considered to respond well to wound treatment, particularly to treatment with the pharmacological agent, e.g., antibiotics. For instance, patients who exhibit better than 50% wound closure after 4 weeks of wound treatment are considered to be responsive to said treatment.
- a patient may be simultaneously diagnosed and treated with the compositions, articles, systems, or devices described herein.
- the term “simultaneously” means performing the stated objectives, e.g., diagnosis and treatment, together.
- a patient may be sequentially diagnosed and treated with the compositions, articles, systems, or devices described herein.
- Embodiments described herein further enable a care giver or a patient to determine quickly and reliably whether a wound is likely to be non-healing, and to select an appropriate therapy based on this determination.
- non-healing wounds may require the application of special wound dressings such as wound dressings comprising specific therapeutic agents, to promote healing.
- embodiments described herein further provide methods of treatment of a wound, e.g., chronic or infected wounds, comprising determining whether a wound is healing or non-healing, followed by applying a wound dressing comprising a therapeutic agent to the wound if it is non-healing.
- Embodiments described herein provide methods and assays for diagnosis or detection of infected wounds.
- the methods are suitable for the detection of bacterial infectious agents.
- the wounds are infected with gram-negative bacteria.
- Typical gram-negative bacteria include proteobacteria such as E. coli, Salmonella, Pseudomonas, and Helicobacter, and cyanobacteria .
- the wounds are infected with gram-positive bacteria.
- gram-positive bacteria is meant a bacterium or bacteria that contain(s) teichoic acid ⁇ e.g., lipoteichoic acid and/or wall teichoic acid), or a functionally equivalent glycopolymer ⁇ e.g., a rhamnopolysaccharide, teichuronic acid, arabinogalactan, lipomannan, and lipoarabinomannan) in its cell wall.
- functionally equivalent glycopolymers are described in Weidenmaier et al, Nature , 6:276-287, 2008.
- the bacteria include pathogenic bacteria that infect mammalian hosts ⁇ e.g. , bovine, murine, equine, primate, feline, canine, and human hosts).
- pathogenic bacteria include, e.g., members of a bacterial species such as Bacteroides, Clostridium, Streptococcus, Staphylococcus, Pseudomonas, Haemophilus, Legionella, Mycobacterium, Escherichia, Salmonella, Shigella, Vibrio, or Listeria .
- the infectious bacteria is selected from the group consisting of Clostridium difficile , Carbapenem-Resistant Enterobacteriaceae (CK- Klebsiella spp; CK- E. coli ), and Neisseria gonorrhoeae .
- the infectious bacteria is selected from the group consisting of multi drug-resistant Acinetobacter , drug-resistant Campylobacter , extended spectrum ⁇ -Lactamase (ESBL)-producing enterobacteriaceae , vancomycin-resistant enterococcus , multidrug-resistant pseudomonas aeruginosa , drug-resistant non-typhoidal Salmonella , drug-resistant Salmonella enterica serovar Typhi , drug-resistant Shigella , methicillin-resistant Staphylococcus aureus (MRSA), drug-resistant Streptococcus pneumoniae , and drug-resistant Tuberculosis .
- multi drug-resistant Acinetobacter drug-resistant Campylobacter
- ESBL extended spectrum ⁇ -Lactamase
- ESBL extended spectrum ⁇ -Lactamase
- ESBL extended spectrum ⁇ -Lactamase
- ESBL extended spectrum ⁇ -Lactamase
- ESBL extended spectrum ⁇ -Lactamas
- the infectious bacteria is selected from the group consisting of vancomycin-resistant Staphylococcus aureus , erythromycin-resistant Group A Streptococcus , clindamycin-Resistant Group B Streptococcus .
- the chronic or infected wounds are found in host subjects.
- the hosts are mammals, e.g., a rodent, a human, a livestock animal, a companion animal, or a non-domesticated or wild animal.
- the subject may be a rodent, e.g. a mouse, a rat, a guinea pig, etc.
- the subject may be a livestock animal.
- suitable livestock animals may include pigs, cows, horses, goats, sheep, llamas and alpacas.
- the subject may be a companion animal.
- companion animals may include pets such as dogs, cats, rabbits, and birds.
- the subject may be a zoo animal.
- a “zoo animal” refers to an animal that may be found in a zoo. Such animals may include non-human primates, large cats, wolves, and bears.
- the subject is a human.
- kits for detecting levels of one or more enzymes in a mammalian wound comprising the steps of: (a) placing the wound dressing material described herein in contact with the mammalian wound; (b) visually comparing the wound dressing material in contact with the mammalian wound with one or more reference samples; and (c) obtaining a qualitative determination of the concentration of reporter molecules in the wound dressing material in contact with the mammalian wound.
- the diagnosis and treatment is conducted in situ.
- Embodiments described herein therefore allow diagnosis and treatment of wounds in an easy, non-invasive manner.
- the diagnosis may be made in real time and the treatment may be applied to the infected wound or to the patient (systemically) and the progress of wound treatment be monitored over real-time, e.g., dissipation of the signal generated by the reporter molecule due to wound-healing.
- a chemical entity comprises one or more components selected from the group consisting of: an anchor region, an enzyme-labile or enzyme-reactive region, and an indicator region.
- the method compromises placing substrates for MPO, elastase, lysozyme, phospholipase, and catalase on a solid surface such that any reaction is visible to the eye.
- the method serves to assess a variety of body fluids including wound, tear, vitreal, CSF, airway aspirates or sputum, synovial, blood, plasma, serum, urine, peritoneal, interstitial, subcutaneous, bile, intestinal or similar fluids, via contacting them with a material containing the substrates and assessing the change of the substrates thereafter.
- Chitosan (10 g, from shrimp shells) was dissolved in 2% acetic acid solution (1 L). The solution was stirred overnight at room temperature and afterwards filtered using a nylon filter (0.45 ⁇ t). Subsequently the pH was adjusted to 8 by the addition of 4 M NaOH to precipitate chitosan. The obtained precipitate was isolated by centrifugation (10000 rpm, 10 min) and thoroughly washed with distilled water until the pH of the washing solution reached ⁇ 7. Afterwards the precipitate was washed with 90% ethanol, the remaining ethanol was allowed to evaporate and the chitosan was freeze-dried. The purified product was analyzed by FTIR (1560 cm ′1 , 1640 cm ′′1 ) and material with an approximate DA of 48% was used further
- chitosan (example 1) was dissolved in 10% acetic acid solution to obtain a 1% chitosan solution. An equal volume of 96% Ethanol was added as well as acetic anhydride. The reaction was stirred for 1 h before the pH was adjusted to 7. The precipitate was isolated by centrifugation and freeze-dried. Subsequently, the obtained acetylated chitosan was several times washed with distilled water and again freeze-dried. The degree of N-acetylation (DA) was analyzed by ⁇ -NMR and FTIR (1560 cm ′′1 , 1640 cm ′′1 ) and found to be 40-60% as indicated in the graphic below. Chitosan derivatives with varying DA were produced, but only material with a DA of 48% was further used
- a solution consisting of 2.5% (w/v) Na 2 SO 4 and 1% (w/v) Na 2 CO 3 in distilled water was added, and the mixture was incubated at 25° C. for 10 min. After a subsequent incubation step at 65° C., the solid was isolated by centrifugation (7800 rpm, 5 min). The precipitate was washed with distilled water until the washing solution remained colorless and subsequently freeze dried.
- the dye content was determined measuring the unbound reactive black 5 after the reaction was completed. The dye was largely associated with the precipitate and high MW fraction. Degree of acylation was 48%.
- chitosan (2.5 g; Example 1) was dissolved in acetate buffer (100 mM, pH 5) to obtain a 1% chitosan solution. Afterwards chitosanase from Streptomyces griseus (1 unit) was added and the reaction mixture was stirred for 5 d on a thermomixer (37° C., 150 rpm). The solution was concentrated in vacuo and non-oligomeric chitosan was precipitated using 1 volumetric equivalent of 96% ethanol. The supernatant was concentrated again and subsequently oligosaccharides were precipitated by the addition of 9 volumetric equivalents of acetone.
- the oligosaccharides were isolated by centrifugation, several times washed with 50% acetone in water, and freeze-dried without prior washing.
- the degree of polymerization was determined by TLC and SEC (TSK gel G5000 PWXL, Pullulan as standard), indicating a mean MW of 5360 associated to a degree of polymerization of ca. 24.
- Mn Number molecular weight
- PDI Polydispersity Index
- DP Degree of polymerization
- a chitooligosaccharide mixture (7 g) (example 4) was dissolved in distilled water (200 mL) before 96% ethanol (400 mL) was added. The solution was stirred for 5 min and acetic anhydride (4.12 mL, 1 molar equiv. calc. to free amines) was added. The mixture was stirred for further 2 h at room temperature before the pH was adjusted to 7 with a 10%) NaOH solution. The solvent was removed, and the remaining precipitate was freeze-dried. The degree of N-acetylation was analyzed by 1 H-NMR, FTIR (1560 cm -1 , 1640 cm -1 ) and dye content (photometrically, 626 nm). The degree of N-acetylation was found to be 48 %.
- Lysozyme digestion of dyed chitosan derivatives The synthesized substrates were investigated in different media: potassium phosphate buffer (66 mM, pH 6.2) as well as artificial wound fluid containing 5000 U of lysozyme from hen egg white, and human wound fluid from infected wounds (see FIGS. 5 and 6 ).
- Two milligrams of the lysozyme substrates was suspended in the respective test medium and incubated at 35° C.
- the sample was briefly centrifuged, 200 ⁇ L of the supernatant was transferred to a 96-well plate and photometrically analyzed at the absorption maximum of the respective dye. After the analysis, the withdrawn sample was returned in the reaction vial and further incubated.
- composition of the artificial wound fluid contained human serum albumin (2%), sodium chloride (0.36%), sodium bicarbonate, (0.05%), sodium citrate (0.02%), sodium lactate (0.1%), glucose (0.1%), calcium chloride dihydrate (0.01%), magnesium chloride (0.02%), and urea (0.01%).
- Example 7 Synthesis of Indol/Chitooligomer Based Substrates for the Detection Of Wound Infection.
- COSs chito oligosaccharides
- DP degree of polymerization
- Example 8 1-chloro,3-O,6-O-Diacetyl-4-O-[3-O,4-O,6-O-triacetyl-2- (acetylamino)-2-deoxy-P-D-glucopyranosyl]-2-(acetylamino)-2-deoxy- ⁇ -D-glucopyranoside (Compound 7)
- Chitobiose octaacetate 2 (20 mg) was suspended in acetyl chloride and the solution was saturated with HCl gas and stirred for 30 h. Afterwards the solution was evaporated and used without further purification.
- Example 9 1-(5-Bromo-4-chloro-N-acetyl-3-indolyl),3-0,6-0-Diacetyl-4-0-[3-0,4-O,6-O-triacetyl-2-(acetylamino)-2-deoxy- ⁇ -D-glucopyranosyl]-2-(acetylamino)-2-deoxy- ⁇ -D-glucopyranoside (Compound 13)
- a 12 g MPLC column was used for the separation with a gradient of pure chloroform to 15 parts chloroform to one part ethanol over 10 column volumes. Then 5 column volumes 15 parts chloroform to one part ethanol were used isocratic. The final flushing step was 10 parts chloroform to one part ethanol for 5 column volumes.
- GlcNAc 14 (100 mg) was dissolved in H 2 0 (1.8 mL) and triethylamine (0.6 mL) was added. The solution was chilled in an ice bath prior to the addition of 2-chloro-1, 3-dimethylimidazolinium chloride (DMC, 230 mg). The solution was stirred for 30 min. DMC and TEA were removed by MPLC (CI 8) using H 2 0 as eluent. The product fractions were pooled and concentrated in vacuo .
- DMC 2-chloro-1, 3-dimethylimidazolinium chloride
- N-Acetyl- ⁇ -D-glucosamine tetraacetate (391 mg, 1.00 mmol) was suspended in acetyl chloride (7 mL) while cooling with an ice bath. The mixture was degassed with argon for 5 min. Afterwards MeOH (1.00 mL) was added dropwise over a period of two hours. During the first 15 min of MeOH addition the reaction mixture was degassed with argon; then it was kept under argon atmosphere (stirred in ice bath all the time). After complete addition of the MeOHl the reaction mixture was stirred additional 10 min with cooling in an ice bath. Afterwards it was allowed to warm to RT and was stirred at RT overnight. The mixture was concentrated to dryness, taken up in DCM (10 mL), concentrated to dryness again, taken up in diisopropyl ether (15 mL) and concentrated to dryness once more to yield a yellow solid which was used without further purification.
- Example 12 (jV-Acetyl-5-bromo-4-chloro-indol-3-yl) 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-D-glucopyranoside (12a) and (5-Bromo-4-chloro-indol-3-yl) 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-D-glucopyranoside (12b)
- Example 19 The crude product of Example 19 was dissolved in acetyl chloride (1 mL) under argon atmosphere and cooled in an ice bath. MeOH (55 ⁇ L) was added dropwise within approximately 1 min. After complete addition the mixture was stirred in the ice bath for additional 10 min, then the solution was allowed to warm to RT; additional acetyl chloride (5 mL) was added. The mixture was stirred at RT overnight. Afterwards it was concentrated to dryness, taken up in dichloromethane (5 mL), concentrated to dryness again, suspended in diisopropyl ether and concentrated to dryness another time to yield 55 mg crude product. The crude product was used for the next step without further purification.
- Example 20 Synthesis of Phenol/Chitosan/Laccases Based Substrates for The Detection of Wound Infection.
- N-acetyl chitosan was dissolved in sodium acetate buffer (100 mM, pH 5.0) to obtain a 1% solution (w/v). 20 mL of this solution were mixed with 20 mL of a sinapic acid solution in ethanol (20 mM). EDC and NHS were added (1.3 g each) and the solution was stirred for 2 h. The reaction was stopped by adding NaOH (1 M) drop-wise, the resulting precipitate was washed with water until no phenol could be detected anymore in the washing solution. Afterwards the product was freeze dried.
- N-acetyl chitosan was dissolved in sodium acetate buffer (100 mM, pH 5.0) and aminomethoxyphenol (dissolved in ethanol) was added to obtain a total concentration of 20 mM. 2.3 mL of this solution were mixed with 1.6 mL of dodecane and applied to a sonicator to produce an emulsion.
- SA grafted N-acetyl chitosan (5 mg) was suspended in 500 potassium phosphate buffer (62 mM, pH 6.2) containing lysozyme (0.1 mg/mL). The solution was incubated for one hour. The reaction supernatant was incubated with laccase (1 U/mL) and an immediate color change was observed.
- N-acetyl chitosan / aminomethoxyphenol nanoparticle emulsion 50 ⁇ L was mixed with 450 ⁇ L potassium phosphate buffer (62 mM, pH 6.2) containing lysozyme (0.1 mg/mL) and laccase (1 U/mL). The nanoparticles were destructed after 15 min (yielding a clear solution) developing strong colour.
- Different reactive dyes can be used for the dying of peptidoglycan (Table 1).
- reactive dyes containing a sulfonylethyl-hydrogensulphate-reactive-group such as reactive black 5, remazol brilliant blue, reactive violet 5 or reactive orange 16.
- dyes containing a dichlortriazine reactive-group such as reactive blue 4, reactive red 120, reactive blue 2, reactive green 19 and reactive brown 10 can be used.
- Dyes were evaluated by consideration of their degree of reaction with peptidoglycan and the speed with which the dye was released when the dyed peptidoglycan was incubated with lysozyme (see earlier section of Example 7 for dying and Example 6 for digestion assay).
- Micrococcus lysodeicticus cell broth from an animal free fermentation was centrifuged at 4000 g and 4° C. for 15 min to gain a wet cell pellet.
- the cell pellet (20 g) was washed twice with ddH20 (800 ml) to get rid of any remaining media components (constant centrifugation conditions).
- the wet Micrococcus lysodeicticus cell pellet (20 g, we dry ration 4: 1, 5 g dry M. lysodeicticus cells) were suspended in 1 M HCl (80 g) and incubated for 1 h at 60° C. and 720 rpm. The sterilized and interrupted cells were then centrifuged at 4000 g and 4° C. for 15 min.
- the peptidoglycan pellet was resuspended and washed with Na-Phosphate buffer (400 ml, 100 mM, pH 7.0) to adjust the pH of the suspension to a neutral pH and to get rid of cell components of the disruption process (constant centrifugation conditions).
- Another washing step with 500 ml of ddH20 was carried out to get rid of disrupted cell components and buffer salts. The gained pellet after the last washing step was ready to use for the staining procedure.
- Peptidoglycan 50 mg
- reactive black 5 5 mg
- Na2C03 10 mg
- Na2S04 25 mg
- ddH20 double-distilled water
- the reaction mixture was incubated at 25° C. and 750 rpm for 10 min followed by a second incubation step at 65° C. and 750 rpm-shaking for another 30 min.
- the dyed peptidoglycan was centrifuged at 10000 g for 10 min. The supernatant was collected, and the pellet was re-suspended in ddH20 and centrifuged again at 10000 g for 10 min. The washing procedure was repeated until the supernatant was clear. Different buffers or organic solvents like ethanol could be used for the washing procedure. The absorbance levels of all supernatants were measured at 597 nm. The supernatant was defined as clear, if the absorbance was below a value of 0.05. The amount of unbound dye in the supernatant was calculated using a calibration curve and the measured absorbance levels of the supernatants. Consequentially, the amount of peptidoglycan-bound dye was calculated. The dyed peptidoglycan was stored at 4-8° C. for a maximum of 2 wks or dried via lyophilization for a longer storage period.
- Reactive black 5 200 mg
- peptidoglycan 300 mg
- ddH20 40 mL
- the reaction solution was stirred at 50° C. for 30 min.
- Na2S04 1 g
- Na3P04 200 mg was added to the reaction solution, which was stirred again for 30 min at 50° C.
- the dyed peptidoglycan was centrifuged at 10000 g for 10 min. The supernatant was collected, and the pellet was re-suspended in ddH20 and was again centrifuged at 10000 g for 10 min. The washing procedure was repeated until the supernatant was clear. Different buffers or organic solvents like ethanol could be used for the washing procedure. The absorbance levels of all supernatants were measured at 597 nm. The supernatant was defined as clear, if the absorbance was below a value of 0.05. The amount of unbound dye in the supernatant was calculated using a calibration curve and the measured absorbance levels of the supernatants. Consequentially, the amount of peptidoglycan-bound dye was calculated. The dyed peptidoglycan was stored at 4-8° C. where it appears to be stable or dried via lyophilisation.
- Peptidoglycan (150 mg, dry weight) was suspended in ddH20 (20 ml) and heated to 50° C.
- the reaction was started by the addition of reactive black 5 (7 different variants with different amounts of reactive dye according to table X).
- the reaction was stirred (210 rpm) at 50° C. for 1 h.
- Na2C03 was added periodically every 10 minutes (5 x 100 mg, after 10, 20, 30, 40 and 50 min reaction time).
- the reaction mixture was stirred for another 10 min after the last addition of Na2C03.
- the reaction solution was centrifuged at 4000 g at 4° C. for 15 min.
- the pellet was resuspended and washed in ddH20 (40 g) 3 times and always centrifuged as before.
- Example 23 Colorimetric Enzyme Assay for Detection of Myeloperoxidase Activity
- Reagents like 3,4-diamino benzoic acid, 3-amino-4-hydroxy benzoic acid, 4-amino- 3-hydroxy benzoic acid, 2,3-diamino benzoic acid, 3,4-dihydroxy benzoic acid, 2-amino phenol, 2-amino-3-methoxy benzoic acid, Methyl-3,4-diaminibenzoate and 2-amino-4-methoxy phenol can be used for the detection of MPO activity (Table 2). Assay conditions: 1 mg/mL DABA or equivalent was dissolved in 100 mM sodium-phosphate-buffer (pH 6.4). H 2 O 2 was added to a final concentration of 5 mM.
- the substrate/H 2 0 2 solution (95 ⁇ L) was added to a 96-well microtiter plate along with 5 ⁇ L of a MPO-containing sample.
- the solution turned brownish upon MPO oxidation.
- the reaction was monitored at 450 nm using a standard photometric plate reader.
- Chimeric gene variants were synthesized encoding one to four concatemers of the hydrophilic carbohydrate binding module (CBM) from Cellobiohydrolase I ( Trichoderma reesei ), or the hydrophobic binding module (PDB) from Polyhydroxyalkanoate depolymerase ( Alcaligenes faecalis ).
- CBM hydrophilic carbohydrate binding module
- PDB hydrophobic binding module
- Chimeric variants with the hydrophilic binding module (CBM) enable the attachment onto cellulose based filter papers/fabrics
- chimeric variants with the hydrophobic binding module (PDM) enable the attachment onto PET (Polyethylene terephthalate) based strips.
- TrxA- ElaSub 1_CBM_His fusion proteins were designed.
- the construct consists of the trxA (thioredoxin) gene, a short spacer sequence that encodes a 6xHis-Tag [SEQ ID NO: 1] and the enterokinase cleavage site (Asp Asp Asp Lys) [SEQ ID NO: 2] for separating the TrxA fusion tag from the protein of interest. Subsequently to the enterokinase site, the newly designed elasub1_cbm coding sequence was introduced into the construct.
- the elasub1 sequence encodes for amino acids that expose a lot of functional groups like thiol-, hydroxyl-, amino- or carboxy groups. These amino acids (cysteine, lysine, arginine, glutamine, asparagine, glutamic acid, aspartic acid, serine, threonine or tyrosine) should facilitate the coupling of dyes or pro-dyes to the chimeric peptides.
- the coding sequence for the natural hydrophilic binding module (CBM) was located directly downstream to the elasub1 sequence, termed elasub1_cbm.
- TrxA_ElaSub1_CBM-His fusion protein [SEQ ID NO: 9]:
- Variant 1 ElaSub1_CBM.
- the ElaSub 1 construct encodes a stretch of mainly hydrophilic amino acids.
- the sequence for the natural hydrophilic binding module (CBM) is located directly downstream to the ElaSub1 protein sequence, termed ElaSub1_CBM.
- ElaSub1_CBM The sequence for the natural hydrophilic binding module (CBM) is located directly downstream to the ElaSub1 protein sequence, termed ElaSub1_CBM.
- a codon for cysteine is inserted.
- the thiol group of the cysteine should facilitate the coupling of dyes or pro-dyes to the chimeric peptide.
- two recognition/cleavage sites for HLE Al-Ala-Pro- Val
- HLE Two recognition/cleavage sites for HLE
- Enzymatic cleavage of the chimeric peptide through HLE should lead to the release of a peptide fragment that carries the coupled dye or pro-dye.
- the HLE enzyme reaction should be visualized by binding the released peptide fragment through the charged groups of the dye.
- the amino sequence of this variant is shown in table 4.
- Variant 2 CatGSub1_CBM.
- the CatGSub 1 construct encodes a stretch of mainly hydrophilic amino acids.
- the sequence for the natural hydrophilic binding module (CBM) is located directly downstream to the ElaSub1 protein sequence, termed CatGSub1_CBM.
- CBM hydrophilic binding module
- a codon for cysteine is inserted into this region.
- the thiol group of the cysteine should facilitate the coupling of dyes or pro-dyes to the chimeric peptide.
- two recognition/cleavage sites for CatG (Ala-Ala-Pro-Phe) [SEQ ID NO: 4] are introduced into the hydrophilic spacer region.
- certain dye molecules comprising positive or negative charged groups can be attached to the thiol group of the cysteine.
- Enzymatic cleavage of the chimeric peptide through CatG should lead to the release of a peptide fragment that carries the coupled dye or pro-dye.
- the CatG enzyme reaction should be visualized by binding the released peptide fragment through the charged groups of the dye.
- the amino sequence of this variant is shown in table 4.
- Variant 3 ElaSub1_CBM_His.
- the ElaSub 1 construct encodes a stretch of mainly hydrophilic amino acids.
- the sequence for the natural hydrophilic binding module (CBM) is located directly downstream to the ElaSub 1 protein sequence, termed ElaSub1_CBM.
- ElaSub1_CBM The sequence for the natural hydrophilic binding module (CBM) is located directly downstream to the ElaSub 1 protein sequence, termed ElaSub1_CBM.
- a codon for cysteine is inserted.
- the thiol group of the cysteine should facilitate the coupling of dyes or pro-dyes to the chimeric peptide.
- two recognition/cleavage sites for HLE Al-Ala-Pro- Val
- HLE Two recognition/cleavage sites for HLE
- Enzymatic cleavage of the chimeric peptide through HLE should lead to the release of a peptide fragment that carries the coupled dye or pro-dye. Through ionic exchange, the HLE enzyme reaction should be visualized by binding the released peptide fragment through the charged groups of the dye.
- a repetitive sequence stretch encoding a His-tag [SEQ ID NO: 1] is attached subsequently to the sequence encoding the carbohydrate binding module. The amino sequence of this variant is shown in table 4.
- Variant 4 CatGSub1 CBM His.
- the CatGSub 1 construct encodes a stretch of mainly hydrophilic amino acids.
- the sequence for the natural hydrophilic binding module (CBM) is located directly downstream to the ElaSubl protein sequence, termed CatGSub 1 CBM.
- CBM hydrophilic binding module
- a codon for cysteine is inserted into this region.
- the thiol group of the cysteine should facilitate the coupling of dyes or pro-dyes to the chimeric peptide.
- two recognition/cleavage sites for CatG (Ala-Ala-Pro-Phe) [SEQ ID NO: 4] are introduced into the hydrophilic spacer region.
- certain dye molecules comprising positive or negative charged groups can be attached to the thiol group of the cysteine.
- Enzymatic cleavage of the chimeric peptide through CatG should lead to the release of a peptide fragment that carries the coupled dye or pro-dye. Through ionic exchange, the CatG enzyme reaction should be visualized by binding the released peptide fragment through the charged groups of the dye.
- a repetitive sequence stretch encoding a His-tag [SEQ ID NO: 1] is attached subsequently to the sequence encoding the carbohydrate binding module. The amino sequence of this variant is shown in table 4.
- Variant 5 ElaSub2_CBM.
- the ElaSub2 construct encodes a stretch of mainly hydrophilic amino acids.
- the sequence for the natural hydrophilic binding module (CBM) is located directly downstream to the ElaSub2 protein sequence, termed ElaSub2_CBM.
- ElaSub2_CBM The sequence for the natural hydrophilic binding module (CBM) is located directly downstream to the ElaSub2 protein sequence, termed ElaSub2_CBM.
- CBM hydrophilic binding module
- Enzymatic cleavage of the chimeric peptide through HLE should lead to the release of a peptide/peptides fragment/fragments that carry the coupled dye or pro- dye.
- the HLE enzyme reaction should be visualized by binding the released peptide fragment/fragments through the charged groups of the dye.
- the amino sequence of this variant is shown in Table 4.
- Variant 6 CatGSub2_CBM.
- the CatGSub2_CBM construct encodes a stretch of mainly hydrophilic amino acids.
- the sequence for the natural hydrophilic binding module (CBM) is located directly downstream to the CatGSub2 protein sequence, termed CatGSub2 CBM.
- CBM hydrophilic binding module
- the thiol group of the cysteines should facilitate the coupling of dyes or pro-dyes to the chimeric peptide.
- three recognition/cleavage sites for CatG (Ala-Ala-Pro-Phe) [SEQ ID NO: 4] are introduced into the hydrophilic spacer region.
- certain dye molecules comprising positive or negative charged groups can be attached to the thiol group of the cysteines.
- Enzymatic cleavage of the chimeric peptide through CatG should lead to the release of a peptide/peptides fragment/fragments that carry the coupled dye or pro- dye.
- the CatG enzyme reaction should be visualized by binding the released peptide fragment/fragments through the charged groups of the dye.
- the amino sequence of this variant is shown in Table 4.
- Variant 7 ElaSub2_CBM_His.
- the ElaSub2 construct encodes a stretch of mainly hydrophilic amino acids.
- the sequence for the natural hydrophilic binding module (CBM) is located directly downstream to the ElaSub2 protein sequence, termed ElaSub2_CBM.
- ElaSub2_CBM The sequence for the natural hydrophilic binding module (CBM) is located directly downstream to the ElaSub2 protein sequence, termed ElaSub2_CBM.
- CBM hydrophilic binding module
- Enzymatic cleavage of the chimeric peptide through HLE should lead to the release of a peptide/peptides fragment/fragments that carry the coupled dye or pro- dye. Through ionic exchange, the HLE enzyme reaction should be visualized by binding the released peptide fragment/fragments through the charged groups of the dye.
- a repetitive sequence stretch encoding a His-tag [SEQ ID NO: 1] is attached subsequently to the sequence encoding the carbohydrate binding module. The amino sequence of this variant is shown in Table 4.
- the CatGSub2_CBM construct encodes a stretch of mainly hydrophilic amino acids.
- the sequence for the natural hydrophilic binding module (CBM) is located directly downstream to the CatGSub2 protein sequence, termed CatGSub2_CBM.
- CBM hydrophilic binding module
- the thiol group of the cysteines should facilitate the coupling of dyes or pro-dyes to the chimeric peptide.
- three recognition/cleavage sites for CatG (Ala-Ala-Pro-Phe) [SEQ ID NO: 4] are introduced into the hydrophilic spacer region.
- certain dye molecules comprising positive or negative charged groups can be attached to the thiol group of the cysteines.
- Enzymatic cleavage of the chimeric peptide through CatG should lead to the release of a peptide/peptides fragment/fragments that carry the coupled dye or pro- dye. Through ionic exchange, the CatG enzyme reaction should be visualized by binding the released peptide fragment/fragments through the charged groups of the dye.
- a repetitive sequence stretch encoding a His-tag [SEQ ID NO: 1] is attached subsequently to the sequence encoding the carbohydrate binding module. The amino sequence of this variant is shown in Table 5.
- Variant 9 to variant 16 could be designed identically as variant 1 to variant 8 with the exception of changing the hydrophilic carbohydrate binding module (CBM) against the hydrophobic binding module (PDB).
- CBM hydrophilic carbohydrate binding module
- PDB hydrophobic binding module
- Table 5B Nucleotide sequence of the chimeric gene variants with the hydrophile carbohydrate binding module. All eight constructs were cloned into a pET-32b(+) expression vector (Novagen) using the Nco I and Xho I restriction sites located in the MCS of the cloning vector.
- Elasubl CBM [SEQ ID NO: 191 ElaSub1_CBM ATGGGTGGTAGCTGCGGTGGTGGTGGTAGCGCAGCACCGGTTGGTGGTGGCGGTTCGCTGCTC CTGTGGGTGGCGGTGGTTCACCGCCTGGTGGTAATCGTGGTACAACCACCACCCGTCCGC AACCACAACCGGTAGCAGTCGGGTCCGACCAGAGCCATTATGGTCAGTGTGGTGGAGGT AACCACAACCGETAGCAGTCCGGGTCCCGACCCAGAGCCATTATGGTCAGTGTGGTGGTATTGGT TATAGCGG7CCGACCGTTTGTGCAAGCGGCACCACCACCTGTCAGGTTCTGAATCCGTAT7ATAGCC AGTGTCTG
- Example 25 Expression of Elastase (HLE) Substrates With Polymer Binding Sequences.
- Variant 3 (Example 9): BL21 Gold (DE3) [pET32b(+)ela Sub1_cbm His]
- the chimeric gene was cloned into a pET32b(+) expression system using Ncol and Xhoi restriction sites/enzymes.
- Final protein expression of the chimeric peptide was carried out in E. coli BL21 Gold (DE3), a protease deficient expression host, which enables a proper protein expression based on the T7 promoter of the pET32b(+) expression vector.
- the proper protein expression of the recombinant protein was monitored with SDS-PAGE, compared to the identically expressed empty pET32b(+) vector.
- Purification of the chimeric construct from crude lysate was done using the IBA -NTA sepharose gravity flow column (1 ml) according to the IBA protocol. Fractions containing the purified protein were examined using SDS-PAGE. In order to prevent protein exposure to the high imidazole concentration after elution, buffer exchange was carried out using PD 10 desalting columns from GE Healthcare. The yield of the purified chimeric fusion construct could be calculated with 30 mg protein per 2 g initial cell pellet.
- the recombinant expressed bovine enterokinase from Merck Millipore was used.
- the separation of the desired chimeric construct from the TrxA-Tag was verified by SDS-PAGE.
- the finished chimeric construct was adsorbed onto a cellulose based filter paper (or fabrics) through the hydrophilic carbohydrate binding module.
- the filter strip containing the chimeric peptide was incubated for 30 min with a 0.1 M sodium phosphate buffer solution (pH 7.4), containing 0.05 U/ml HLE, as well as with human wound fluids.
- a 0.1 M sodium phosphate buffer solution pH 7.4
- a 0.1 M sodium phosphate buffer solution pH 7.4
- 0.05 U/ml HLE containing 0.05 U/ml HLE
- Initially non coloured samples (clear supernatant) that exhibit elastase activity developed a blue colour, depending on the attached dye. Due to enzymatic cleavage at one or both of the internal HLE restriction sites (Ala-Ala-Pro-Val), peptide fragments with the attached Remazol Brilliant Blue dye molecules get uncoupled, resulting in a blue coloured supernatant.
- chimeric constructs with the hydrophobic binding module can be used for adsorption of PET (Polyethylene terephthalate) based carrier materials.
- PET Polyethylene terephthalate
- the PDM group can be interchanged with the CBD in a manner described before.
- the polyhydroxybutyrate depolymerase from A. faecalis (PBM or PDM) sequences are described in Ribitsch et al., “Fusion of Binding Domains to Thermobifida cellulosilytica Cutinase to Tune Sorption Characteristics and Enhancing PET Hydrolysis,” Biomacromolecules , 14 (6), pp 1769-1776, 2013.
- the disclosure in Ribitsch is incorporated by reference herein in its entirety. Analogously, any solid phase binding domain can be used in this manner.
- Other types of CBD peptides may be employed interchangably to achieve the desired functionality.
- the constructs disclosed herein comprise a non-soluble ancher like CBD, this can be interchanged with other anchors, notably other CBDs or PDMs. Smaller anchors are preferred for stoiciometric reasons.
- elastase As exemplified herein, has broad preferences, wherein AAPV [SEQ ID NO: 3] sequence is most preferred, however, AAPF [SEQ ID NO: 4] is almost the same in terms of turnover and AAAA [SEQ ID NO: 4] is similar. Thus, anyone of these sequences could be exchanged for the other without loss of function.
- Cyteines are particularly employed as a means to anchor dyes and particularly not more than one per construct, preferably one per cutting site. They should be distal from the cutting sites to ensure that the sulfonated dye does not interact with the enzyme more than necessary.
- elastase is a basic enzyme and it is inhibited by strong negatively charged groups. This means that more than one sulfonated dye per cutting site is not required. It is desirable that the number of sulfonate groups is lower than 4 per cutting site. With greater number of such sulfonate groups, there is a risk that they will mask access to the cutting site.
- Trx-Ela-Subl Purified and lyophilised Trx-Ela-Subl was dissolved in 3 ⁇ 40 (0.01 g/2.5 ml) (protein concentration ⁇ 0.2 mg/ml). The buffer was exchanged from Tris-HCl to a Na 2 P0 4 /Na 2 S0 4 solution using a PD-10 column.
- the stained and purified peptide construct was applied on a cellulose surface and dried at 37° C. for 2 h. Unbound Trx-Ela-Sub 1-RBB was removed with H 2 0. The stripes with the applied Elastase substrate were incubated with and without Elastase containing buffer, respectively. The Elastase responsive dye release can be seen in FIG. 10 .
- Example 28 3-Step-Immobilisation of Bromocresol Purple Onto OH-Rich Surfaces Like Cellulose as pH Indicator.
- Step Soaking of OH-rich surface (e.g. cellulose) in reaction solution. Incubation of soaked material at 80 - 120° C. for 5-20 min.
- OH-rich surface e.g. cellulose
- Step 3 Bromocresol purple (0.1 - 3.3 mg/ml) applied on pretreated material and dried at 120° C. for 20 min.
- p-Nitrophenylphosphorylcholine as substrate for Phospholipase C was used.
- p-Mtrophenylphosphorylcholine is dissolved in water (50-100 mM).
- 230 ⁇ l of the buffer and 100 ⁇ l of the substrate are pipetted into a microtiterplate.
- Diagnosis A volume between 5 and 12 ⁇ L of wound fluid sample is added to the test system, preferentially between 8 and 10 ⁇ L and mixed by manual shaking for 10 seconds. This mixture is incubated at room temperature for 30 minutes. Thereafter, infection will be indicated by a colour change from colourless to yellow.
- Infected wound fluid samples A, B, C
- non-infected samples D, E, F
- IA Visual inspection of the samples after 30 minutes of incubation indicated a colour change to yellow only for infected samples A, B, and C.
- Example 30 Phospholipase A2 Based Test - Liquid System
- Diagnosis A volume between 5 and 12 pL of wound fluid sample is added to the test system, preferentially between 8 and 10 ⁇ l and mixed by manual shaking for 10 seconds. This mixture is incubated at room temperature for 30 minutes. Thereafter, infection will be indicated by a colour change from colourless to yellow.
- Example 31 Catalase Based Test - Liquid System
- Purpald as substrate for Catalase was used. Purpalt is dissolved in water (50-100 mM). 200 ⁇ l of substrate solution are pipetted into a microtiterplate.
- Diagnosis A volume between 5 and 12 ⁇ L of wound fluid sample is added to the test system, preferentially between 8 and 10 ⁇ l and mixed by manual shaking for 10 seconds. This mixture is incubated at room temperature for 30 minutes. Thereafter, infection will be indicated by a colour change from colourless to dark violet.
- a material containing substrates for one or more of MPO, elastase, lysozyme, phospholipase, and catalase and optionally a pH indicator is contacted with a body fluids such as wound, tear, vitreal, CSF, airway aspirates or sputum, synovial, blood, plasma, serum, urine, peritoneal, interstitial, subcutaneous, bile, intestinal or similar fluids. Samples from infected organisms or tissues tend to show a higher degree of reaction. A combination of one or more of the reactions is used to detect the infection and its degree.
- N-methoxysuccinyl-ala-ala-pro-val-p- nitroanilide dissolved at a concentration of 20 mM in DMSO in 0.1 M HEPES buffer (pH 7.4, containing 0.5 M NaCl) is pipetted into a transparent eppendorf tube.
- the final concentration of N- methoxysuccinyl-ala-ala-pro-val-p-nitroanilide can be between 0.05 to 2.50 mM, and is preferentially between 0.80 and 1.20 mM.
- a volume between 1 and 15 L of sputum sample is added to the test system, preferentially between 2-5 ⁇ L. and mixed by manual shaking for 10 seconds.
- Example 34 Elastase Based Test - Cellulose Paper Based System
- N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide is dissolved at a concentration of 281 mM in dimethoxysulfoxide. 2-5 ⁇ l of this solution, preferentially 2 ⁇ l were pipetted onto Whatman-Filterpapier.
- test system of Whatman-Filterpapier incubated with N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide is then incubated with 1-5 ⁇ l, preferentially 2 ⁇ l sputum sample and 2 ⁇ l 2 ⁇ l NaCl (50 mM) and incubated at room temperature for 5 minutes. Thereafter, infection will be indicated by a colour change of the filterpaper to yellow. Non infected sputum samples will not change colour.
- infected samples (A, B) and non infected samples (C, D) were taken and placed into the diagnostic system described in 1C containing the substrate mM N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide .
- Example 35 Cathepsin Based Test - Liquid System
- N-succinyl-ala-ala-pro-phe-p-nitroanilide is dissolved at a concentration of 20 mM in dimethoxysulfoxide and diluted in 0.1 M HEPES buffer (pH 7.4, containing 0.5 M NaCl).
- the final concentration of N-methoxysuccinyl-ala-ala-pro-phe p-nitroanilide can be between 0.5 to 5 mM, and is preferentially 3 mM.
- a volume between 1 and 5 ⁇ L of sputum sample is added to the test system, preferentially 2-4 uL and mixed by manual shaking. This mixture is incubated at 37° C. for 20 minutes. Thereafter, infection will be indicated by a colour change to yellow. Mixtures containing non infected samples will not change colour.
- Example 36 Cathepsin Based Test - Cellulose Based System
- N-methoxysuccinyl-ala-ala-pro-phe-p-nitroanilide is dissolved at a concentration of 20 mM in dimethoxysulfoxide and diluted in 0.1 M HEPES buffer (pH 7.4, containing 0.5 M NaCl).
- the final concentration of N-methoxysuccinyl-ala-ala-pro-phe-p- nitroanilide can be between 0.5 to 10 mM, and is preferentially 5.00 mM. 10 ⁇ L of this solution were pipetted onto Whatman filter paper.
- test system of Whatman-Filterpapier incubated with N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide is then incubated with 1-5 ⁇ l preferentially 2 ⁇ l sputum sample and 2 ⁇ l 2 ⁇ l NaCl (50 mM) and incubated at room temperature for 20 minutes. Thereafter, infection will be indicated by a colour change of the filterpaper to yellow. Non infected sputum samples will not change colour,
- infected samples (A, B) and non- infected samples (C, D) were taken and placed into the diagnostic system described in 1C containing the substrate mM -methoxysuccinyl-ala-ala-pro-val-p-nitroanilide .
- Example 37 Myeloperoxidase Based Test - Liquid System
- TMB TMB
- ABTS ABTS
- Guaiacol 4-Amino-3 -methoxy benzoic acid
- Fast Blue RR 3350 ⁇ l of succinate buffer (pH 5.4) comprising 0.3 M sucrose 15 ⁇ l 1% H202 and 7 ⁇ l of the substrates (5-40 mM ABTS, 20-150 mM TMB, 0.025 mM of Fast Blue RR, 10-50 mM 4- Amino-3 -methoxy benzoic acid and 10-20 mM Guaiacol) were added.
- TMB (3, 3′, 5, 5′ -Tetramethylbenzidine) is firstly dissolved in N, N- Methylformamide, Fast Blue RR is dissolved in ethanol, while ABTS can be dissolved in water and 4- Amino-3 -methoxy benzoic acid is dissolved in DMSO. Guaiacol. 100 ⁇ l of the solutions are pipetted into a microtiterplate.
- a volume between 1 and 7 pL of sputum sample is added to the test system, preferentially between 4-6 pL and mixed by manual shaking for 10 seconds. This mixture is incubated at room temperature for 10 minutes. Thereafter, infection will be indicated by a colour change from colourless to blue (TMB or green (ABTS), respectively and to brown to red (4-Amino-3 -methoxy benzoic acid and Guaiacol) Mixtures containing non infected samples will not change colour
- Infected Sputum samples of (A, B, C) and non infected sputum samples (D, E, F) are incubated with the diagnostic system described in IA containing the different substrates. Visual inspection of the samples after 5 minutes of incubation indicated a colour change to blue in case of TMB only for infected samples A, B, and C.
- Example 38 Myeloperoxidase Based Test - Cellulose Based System
- test system of Whatman-Filterpapier incubated with the different MPO substrates is then incubated with 1 -5 ⁇ l preferentially 2 ⁇ l sputum sample and incubated at room temperature for 5 minutes. Thereafter, infection will be indicated by a colour change of the filterpaper to blue, green or brown-red. Non infected sputum samples will not change colour.
- infected samples (A, B) and non infected samples (C, D) were taken and placed into the diagnostic system described in 1C containing the substrates TMB, ABTS, Fast Blue RR, Guaiacol and 4A3Mba. Visual inspection of the samples after 5 minutes of incubation indicated a colour change to brown (4A3Mba) in case of for infected samples A, B.
- Example 39 Phospholipase A2 Based Test - Liquid System
- 4-Nitro-3-octanoylbenzoic acid as Phospholipase A2 - substrate was used.
- 4-Nitro-3-octanoylbenzoic acid (1.7 mM) is dissolved in assay buffer containing 50 mM Tris/HCl buffer pH 7.2, 150 mM KCL and 10 mM CaC12. 190 ⁇ l of the buffer are pipetted into a microtiterplate.
- a volume between 5 and 12 ⁇ L ⁇ o ⁇ sputum wound fluid sample is added to the test system, preferentially between 8 and 10 ⁇ l and mixed by manual shaking for 10 seconds. This mixture is incubated at room temperature for 30 minutes. Thereafter, infection will be indicated by a colour change from colourless to yellow.
- Infected sputum samples (A, B) and non infected samples (E, F) are incubated with the diagnostic system described in IA. Visual inspection of the samples after 30 minutes of incubation indicated a colour change to yellow only for infected samples A, B, and C.
- Example 40 Catalase Based Test - Liquid System
- Purpald as substrate for catalase was used. Purpalt is dissolved in water (50-100 mM?). 200 ⁇ l of substrate solution are pipetted into a microtiterplate.
- a volume between 5 and 12 ⁇ L of sputum sample is added to the test system, preferentially between 8 and 10 ⁇ l and mixed by manual shaking for 10 seconds. This mixture is incubated at room temperature for 30 minutes. Thereafter, infection will be indicated by a colour change from colourless to dark violet.
- Infected wound fluid samples A, B, C
- non-infected samples D, E, F
- IA Visual inspection of the samples after 30 minutes of incubation indicated a colour change to violet only for infected sputum samples A, B, and C.
- Example 41 Lysozyme Based Test - Liquid System
- Micrococcus lysodeikticus pep- tidoglycan is suspended in 15 ml 0.1 M KH2PO4 buffer (pH 7.0) . Preferentially, an amount between 8 and 10 mg is suspended. 290 ⁇ L of this solution is pipetted into a transparent microtiterplate.
- a volume of 10 ⁇ L of sputum is added to the test system and mixed by manual shaking for 10 seconds. This mixture is incubated at 37° C. for 15 minutes. Thereafter, infection will be indicated by a decrease in turbidity. Mixtures containing non infected samples will not change.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Gastroenterology & Hepatology (AREA)
- Cephalosporin Compounds (AREA)
- Indole Compounds (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/090,091 US20230213525A1 (en) | 2016-03-30 | 2017-03-30 | Detecting microbial infection in wounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662315556P | 2016-03-30 | 2016-03-30 | |
US201662315546P | 2016-03-30 | 2016-03-30 | |
US16/090,091 US20230213525A1 (en) | 2016-03-30 | 2017-03-30 | Detecting microbial infection in wounds |
PCT/IB2017/000442 WO2017168249A2 (fr) | 2016-03-30 | 2017-03-30 | Détection d'une infection microbienne dans les plaies |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230213525A1 true US20230213525A1 (en) | 2023-07-06 |
Family
ID=58709502
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/090,091 Pending US20230213525A1 (en) | 2016-03-30 | 2017-03-30 | Detecting microbial infection in wounds |
US16/090,075 Active 2039-12-20 US11740241B2 (en) | 2016-03-30 | 2017-03-30 | Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds |
US18/312,017 Pending US20240027454A1 (en) | 2016-03-30 | 2023-05-04 | Detecting microbial infection in wounds |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/090,075 Active 2039-12-20 US11740241B2 (en) | 2016-03-30 | 2017-03-30 | Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds |
US18/312,017 Pending US20240027454A1 (en) | 2016-03-30 | 2023-05-04 | Detecting microbial infection in wounds |
Country Status (14)
Country | Link |
---|---|
US (3) | US20230213525A1 (fr) |
EP (2) | EP3436820A2 (fr) |
JP (3) | JP2019512556A (fr) |
KR (2) | KR20190015210A (fr) |
CN (2) | CN109416355A (fr) |
AU (3) | AU2017278022B2 (fr) |
BR (2) | BR112018070238A2 (fr) |
CA (2) | CA3019445A1 (fr) |
CL (2) | CL2018002774A1 (fr) |
CO (2) | CO2018011706A2 (fr) |
EC (2) | ECSP18081945A (fr) |
IL (2) | IL262024A (fr) |
SG (1) | SG11201808598UA (fr) |
WO (2) | WO2017168249A2 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111601545B (zh) | 2017-11-09 | 2024-05-07 | 康沃特克科技公司 | 造口术监测系统和方法 |
FR3074047B1 (fr) * | 2017-11-30 | 2019-12-20 | Biomerieux | Dispositifs medicaux non-implantables integrant un dispositif de detection et/ou d'identification d'infections microbiologiques |
CN108922620A (zh) * | 2018-06-20 | 2018-11-30 | 南华大学 | 一种手术切口感染风险评估系统 |
TR201809384A2 (tr) * | 2018-07-02 | 2018-07-23 | Arkan Tic Paz Teks Ins Kag San Ltd Sti | İdrar yolu bakteri̇yel enfeksi̇yon tespi̇ti̇ yapan bebek bezi̇ |
EP3591066A1 (fr) | 2018-07-05 | 2020-01-08 | Qualizyme Diagnostics GmbH&Co KG | Procédé de detection d'infections synoviales articulaires |
WO2020060491A1 (fr) * | 2018-09-19 | 2020-03-26 | Nanyang Technological University | Oligomères de peptidoglycanes biohybrides |
USD893514S1 (en) | 2018-11-08 | 2020-08-18 | 11 Health And Technologies Limited | Display screen or portion thereof with graphical user interface |
WO2020220300A1 (fr) * | 2019-04-30 | 2020-11-05 | 钟春燕 | Fibre de biocellulose, pansement hémostatique comprenant ladite fibre et application associée |
WO2020250037A1 (fr) * | 2019-06-14 | 2020-12-17 | Qualizyme Diagnostics GmbH & Co. KG | Matériaux sensibles au ph pour surveillance optique d'état d'une plaie |
CN112169717B (zh) * | 2020-09-30 | 2022-06-03 | 深圳大学 | 一种微胶囊化氯化血红素及其制备方法与应用 |
TWI757149B (zh) * | 2021-04-14 | 2022-03-01 | 正美企業股份有限公司 | 敷料及傷口判讀系統 |
CN113484386B (zh) * | 2021-05-21 | 2024-02-13 | 郑州轻工业大学 | 一种金属聚酞菁纳米材料的制备方法及其应用,适配体传感器及其制备方法 |
CN113671077B (zh) * | 2021-08-17 | 2023-08-18 | 成都倍特药业股份有限公司 | 丙烯酰氯及其有关物质检测方法 |
EP4180121A1 (fr) * | 2021-11-15 | 2023-05-17 | Universidad Autónoma de Madrid | Composition pour évaluer la présence de micro-organismes dans un échantillon d'essai |
JP2023133892A (ja) * | 2022-03-14 | 2023-09-27 | 国立大学法人 東京大学 | 精子の検出方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100178203A1 (en) * | 2009-01-15 | 2010-07-15 | Polestar Technologies, Inc. | Non-Invasive Colorimetric-Based Infection Detector And Infection Detecting Bandage |
US20110158917A1 (en) * | 2009-12-31 | 2011-06-30 | Macdonald John Gavin | Anti-viral tissue product with visual efficacy indicator |
Family Cites Families (625)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3911116A (en) | 1970-04-13 | 1975-10-07 | Leslie L Balassa | Process for promoting wound healing with chitin derivatives |
US3762859A (en) * | 1971-03-15 | 1973-10-02 | Colgate Palmolive Co | Enhancing the apparent whiteness of fabrics by applying an effective amount of an alkali and heat stable water soluble disazo blue dyestuff fabric softening and detergent composition therefor |
DE2905531A1 (de) * | 1979-02-14 | 1981-01-08 | Boehringer Mannheim Gmbh | Diagnostisches mittel zum nachweis von leukozyten in koerperfluessigkeiten |
US5017359A (en) | 1985-11-01 | 1991-05-21 | Centre National De La Recherche Scientifique | Aerosol compositions for in vivo imaging and therapy |
JPH0762027B2 (ja) * | 1986-05-29 | 1995-07-05 | 焼津水産化学工業株式会社 | 新規リゾチ−ム活性測定基質 |
US5700636A (en) * | 1990-10-19 | 1997-12-23 | Becton Dickinson And Company | Methods for selectively detecting microorganisms associated with vaginal infections in complex biological samples |
US5599916A (en) | 1994-12-22 | 1997-02-04 | Kimberly-Clark Corporation | Chitosan salts having improved absorbent properties and process for the preparation thereof |
DE69611319T2 (de) * | 1995-05-15 | 2001-04-26 | Xerox Corp | Bilderzeugungselemente nach dem Migrationsverfahren |
TW389694B (en) | 1995-08-17 | 2000-05-11 | Novartis Ag | Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics |
US6806260B1 (en) | 1998-11-10 | 2004-10-19 | Netech, Inc. | Functional chitosan derivative |
ATE337765T1 (de) | 1999-04-02 | 2006-09-15 | Kinetic Concepts Inc | Vakuumunterstütze verschlussvorrichtung mit heiz- und kühlvorrichtung |
US6716970B2 (en) | 2000-04-21 | 2004-04-06 | Adjuvant Pharmaceuticals, Llc | Water soluble, randomly substituted partial N-partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof |
GB0011202D0 (en) | 2000-05-09 | 2000-06-28 | Kci Licensing Inc | Abdominal wound dressing |
GB0025084D0 (en) | 2000-10-13 | 2000-11-29 | Cambridge Meditech | Improvements in detection |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
DK1455802T3 (da) | 2001-12-14 | 2009-02-16 | Dnp Canada Inc | Anvendelser af chitosanoligosaccharider |
US20030204070A1 (en) | 2002-01-23 | 2003-10-30 | Jian Chen | Polynucleotide encoding a novel methionine aminopeptidase, protease-39 |
JP4002541B2 (ja) * | 2002-07-19 | 2007-11-07 | 株式会社日本触媒 | 光拡散剤 |
JP4123351B2 (ja) * | 2002-08-09 | 2008-07-23 | 三菱瓦斯化学株式会社 | ポリエステル樹脂の製造方法 |
GB2393120A (en) | 2002-09-18 | 2004-03-24 | Johnson & Johnson Medical Ltd | Compositions for wound treatment |
GB2393656B (en) * | 2002-10-01 | 2005-11-16 | Johnson & Johnson Medical Ltd | Enzyme-sensitive therapeutic wound dressings |
GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
AU2004204561B2 (en) | 2003-01-09 | 2010-11-25 | Stryker European Operations Holdings Llc | Biomedical foams |
US20050250214A1 (en) * | 2004-05-05 | 2005-11-10 | Gee Kyle R | Zinc binding compounds and their method of use |
GB2402882B (en) | 2003-06-20 | 2007-03-28 | Johnson & Johnson Medical Ltd | Antioxidant wound dressing materials |
US20050011261A1 (en) | 2003-07-14 | 2005-01-20 | Lyon Mark Damon | Container and method for measuring and mixing micro and macro amounts |
CN101669967B (zh) | 2003-08-14 | 2013-06-05 | 美利肯公司 | 含银创伤护理装置、其组合物及制造方法 |
CN100554279C (zh) | 2003-09-17 | 2009-10-28 | 伊莱利利公司 | 用于疾病免疫干预的合成多糖抗原 |
GB0325129D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus in situ |
DE602004011105T2 (de) | 2003-11-03 | 2008-12-18 | Ethicon, Inc. | Verfahren, peptide und biosensoren mit eignung zum nachweis eines breiten spektrums von bakterien |
GB2422664A (en) | 2005-01-28 | 2006-08-02 | Ethicon Inc | Device for detecting an enzyme in a sample |
US7909805B2 (en) | 2004-04-05 | 2011-03-22 | Bluesky Medical Group Incorporated | Flexible reduced pressure treatment appliance |
GB0409446D0 (en) | 2004-04-28 | 2004-06-02 | Smith & Nephew | Apparatus |
US10413644B2 (en) | 2004-04-27 | 2019-09-17 | Smith & Nephew Plc | Wound treatment apparatus and method |
US20060275905A1 (en) * | 2004-07-26 | 2006-12-07 | The University Of Chicago | Gram positive bacterial mutants and methods of generating and using such mutants |
US9162005B2 (en) | 2005-04-25 | 2015-10-20 | Arch Biosurgery, Inc. | Compositions for prevention of adhesions and other barrier applications |
EP1922095A2 (fr) | 2005-09-07 | 2008-05-21 | Tyco Healthcare Group LP | Pansement de plaies avec un reservoir a vide |
CA2923372C (fr) | 2005-09-07 | 2019-07-30 | Smith & Nephew, Inc. | Dispositif integre a un pansement |
ATE506486T1 (de) * | 2006-01-05 | 2011-05-15 | Basf Se | Mit reaktivfarbstoff gepfropfte bindemittel |
US8075503B2 (en) | 2006-01-23 | 2011-12-13 | Kci Licensing, Inc. | System and method for treating a wound using ultrasonic debridement |
RU2436597C2 (ru) | 2006-02-06 | 2011-12-20 | КейСиАй ЛАЙСЕНЗИНГ, ИНК. | Способы и устройства для усовершенствованного присоединения раневых повязок к системам лечения ран пониженным давлением |
US7779625B2 (en) | 2006-05-11 | 2010-08-24 | Kalypto Medical, Inc. | Device and method for wound therapy |
GB2439928A (en) | 2006-07-13 | 2008-01-16 | Ethicon Inc | Hydrogel wound dressings exhibiting reduced fiber losses |
CA2776011C (fr) | 2006-10-13 | 2017-01-10 | Kci Licensing, Inc. | Systeme d'application de pression reduite equipe d'une pompe a commande manuelle pour traiter des blessures peu severes |
GB0620504D0 (en) | 2006-10-16 | 2006-11-22 | Queen Mary & Westfield College | Method |
FR2916356B1 (fr) | 2007-05-25 | 2009-08-28 | Urgo Soc Par Actions Simplifie | Nouvel agent permettant le relargage d'actifs dans des pansements contenant au moins un corps gras |
US20090075891A1 (en) | 2007-08-06 | 2009-03-19 | Macphee Martin | Methods and dressings for sealing internal injuries |
GB2452720A (en) | 2007-09-11 | 2009-03-18 | Ethicon Inc | Wound dressing with an antimicrobial absorbent layer and an apertured cover sheet |
JP5511670B2 (ja) | 2007-10-11 | 2014-06-04 | スピレイカー・インコーポレイテッド | 縫合された切開の陰圧創傷治療装置および使用方法 |
ES2715605T3 (es) | 2007-11-21 | 2019-06-05 | Smith & Nephew | Apósito para heridas |
ES2555204T3 (es) | 2007-11-21 | 2015-12-29 | T.J. Smith & Nephew Limited | Dispositivo de succión y venda |
JP5432175B2 (ja) | 2007-12-12 | 2014-03-05 | スリーエム イノベイティブ プロパティズ カンパニー | 物品の製造方法及び物品 |
CN101946171B (zh) * | 2007-12-14 | 2014-03-12 | 拜奥蒂乌姆股份有限公司 | 荧光化合物 |
US20090234306A1 (en) | 2008-03-13 | 2009-09-17 | Tyco Healthcare Group Lp | Vacuum wound therapy wound dressing with variable performance zones |
US9199012B2 (en) | 2008-03-13 | 2015-12-01 | Smith & Nephew, Inc. | Shear resistant wound dressing for use in vacuum wound therapy |
GB0805162D0 (en) | 2008-03-19 | 2008-04-23 | Bristol Myers Squibb Co | Antibacterial wound dressing |
US20110027548A1 (en) * | 2008-03-28 | 2011-02-03 | Clariant Finance (Bvi) Limited | Influencing the Near Infrared Reflectance of Dyed Textile Materials |
EP2282707A1 (fr) | 2008-04-04 | 2011-02-16 | 3M Innovative Properties Company | Pansement avec micropompe |
GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
CN102083478B (zh) | 2008-05-21 | 2014-05-21 | 莫利斯·托帕斯 | 伤口愈合装置 |
ITAR20080022A1 (it) | 2008-05-26 | 2009-11-27 | Daniele Guidi | Dispositivo per drenaggio, in particolare per aspirazione in caso di terapie in aspirazione, fistole, deiscenze di ferite chirurgiche, piaghe da decubito, traumi e lesioni similari. |
US8187237B2 (en) | 2008-05-30 | 2012-05-29 | Kci Licensing, Inc | Reduced-pressure, linear wound closing bolsters and systems |
US20200113741A1 (en) | 2008-05-30 | 2020-04-16 | Kci Licensing, Inc. | Dressing with tissue viewing capability |
WO2009158130A1 (fr) | 2008-05-30 | 2009-12-30 | Kci Licensing, Inc. | Systèmes et appareils de compression à pression réduite destinés à être utilisés sur une partie incurvée du corps |
EP2145904A1 (fr) * | 2008-07-18 | 2010-01-20 | Basf Se | Procédé d'hydrolyse catalysée par enzymes d'esters d'acide polyacrylique et estérases utilisées à cet effet |
US8460698B2 (en) | 2008-08-01 | 2013-06-11 | Milliken & Company | Composite article suitable for use as a wound dressing |
CA2731427C (fr) | 2008-08-08 | 2020-01-28 | Tyco Healthcare Group Lp | Pansement de fibres continues |
WO2010021930A1 (fr) | 2008-08-16 | 2010-02-25 | Synedgen, Inc. | Prévention et traitement d’infections à staphylococcus aureus résistant à la méthicilline (mrsa) avec des dérivés de chitosane |
GB2463523B (en) | 2008-09-17 | 2013-05-01 | Medtrade Products Ltd | Wound care device |
AU2009293593C1 (en) | 2008-09-18 | 2014-07-10 | Kci Licensing, Inc. | Therapy delivery systems and methods |
GB0904582D0 (en) | 2008-09-24 | 2009-04-29 | Lumina Adhesives | Switchable adhesives |
GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
US8624077B2 (en) | 2008-10-02 | 2014-01-07 | L.R.R.&D. Ltd. | Interface layer wound dressing |
CN103877628B (zh) | 2008-10-29 | 2018-04-06 | 凯希特许有限公司 | 减压伤口闭合和处理系统及方法 |
US8460257B2 (en) | 2008-11-07 | 2013-06-11 | Kci Licensing, Inc. | Reduced-pressure, wound-treatment dressings and systems |
MX2011005075A (es) | 2008-11-14 | 2011-05-25 | Kci Licensing Inc | Bolsa para fluidos, sistema y metodo para almacenar fluido proveniente de un sitio de tejido. |
WO2010059612A2 (fr) | 2008-11-18 | 2010-05-27 | Kci Licensing, Inc. | Collecteurs composites à pression réduite |
EP2358425B1 (fr) | 2008-11-25 | 2014-11-12 | Spiracur Inc. | Dispositif d'application de pression réduite à des surfaces corporelles |
US8361043B2 (en) | 2009-01-07 | 2013-01-29 | Spiracur Inc. | Reduced pressure therapy of the sacral region |
US8162907B2 (en) | 2009-01-20 | 2012-04-24 | Tyco Healthcare Group Lp | Method and apparatus for bridging from a dressing in negative pressure wound therapy |
CA2751386C (fr) | 2009-02-03 | 2018-03-06 | Microbion Corporation | Bismuth-thiols comme antiseptiques pour tissus epitheliaux, plaies aigues et chroniques, biofilms bacteriens et autres indications |
GB0913775D0 (en) * | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
GB0902368D0 (en) | 2009-02-13 | 2009-04-01 | Smith & Nephew | Wound packing |
US20190298578A1 (en) | 2009-03-26 | 2019-10-03 | Stephen Shulman | Vented emergency wound dressings with anti-thrombogenic layers |
US10792404B2 (en) | 2009-04-10 | 2020-10-06 | Kci Licensing, Inc. | Methods and devices for applying closed incision negative pressure wound therapy |
GB2470040A (en) | 2009-05-06 | 2010-11-10 | Systagenix Wound Man Ip Co Bv | Wound dressing material comprising N-acetyl cysteine |
PT2433138T (pt) | 2009-05-18 | 2016-12-19 | Technische Universität Graz | Método para detectar infecções numa ferida |
EP2442835B1 (fr) | 2009-06-16 | 2014-12-10 | Baxter International Inc | Éponge hémostatique |
EP2442770B1 (fr) | 2009-06-16 | 2016-03-30 | 3M Innovative Properties Company | Pansement médical conformable avec substrat autoporteur |
US20100324516A1 (en) | 2009-06-18 | 2010-12-23 | Tyco Healthcare Group Lp | Apparatus for Vacuum Bridging and/or Exudate Collection |
KR101736517B1 (ko) * | 2009-07-08 | 2017-05-16 | 더루우브리졸코오포레이션 | 분산제 점도 조정제 |
US8469936B2 (en) | 2009-07-15 | 2013-06-25 | Kci Licensing, Inc. | Reduced-pressure dressings, systems, and methods employing desolidifying barrier layers |
US8690844B2 (en) | 2009-08-27 | 2014-04-08 | Kci Licensing, Inc. | Re-epithelialization wound dressings and systems |
US20110066123A1 (en) | 2009-09-15 | 2011-03-17 | Aidan Marcus Tout | Medical dressings, systems, and methods employing sealants |
CN102596560B (zh) | 2009-11-09 | 2015-11-25 | 3M创新有限公司 | 医疗制品及使用可混溶组合物进行制备的方法 |
EP2498828B1 (fr) | 2009-11-09 | 2018-12-26 | 3M Innovative Properties Company | Articles médicaux et procédés de fabrication utilisant des matériaux non miscibles |
GB0919659D0 (en) | 2009-11-10 | 2009-12-23 | Convatec Technologies Inc | A component for a wound dressing |
CN102770165B (zh) | 2009-12-22 | 2016-07-06 | 史密夫和内修有限公司 | 用于负压伤口治疗的设备 |
AU2011207572A1 (en) | 2010-01-20 | 2012-07-05 | Kci Licensing, Inc. | Foam wound inserts with regions of higher and lower densities, wound dressings, and methods |
US8791315B2 (en) | 2010-02-26 | 2014-07-29 | Smith & Nephew, Inc. | Systems and methods for using negative pressure wound therapy to manage open abdominal wounds |
CN102933554A (zh) | 2010-03-02 | 2013-02-13 | 黄玉梅 | 用于研究蛋白质-蛋白质相互作用的交联试剂、方法和组合物 |
US10709883B2 (en) | 2010-03-04 | 2020-07-14 | Donald Spector | Bandage with microneedles for antimicrobial delivery and fluid absorption from a wound |
US8721606B2 (en) | 2010-03-11 | 2014-05-13 | Kci Licensing, Inc. | Dressings, systems, and methods for treating a tissue site |
US8469935B2 (en) | 2010-03-11 | 2013-06-25 | Kci Licensing, Inc. | Abdominal treatment systems, delivery devices, and methods |
US8430867B2 (en) | 2010-03-12 | 2013-04-30 | Kci Licensing, Inc. | Reduced-pressure dressing connection pads, systems, and methods |
US9358158B2 (en) | 2010-03-16 | 2016-06-07 | Kci Licensing, Inc. | Patterned neo-epithelialization dressings, systems, and methods |
US8814842B2 (en) | 2010-03-16 | 2014-08-26 | Kci Licensing, Inc. | Delivery-and-fluid-storage bridges for use with reduced-pressure systems |
WO2011121394A1 (fr) | 2010-03-31 | 2011-10-06 | Pharmaplast Sae | Pansement pour soins des plaies, procédé et ligne de production pour la fabrication du pansement pour soins des plaies |
US8632512B2 (en) | 2010-04-09 | 2014-01-21 | Kci Licensing, Inc. | Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds |
JP6075732B2 (ja) | 2010-04-13 | 2017-02-08 | ケーシーアイ ライセンシング インク | 反応性成分を含む組成物ならびに創傷被覆材、装置および方法 |
US20190381222A9 (en) | 2010-04-16 | 2019-12-19 | Kci Licensing, Inc. | Reduced-Pressure Sources, Systems, And Methods Employing A Polymeric, Porous, Hydrophobic Material |
US8604265B2 (en) | 2010-04-16 | 2013-12-10 | Kci Licensing, Inc. | Dressings and methods for treating a tissue site on a patient |
GB201008347D0 (en) | 2010-05-19 | 2010-07-07 | Smith & Nephew | Wound protection |
GB201006986D0 (en) | 2010-04-27 | 2010-06-09 | Smith & Nephew | Wound dressing |
USRE48117E1 (en) | 2010-05-07 | 2020-07-28 | Smith & Nephew, Inc. | Apparatuses and methods for negative pressure wound therapy |
US10639404B2 (en) | 2010-06-03 | 2020-05-05 | Wound Healing Technologies, Llc | Wound dressing |
KR101988418B1 (ko) | 2010-06-17 | 2019-09-24 | 코블론 테크놀로지스 인코포레이티드 | 미립자 클로로헥시딘을 함유하는 항균 실리콘계 상처 드레싱 및 제조방법 |
US9265665B2 (en) | 2010-07-19 | 2016-02-23 | Kci Licensing, Inc. | Inflatable off-loading wound dressing assemblies, systems, and methods |
EP2412690A2 (fr) | 2010-07-28 | 2012-02-01 | Dow Global Technologies LLC | Dérivés de polysaccharide dotés d'une morphologie de particules ajustée pour la prise hydrolytique de compositions |
US8795246B2 (en) | 2010-08-10 | 2014-08-05 | Spiracur Inc. | Alarm system |
GB201015656D0 (en) | 2010-09-20 | 2010-10-27 | Smith & Nephew | Pressure control apparatus |
EP2627769A2 (fr) * | 2010-10-14 | 2013-08-21 | Regado Biosciences, Inc. | Modulateurs d'acide nucléique de clec-2 |
JP6078472B2 (ja) | 2010-11-25 | 2017-02-08 | スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company | 組成物i−iiおよび生成物ならびにそれらの使用 |
US8613733B2 (en) | 2010-12-15 | 2013-12-24 | Kci Licensing, Inc. | Foam dressing with integral porous film |
EP2666021A1 (fr) * | 2011-01-21 | 2013-11-27 | IR2DX, Inc. | Biomarqueurs pour détermination rapide de l'efficacité d'un médicament |
GB2488749A (en) | 2011-01-31 | 2012-09-12 | Systagenix Wound Man Ip Co Bv | Laminated silicone coated wound dressing |
US9932622B2 (en) | 2011-01-31 | 2018-04-03 | Woundchek Laboratories B.V. | Wound prognosis |
EP3932327A1 (fr) | 2011-02-04 | 2022-01-05 | University Of Massachusetts | Dispositif de fermeture de plaie par pression négative |
US9107990B2 (en) | 2011-02-14 | 2015-08-18 | Kci Licensing, Inc. | Reduced-pressure dressings, systems, and methods for use with linear wounds |
EP2696826B1 (fr) | 2011-04-12 | 2018-09-19 | KCI Licensing, Inc. | Poche de fluide à évaporation et systèmes pour utilisation avec des liquides organiques |
GB201106491D0 (en) | 2011-04-15 | 2011-06-01 | Systagenix Wound Man Ip Co Bv | Patterened silicone coating |
AU2012249615A1 (en) | 2011-04-29 | 2013-08-29 | Kci Licensing, Inc. | Aptamer-modified polymeric materials for the binding of therapeutic factors in a wound environment |
GB201108229D0 (en) | 2011-05-17 | 2011-06-29 | Smith & Nephew | Tissue healing |
CA2834702C (fr) | 2011-05-26 | 2019-03-26 | Kci Licensing, Inc. | Systemes et procedes de stimulation et d'activation de fluides destines a etre utilises dans une therapie par instillation |
WO2012170744A2 (fr) | 2011-06-07 | 2012-12-13 | Spiracur, Inc. | Solutions pour le pontage et la réduction de concentration de pression à des sites de plaie |
ES2610233T3 (es) | 2011-06-07 | 2017-04-26 | Smith & Nephew Plc | Miembros y métodos para poner en contacto con heridas |
FR2977491B1 (fr) | 2011-07-05 | 2013-07-26 | Melvita Production | Composition cosmetique comprenant un melange de miels |
CN103764186B (zh) | 2011-07-26 | 2016-05-04 | 凯希特许有限公司 | 用减压治疗组织部位的系统和方法,牵涉一个具有用于接触歧管的多管腔导管的减压接口 |
JP6131253B2 (ja) | 2011-07-26 | 2017-05-17 | スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company | 減圧治療システムの動作を制御するためのシステム及び方法 |
GB201113515D0 (en) | 2011-08-04 | 2011-09-21 | Convatec Technologies Inc | A dressing |
US11534523B2 (en) | 2011-08-30 | 2022-12-27 | Avery Dennison Corporation | Silicone absorbent adhesive layer |
DE102011081818A1 (de) | 2011-08-30 | 2013-02-28 | Beiersdorf Ag | Wirkstoffhaltige Hautauflagen |
EP2944298B1 (fr) | 2011-08-31 | 2017-05-17 | KCI Licensing, Inc. | Poches de stockage en ligne destinées à être utilisées avec des fluides corporels |
DE102011120492A1 (de) | 2011-09-02 | 2013-03-07 | BLüCHER GMBH | Wundauflage mit luftdurchlässiger Lage |
ES2523377T5 (es) | 2011-09-09 | 2018-04-19 | Paul Hartmann Ag | Apósito abdominal con ayuda de aplicación |
CR20190006A (es) | 2011-09-12 | 2019-03-18 | Protege Biomedical Llc | Composición y aposito para tratamiento de heridas |
DK2572737T3 (en) | 2011-09-26 | 2016-06-27 | Bsn Medical Gmbh | improved wound dressing |
US9393354B2 (en) | 2011-11-01 | 2016-07-19 | J&M Shuler Medical, Inc. | Mechanical wound therapy for sub-atmospheric wound care system |
US20140309574A1 (en) | 2011-11-01 | 2014-10-16 | Brightwake Limited | Wound dressings, and yarn useful therein |
EP2779975B1 (fr) | 2011-11-15 | 2020-02-19 | KCI Licensing, Inc. | Pansements médicaux, systèmes, et procédés avec transmission de vapeur thermiquement améliorée |
US9132040B2 (en) | 2011-11-17 | 2015-09-15 | Ethicon, Inc. | Dressing device |
WO2013074829A1 (fr) | 2011-11-18 | 2013-05-23 | Kci Licensing, Inc. | Systèmes et procédés de traitement de tissus comprenant un substrat poreux doté d'une région comprimée et d'une région expansée |
US9204801B2 (en) | 2011-11-21 | 2015-12-08 | Kci Licensing, Inc. | Systems, devices, and methods for identifying portions of a wound filler left at a tissue site |
US10940047B2 (en) | 2011-12-16 | 2021-03-09 | Kci Licensing, Inc. | Sealing systems and methods employing a hybrid switchable drape |
CN104203301B (zh) | 2012-01-10 | 2017-12-15 | 凯希特许有限公司 | 用于向伤口治疗敷件递送流体的系统和方法 |
CN107522880B (zh) | 2012-01-25 | 2020-07-24 | 阿克伦大学 | 水凝胶及其制备方法 |
GB201201751D0 (en) | 2012-02-01 | 2012-03-14 | Haemostatix Ltd | Haemostatic wound dressing |
CN104053420B (zh) | 2012-02-02 | 2020-07-14 | 凯希特许有限公司 | 用于定向肉芽形成的泡沫结构伤口插入物 |
EP2817038B2 (fr) | 2012-02-21 | 2023-06-07 | KCI Licensing, Inc. | Récipient à orientations multiples destiné à être utilisé avec un système de traitement à pression réduite |
CN107496932A (zh) * | 2012-02-27 | 2017-12-22 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
US10470936B2 (en) | 2012-02-29 | 2019-11-12 | Hollister Incorporated | Buffered adhesive compositions for skin-adhering medical products |
JP6092243B2 (ja) | 2012-02-29 | 2017-03-08 | ホリスター・インコーポレーテッドHollister Incorporated | 皮膚粘着医療製品用の緩衝粘着剤組成物 |
EP2636417B1 (fr) | 2012-03-05 | 2017-04-26 | Lohmann & Rauscher GmbH | Agencement de pansement de plaies et dispositif de revêtement correspondant |
CA3122007A1 (en) | 2012-03-12 | 2013-09-19 | Smith & Nephew Plc | Reduced pressure apparatus and methods |
US10576037B2 (en) | 2012-03-14 | 2020-03-03 | MAM Holdings of West Florida, L.L.C. | Compositions comprising placental collagen for use in wound healing |
US9427505B2 (en) | 2012-05-15 | 2016-08-30 | Smith & Nephew Plc | Negative pressure wound therapy apparatus |
EP2852419B1 (fr) | 2012-05-22 | 2019-11-20 | Smith & Nephew plc | Dispositif de fermeture de blessure |
EP3650055A1 (fr) | 2012-05-23 | 2020-05-13 | Smith & Nephew plc | Appareils et procédés pour le traitement de plaies par pression négative |
GB201209745D0 (en) | 2012-05-31 | 2012-07-18 | Convatec Technologies Inc | Wound dressing |
EP2854893B1 (fr) | 2012-06-03 | 2019-10-02 | Daniel Eduard Kleiner | Dispositif endoluminal de thérapie par le vide |
WO2014004701A1 (fr) | 2012-06-28 | 2014-01-03 | Kci Licensing, Inc. | Tampon de liaison de plaie à dispositif d'identification par radiofréquence (rfid) et capteur de pression à extensomètre intégré |
CN109316279B (zh) | 2012-07-16 | 2022-10-25 | 马萨诸塞州大学 | 负压伤口闭合设备 |
WO2014012171A1 (fr) | 2012-07-19 | 2014-01-23 | Innovotech, Inc. | Formulations de gel antimicrobien contenant un periodate d'argent (i) |
EP2879633B1 (fr) | 2012-07-30 | 2018-08-22 | KCI Licensing, Inc. | Pansement absorbant à pression réduite, système pour le traitement d'un site tissulaire, et procédé de fabrication du pansement |
BR112015002154A2 (pt) | 2012-08-01 | 2017-07-04 | Smith & Nephew | curativo de ferimento |
US9662427B2 (en) | 2012-08-13 | 2017-05-30 | Kci Licensing, Inc. | Intelligent therapy system with evaporation management |
AU2013306023A1 (en) * | 2012-08-20 | 2015-02-26 | The Lubrizol Corporation | Lubricating composition including esterified copolymer and diene rubber polymer |
CA2883373A1 (fr) | 2012-08-28 | 2014-03-06 | 3M Innovative Properties Company | Compositions de gluconate de chlorhexidine, systemes de resine et articles |
EP3763397B1 (fr) | 2012-08-31 | 2023-07-12 | Stryker European Operations Holdings LLC | Mousse hémostatique |
WO2014039557A1 (fr) | 2012-09-04 | 2014-03-13 | Integrated Healing Technologies | Pansement de plaie |
WO2014039715A1 (fr) * | 2012-09-07 | 2014-03-13 | University Of Rochester | Procédés et compositions pour le marquage spécifique d'un site de peptides et de protéines |
CA2884419A1 (fr) | 2012-09-12 | 2014-03-20 | Kci Licensing, Inc. | Systemes et methodes de collecte d'exsudats en therapie sous pression reduite |
BR112015005996A2 (pt) | 2012-09-20 | 2017-08-22 | Loske Gunnar | Disposição para tratamento a vácuo e filme para produção de disposição de tratamento a vácuo |
GB201216928D0 (en) | 2012-09-21 | 2012-11-07 | I2R Medical Ltd | Portable medical device system |
US9877875B2 (en) | 2012-10-09 | 2018-01-30 | Parasol Medical LLC | Antimicrobial hydrogel formulation |
US9572968B2 (en) | 2012-10-11 | 2017-02-21 | Hanuman Pelican, Inc. | Compressive oxygen diffusive wound dressings |
JP6183831B2 (ja) | 2012-10-23 | 2017-08-23 | 義之 小山 | ハイドロゲル形成材 |
US9657132B2 (en) | 2012-10-24 | 2017-05-23 | Kci Licensing, Inc. | Amine-functionalized polymeric compositions for medical devices |
US9616151B2 (en) | 2012-10-24 | 2017-04-11 | Kci Licensing, Inc. | Sulfhydryl-functionalized polymeric compositions for medical devices |
JP2016507663A (ja) | 2012-12-20 | 2016-03-10 | コンバテック・テクノロジーズ・インコーポレイテッドConvatec Technologies Inc | 化学修飾セルロース系繊維の加工 |
JP6495178B2 (ja) | 2012-12-21 | 2019-04-03 | スリーエム イノベイティブ プロパティズ カンパニー | フラップを有する医療用手当用品 |
EP2941232B2 (fr) | 2013-01-03 | 2019-04-10 | KCI Licensing, Inc. | Couverture étanche absorbant l'humidité |
GB201309369D0 (en) | 2013-05-24 | 2013-07-10 | Smith & Nephew | Moisture indicating system |
US10973962B2 (en) | 2013-01-16 | 2021-04-13 | Kci Licensing, Inc. | Ion exchange enhanced absorbent systems |
EP3019547B1 (fr) | 2013-03-05 | 2020-07-22 | The Penn State Research Foundation | Matériaux composites |
EP2968702B1 (fr) | 2013-03-13 | 2019-12-11 | KCI Licensing, Inc. | Absorbeur extensible de collecte de fluide |
CN105188792B (zh) | 2013-03-14 | 2017-05-10 | 凯希特许有限公司 | 微孔导管 |
WO2014158529A1 (fr) | 2013-03-14 | 2014-10-02 | Kci Licensing, Inc. | Récipient destiné à la collecte de fluide et piège à humidité intégré |
WO2014158526A1 (fr) | 2013-03-14 | 2014-10-02 | Kci Licensing, Inc. | Traitement par pression négative à capacité de profil dynamique |
US20160022861A1 (en) | 2013-03-15 | 2016-01-28 | Martin MacPhee | Compositions having absorbable materials, methods, and applicators for sealing injuries |
CA2902181A1 (fr) | 2013-03-15 | 2014-09-25 | Smith & Nephew, Inc. | Film soluble formant un gel servant a delivrer des agents actifs |
ES2964341T3 (es) | 2013-03-15 | 2024-04-05 | Euromed Inc | Composición adhesiva |
US20160120706A1 (en) | 2013-03-15 | 2016-05-05 | Smith & Nephew Plc | Wound dressing sealant and use thereof |
US10492956B2 (en) | 2013-03-15 | 2019-12-03 | Kci Licensing, Inc. | Topical vacuum-press surgical incisional dressings, surgical adjuncts, hybrids and composites |
RU2015143729A (ru) | 2013-03-15 | 2017-04-21 | СМИТ ЭНД НЕФЬЮ ПиЭлСи | Раневая повязка и способ лечения |
US10792337B2 (en) | 2013-03-15 | 2020-10-06 | Kci Licensing, Inc. | Wound healing compositions |
ES2778375T3 (es) | 2013-04-08 | 2020-08-10 | Univ Yeditepe | Hidrogel a base de polímeros |
GB2512841B (en) | 2013-04-08 | 2020-07-15 | Brightwake Ltd | Absorbent wound dressings |
WO2014169250A1 (fr) | 2013-04-11 | 2014-10-16 | President And Fellows Of Harvard College | Bandages préfabriqués à base de médicament et d'alginate |
WO2014170461A1 (fr) | 2013-04-17 | 2014-10-23 | Molnlycke Health Care Ab | Pansements pour plaies |
US10016380B2 (en) | 2013-05-01 | 2018-07-10 | Lanny Leo Johnson | Antimicrobials and methods of use thereof |
US9884087B1 (en) | 2013-05-03 | 2018-02-06 | Chan Soon-Shiong Nanthealth Foundation | Compositions and methods of improved wound healing |
EP2994176B1 (fr) | 2013-05-10 | 2020-07-08 | Smith & Nephew plc | Raccord fluidique pour irrigation et aspiration de plaies |
AU2014268601B2 (en) | 2013-05-22 | 2017-06-15 | The Penn State Research Foundation | Wound dressings and applications thereof |
EP3013294B1 (fr) | 2013-06-28 | 2019-09-25 | 3M Innovative Properties Company | Pansement revêtu de fibrine |
WO2015002888A1 (fr) | 2013-07-01 | 2015-01-08 | Trustees Of Boston University | Compositions d'hydrogels dissolvables pour le traitement des plaies et procédés d'utilisation |
US10765774B2 (en) | 2013-07-09 | 2020-09-08 | Ethicon, Inc. | Hemostatic pad assembly kit and method |
CA2919973A1 (fr) | 2013-08-05 | 2015-02-12 | 3M Innovative Properties Company | Dispositif de support ayant un element d'amortissement contenu |
BR112016002822B1 (pt) | 2013-08-12 | 2022-07-12 | Bsn Medical Gmbh | Artigo para o tratamento de feridas plano e seu uso |
WO2015022907A1 (fr) | 2013-08-13 | 2015-02-19 | 生化学工業株式会社 | Médicament contenant du chitosane cationisé |
US10117978B2 (en) | 2013-08-26 | 2018-11-06 | Kci Licensing, Inc. | Dressing interface with moisture controlling feature and sealing function |
GB2518199A (en) | 2013-09-13 | 2015-03-18 | Xiros Ltd | Method of producing a swellable polymer fibre |
US10342891B2 (en) | 2013-09-19 | 2019-07-09 | Medline Industries, Inc. | Wound dressing containing saccharide and collagen |
EP3281651B1 (fr) | 2013-10-02 | 2019-12-11 | KCI Licensing, Inc. | Système de thérapie jetable à pression réduite avec retour mécanique |
EP3054908B1 (fr) | 2013-10-10 | 2018-04-04 | Roche Diabetes Care GmbH | Système de support pour un objet porté par un corps et procédé de fabrication |
US20160271178A1 (en) | 2013-10-18 | 2016-09-22 | Agency For Science, Technology And Research | Nanoparticle-containing hydrogels |
EP3060181B1 (fr) | 2013-10-21 | 2021-11-03 | Smith & Nephew, Inc. | Dispositif de fermeture de plaie par pression négative |
GB201318842D0 (en) | 2013-10-24 | 2013-12-11 | First Water Ltd | Flexible hydrogel wound dressings |
US10946124B2 (en) | 2013-10-28 | 2021-03-16 | Kci Licensing, Inc. | Hybrid sealing tape |
WO2015065612A1 (fr) | 2013-10-30 | 2015-05-07 | Kci Licensing, Inc. | Système d'absorption et de dissipation d'un condensat |
MX351120B (es) | 2013-11-07 | 2017-10-03 | Bsn Medical Gmbh | Apósito médico. |
GB2522178B (en) | 2013-11-12 | 2018-07-18 | First Water Ltd | Multilayer composition |
WO2015075406A1 (fr) | 2013-11-19 | 2015-05-28 | Lipopeptide Ab | Nouveau traitement d'ulcères chroniques |
RU2682642C1 (ru) | 2013-12-12 | 2019-03-20 | Инновейшн Текнолоджиз, Инк. | Материалы и способы борьбы c инфекциями |
WO2015102981A1 (fr) | 2013-12-31 | 2015-07-09 | 3M Innovative Properties Company | Bandage couvrant conformable |
EP3096727B1 (fr) | 2014-01-24 | 2018-03-14 | Avent, Inc. | Système de pansement traumatique à feuille externe conformable |
WO2015123340A1 (fr) | 2014-02-11 | 2015-08-20 | Spiracur Inc. | Procédés et dispositifs pour l'application d'une thérapie par pression négative sur une incision fermée |
DE102014202578A1 (de) | 2014-02-12 | 2015-08-13 | Aesculap Ag | Medizinisches Produkt und Verfahren zu seiner Herstellung |
AU2015218302B2 (en) | 2014-02-14 | 2019-11-07 | Atomic Medical Innovations, Inc. | Systems and methods for tissue healing |
WO2015123353A1 (fr) | 2014-02-14 | 2015-08-20 | Kci Licensing, Inc. | Systèmes et procédés pour l'augmentation de la capacité absorbante d'un pansement |
EP3848009A1 (fr) | 2014-02-28 | 2021-07-14 | 3M Innovative Properties Company | Pansement hybride ayant une grille perforée recouverte d'un gel |
GB201404021D0 (en) | 2014-03-05 | 2014-04-23 | Lumina Adhesives Ab | Low cytotoxity switchable adhesive compositions, medical dressings and skin coverings, and methods of treatment using same |
US20150367019A1 (en) | 2014-03-12 | 2015-12-24 | Stb, Ltd. | Hemostatic compositions and methods |
EP3119360B1 (fr) | 2014-03-21 | 2020-08-12 | Medline Industries, Inc., | Système de traitement des plaies et méthodes d'utilisation associées |
US10124084B2 (en) | 2014-03-24 | 2018-11-13 | Datt Life Sciences Private Limited | Ready to use biodegradable and biocompatible device and a method of preparation thereof |
GB2524510B (en) | 2014-03-25 | 2020-02-19 | Brightwake Ltd | Wound dressing impregnated with honey |
CA2947390C (fr) | 2014-04-30 | 2022-10-18 | Matoke Holdings Limited | Compositions antimicrobiennes |
WO2015168681A1 (fr) | 2014-05-02 | 2015-11-05 | Kci Licensing, Inc. | Dispositifs, systèmes et procédés de stockage de fluide |
CN111839658A (zh) | 2014-05-09 | 2020-10-30 | 凯希特许有限公司 | 用于与负压和流体滴注一起使用的破坏性敷件 |
US9974694B2 (en) | 2014-05-09 | 2018-05-22 | RCI Licensing, Inc. | Dressing with contracting layer for linear tissue sites |
US10398610B2 (en) | 2014-05-13 | 2019-09-03 | The Procter & Gamble Company | Absorbent article with dual core |
GB2526267B (en) | 2014-05-14 | 2020-10-28 | Brightwake Ltd | Dressing for surgical drain |
US11026847B2 (en) | 2014-06-02 | 2021-06-08 | Zdzislaw Harry Piotrowski | Systems and methods for wound healing |
AU2015269359B2 (en) | 2014-06-05 | 2019-08-15 | Kci Licensing, Inc. | Dressing with fluid acquisition and distribution characteristics |
KR101743274B1 (ko) | 2014-06-12 | 2017-06-02 | 주식회사 엘지화학 | 고흡수성 수지 |
KR101786825B1 (ko) | 2014-06-18 | 2017-10-18 | 도레이 카부시키가이샤 | 적층체 및 그 제조 방법 |
JP6586431B2 (ja) | 2014-06-18 | 2019-10-02 | スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company | 創傷包帯および治療方法 |
JP6659540B2 (ja) | 2014-07-07 | 2020-03-04 | 株式会社村田製作所 | 陰圧閉鎖治療装置 |
BR112017000338B1 (pt) | 2014-07-09 | 2021-02-23 | Lubrizol Advanced Materials, Inc | Composição de combinação de hidrogel, cobertura para feridas, gel,creme ou loção, e, processo para preparação de uma composição de combinaçãode hidrogel |
CN106687801A (zh) | 2014-07-10 | 2017-05-17 | 史密夫及内修公开有限公司 | 聚合物材料以及关于聚合物材料的改进 |
WO2016014158A1 (fr) | 2014-07-24 | 2016-01-28 | Arthrocare Corporation | Mousses élastiques de polysaccharide et leurs utilisations |
US10416144B2 (en) * | 2014-07-28 | 2019-09-17 | Kansas State University Research Foundation | Nanosensors for detecting enzymatic activity in dairy production |
AU2014402290B2 (en) | 2014-07-31 | 2020-05-21 | Smith & Nephew, Inc. | Systems and methods for applying reduced pressure therapy |
US20200289723A1 (en) | 2014-07-31 | 2020-09-17 | Smith & Nephew, Inc. | Reduced pressure therapy apparatus construction and control |
CN106794275A (zh) | 2014-08-04 | 2017-05-31 | 圣胡安德申医院 | 用于立即释放活性剂的系统 |
US9770369B2 (en) | 2014-08-08 | 2017-09-26 | Neogenix, Llc | Wound care devices, apparatus, and treatment methods |
US10583042B2 (en) | 2014-08-08 | 2020-03-10 | Neogenix, Llc | Wound care devices, apparatus, and treatment methods |
US10076587B2 (en) | 2014-08-11 | 2018-09-18 | Kci Licensing, Inc. | Protease modulating wound interface layer for use with negative pressure wound therapy |
JP6709780B2 (ja) | 2014-09-09 | 2020-06-17 | ユニバーシティ・オブ・ワシントン | 官能性双性イオン性ポリマーおよび混合電荷ポリマー、関連するヒドロゲルならびにこれらの使用方法 |
EP2995287A1 (fr) | 2014-09-11 | 2016-03-16 | Mölnlycke Health Care AB | Pansement médical |
EP2995324A1 (fr) | 2014-09-11 | 2016-03-16 | Mölnlycke Health Care AB | Pansement médical |
CN107073161B (zh) | 2014-10-01 | 2020-11-03 | 3M创新有限公司 | 用于清创术的多孔装置、套件和方法 |
AU2015328825B2 (en) | 2014-10-06 | 2019-02-21 | Gatt Technologies B.V. | Tissue-adhesive porous haemostatic product |
EP3446665B1 (fr) | 2014-10-06 | 2021-12-15 | 3M Innovative Properties Company | Systèmes et appareils absorbants d'échange d'ions |
US9855364B2 (en) | 2014-10-15 | 2018-01-02 | Allison Coomber | Wound dressing materials incorporating anthocyanins derived from fruit or vegetable sources |
ES2636823T3 (es) | 2014-10-24 | 2017-10-09 | Sefar Ag | Material para recubrimiento de heridas y procedimiento para su fabricación |
US10485893B2 (en) | 2014-11-13 | 2019-11-26 | Sarasota Medical Products, Inc. | Antimicrobial hydrocolloid dressing containing sequestered peroxide and preparation thereof |
EP3023083A1 (fr) | 2014-11-20 | 2016-05-25 | Mölnlycke Health Care AB | Pansements pour plaies |
WO2016086088A2 (fr) | 2014-11-25 | 2016-06-02 | Northwestern University | Cicatrisation par surexpression de sirt1 |
CN106999622A (zh) | 2014-12-04 | 2017-08-01 | 3M创新有限公司 | 包含生物玻璃的抗微生物组合物 |
US10525170B2 (en) | 2014-12-09 | 2020-01-07 | Tangible Science, Llc | Medical device coating with a biocompatible layer |
TW201622668A (zh) | 2014-12-16 | 2016-07-01 | 準訊生醫股份有限公司 | 長效型貼片敷料結構 |
WO2016100098A1 (fr) | 2014-12-17 | 2016-06-23 | Kci Licensing, Inc. | Pansement avec capacité de mise en décharge |
EP3233492B1 (fr) | 2014-12-18 | 2021-11-10 | Kindeva Drug Delivery L.P. | Procédés de manipulation de pièces de stratifié adhésives |
EP3234052B1 (fr) | 2014-12-19 | 2020-09-16 | 3M Innovative Properties Company | Article adhésif comprenant une couche d'apprêt à base de poly(méth)acrylate et méthodes de préparation de ceci |
CA2971796C (fr) | 2014-12-22 | 2023-05-16 | Smith & Nephew Plc | Appareil et procedes de traitement des plaies par pression negative |
JP2018510035A (ja) | 2014-12-29 | 2018-04-12 | スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company | 陰圧閉鎖治療器及び器具を動作させる方法 |
CN107106742B (zh) | 2014-12-30 | 2020-12-15 | 史密夫和内修有限公司 | 用于应用减压治疗的系统和方法 |
WO2016109418A1 (fr) | 2014-12-30 | 2016-07-07 | 3M Innovative Properties Company | Pansement à multiples couches adhésives |
US10660851B2 (en) | 2015-01-02 | 2020-05-26 | Rxos Medical | Polyfunctional radical scavenger hydrogel formulation |
KR101949455B1 (ko) | 2015-01-07 | 2019-02-18 | 주식회사 엘지화학 | 내고화성이 향상된 고흡수성 수지 및 그 제조 방법 |
GB201500430D0 (en) | 2015-01-12 | 2015-02-25 | Univ Birmingham | Dressing |
WO2016115448A1 (fr) | 2015-01-15 | 2016-07-21 | Marshall University Research Corporation | Couvertures de plaie comprenant de la vitamine d et procédés associés |
GB201501334D0 (en) | 2015-01-27 | 2015-03-11 | Medtrade Products Ltd | Composition for a wound dressing |
GB201501330D0 (en) | 2015-01-27 | 2015-03-11 | Medtrade Products Ltd | Composition for a wound dressing |
GB201501333D0 (en) | 2015-01-27 | 2015-03-11 | Medtrade Products Ltd | Composition for a wound dressing |
WO2016123539A1 (fr) | 2015-01-29 | 2016-08-04 | Wardell Mark R | Compositions pour cicatrisation des plaies comprenant du miel ayant des propriétés médicinales, des ions minéraux et du méthylglyoxal, et leurs procédés d'utilisation |
US20200093756A1 (en) | 2015-01-29 | 2020-03-26 | Sanmelix Laboratories, Inc. | Buckwheat honey and povidone-iodine wound-healing dressing |
KR101841469B1 (ko) | 2015-01-30 | 2018-03-23 | (주)메디팁 | 바이오폴리머를 이용한 창상 피복재의 제조방법 및 이를 이용하여 제조된 바이오폴리머를 이용한 창상 피복재 |
WO2016126444A1 (fr) | 2015-02-02 | 2016-08-11 | Kci Licensing, Inc. | Pansement personnalisable fermé de site tissulaire pour une meilleure élimination post-opératoire |
US10512707B2 (en) | 2015-02-02 | 2019-12-24 | University Of Southern California | System for sutureless closure of scleral perforations and other ocular tissue discontinuities |
EP3253426B1 (fr) | 2015-02-02 | 2019-11-20 | KCI Licensing, Inc. | Commutateur actionné par pression |
JP2018507033A (ja) | 2015-02-03 | 2018-03-15 | マトケ・ホールディングス・リミテッド | 抗微生物繊維及び組成物 |
GB201501965D0 (en) | 2015-02-05 | 2015-03-25 | Lumina Adhesives Ab | Polyurethane based switchable adhesives |
US10485892B2 (en) | 2015-03-10 | 2019-11-26 | Covalon Technologies Inc. | Method for local reduction of microbial skin flora |
ES2815660T3 (es) | 2015-03-10 | 2021-03-30 | Covalon Tech Inc | Procedimiento de reducción local de la flora microbiana cutánea |
US10478394B2 (en) | 2015-03-11 | 2019-11-19 | Wayne State University | Compositions and methods to promote wound healing |
GB201506236D0 (en) | 2015-04-13 | 2015-05-27 | Jellagen Pty Ltd | Modified collagen, methods of manufacture thereof |
EP3085344B1 (fr) | 2015-04-21 | 2019-12-04 | Mölnlycke Health Care AB | Tampon pour plaies et élément auto-adhésif comprenant un tampon pour plaies |
AU2016294135A1 (en) | 2015-04-23 | 2017-11-09 | Sharklet Technologies, Inc. | Bilayered devices for enhanced healing |
US10898388B2 (en) | 2015-04-27 | 2021-01-26 | Smith & Nephew Plc | Reduced pressure apparatuses and methods |
EP3936163B1 (fr) | 2015-05-07 | 2024-04-03 | Solventum Intellectual Properties Company | Structure de libération contrôlée d'iode destinée à être utilisée pour les soins des plaies |
WO2016182861A1 (fr) | 2015-05-08 | 2016-11-17 | Kci Licensing, Inc. | Débridement de blessure par irrigation à microbulles activées par ultrasons |
WO2016182977A1 (fr) | 2015-05-08 | 2016-11-17 | Kci Licensing, Inc. | Pansement à faible acuité doté d'une pompe intégrée |
US10507259B2 (en) | 2015-05-08 | 2019-12-17 | First Quality Retail Services, Llc | Flexible absorbent pad |
US20190298580A1 (en) | 2015-05-08 | 2019-10-03 | Kci Licensing, Inc. | Low-acuity dressing with integral pump |
EP3093031A1 (fr) | 2015-05-11 | 2016-11-16 | 3M Innovative Properties Company | Système de traitement des plaies |
EP3092987A1 (fr) | 2015-05-11 | 2016-11-16 | 3M Innovative Properties Company | Système de traitement de plaies à l'aide de sérum |
WO2016184918A1 (fr) | 2015-05-18 | 2016-11-24 | Smith & Nephew Plc | Systèmes de pompe thermo-assistés pour utilisation dans le traitement des plaies par pression négative |
US10076594B2 (en) | 2015-05-18 | 2018-09-18 | Smith & Nephew Plc | Fluidic connector for negative pressure wound therapy |
AU2016267402A1 (en) | 2015-05-26 | 2017-11-30 | Monash University | Antibacterial bismuth complexes |
KR101889677B1 (ko) | 2015-06-12 | 2018-08-17 | 제이에프이미네라르 가부시키가이샤 | 피부 창상 또는 피부 거침 치료제 |
US11559421B2 (en) | 2015-06-25 | 2023-01-24 | Hill-Rom Services, Inc. | Protective dressing with reusable phase-change material cooling insert |
US11083884B2 (en) | 2015-06-29 | 2021-08-10 | Kci Licensing, Inc. | Apparatus for negative-pressure therapy and irrigation |
WO2017011204A1 (fr) | 2015-07-14 | 2017-01-19 | Kci Licensing, Inc. | Dispositifs, systèmes et procédés d'interface de pansements médicaux |
EP3117806B1 (fr) | 2015-07-16 | 2020-06-10 | Lohmann & Rauscher GmbH | Systeme de traitement des plaies |
ES2945437T3 (es) | 2015-07-24 | 2023-07-03 | Moelnlycke Health Care Ab | Apósitos para heridas antimicrobianos absorbentes |
US10583228B2 (en) | 2015-07-28 | 2020-03-10 | J&M Shuler Medical, Inc. | Sub-atmospheric wound therapy systems and methods |
US10682257B2 (en) | 2015-07-29 | 2020-06-16 | Evophancie Biotech Ltd | Biological fiber composite dressing |
EP3328414B1 (fr) | 2015-07-31 | 2020-08-12 | Blue Blood Biotech Corp. | Composition destinée à être utilisée pour favoriser la cicatrisation de plaies |
US10639350B2 (en) | 2015-08-10 | 2020-05-05 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods and pharmaceutical compositions for improving wound healing using CD24 |
KR101787192B1 (ko) | 2015-08-12 | 2017-10-18 | 주식회사 제네웰 | 항균 드레싱재 및 그 제조방법 |
EP3135304A1 (fr) | 2015-08-26 | 2017-03-01 | Mölnlycke Health Care AB | Silicone expansé pour soins de plaies |
EP3344206B1 (fr) | 2015-08-31 | 2020-09-23 | 3M Innovative Properties Company | Pansements de traitement des plaies à pression négative comprenant des adhésifs (méth)acrylate sensibles à la pression présentant une meilleure adhérence à des surfaces humides |
US11096830B2 (en) | 2015-09-01 | 2021-08-24 | Kci Licensing, Inc. | Dressing with increased apposition force |
US10617608B2 (en) | 2015-09-25 | 2020-04-14 | Lotte Fine Chemical Co., Ltd. | Composition for hydrogel sheet, hydrogel sheet manufactured therefrom, and method for manufacturing same |
EP3356485B1 (fr) | 2015-09-30 | 2020-08-05 | 3M Innovative Properties Company | Compositions d'hydrogel liées à des substrats polymères |
GB2543307B (en) | 2015-10-14 | 2020-12-09 | Selentus Science Ltd | Haemostatic device |
KR20180078258A (ko) | 2015-10-30 | 2018-07-09 | 로레인 카운티 커뮤니티 칼리지 이노베이션 파운데이션 | 상처 치료 디바이스 및 방법 |
WO2017083166A1 (fr) | 2015-11-13 | 2017-05-18 | 3M Innovative Properties Company | Articles antimicrobiens et leurs procédés d'utilisation |
GB2544342B (en) | 2015-11-13 | 2020-06-03 | First Water Ltd | Compositions for application to wounds |
EP3377014A1 (fr) | 2015-11-18 | 2018-09-26 | KCI Licensing, Inc. | Champs opératoires et procédés permettant de réduire le traumatisme lors de leur retrait |
EP3669840B1 (fr) | 2015-11-20 | 2022-12-28 | 3M Innovative Properties Company | Système médical avec pont flexible de stockage des fluides |
GB201520990D0 (en) | 2015-11-27 | 2016-01-13 | Edixomed Ltd | Dressing system |
FR3044893B1 (fr) | 2015-12-09 | 2018-05-18 | Emile Droche | Pansement pour soins de la peau en milieu humide |
US11471586B2 (en) | 2015-12-15 | 2022-10-18 | University Of Massachusetts | Negative pressure wound closure devices and methods |
US10575991B2 (en) | 2015-12-15 | 2020-03-03 | University Of Massachusetts | Negative pressure wound closure devices and methods |
EP3511031B1 (fr) | 2015-12-30 | 2023-05-03 | Paul Hartmann AG | Dispositifs permettant de commander le traitement de plaies par pression négative |
WO2017114745A1 (fr) | 2015-12-30 | 2017-07-06 | Smith & Nephew Plc | Appareil de traitement des plaies en pression négative |
WO2017115146A1 (fr) | 2015-12-30 | 2017-07-06 | Smith & Nephew Plc | Pansement de thérapie par pression négative pour les plaies |
JP7082057B2 (ja) | 2016-01-06 | 2022-06-07 | スリーエム イノベイティブ プロパティズ カンパニー | 閉鎖セルを有するドレッシングによる創傷の治療のためのシステム |
US10426809B2 (en) | 2016-01-12 | 2019-10-01 | Council Of Scientific & Industrial Research | Nanobiocomposite formulation for wound healing and a process for the preparation thereof |
DE102016000569B3 (de) | 2016-01-20 | 2017-06-22 | Lohmann & Rauscher Gmbh | Verfahren zum Herstellen eines Folienschlauchs |
US10918770B2 (en) | 2016-02-12 | 2021-02-16 | Corning Incorporated | Vacuum assisted wound closure assembly and methods of irradiating a wound using the same |
FR3047901B1 (fr) | 2016-02-22 | 2018-02-23 | Universite Pierre Et Marie Curie (Paris 6) | Biomateriaux composites a liberation controlee de principe actif |
EP3423011B1 (fr) | 2016-03-01 | 2020-07-08 | KCI Licensing, Inc. | Champ opératoire pour utilisation avec des systèmes de thérapie médicale |
KR101958014B1 (ko) | 2016-03-14 | 2019-03-13 | 주식회사 엘지화학 | 고흡수성 수지의 제조 방법 |
FR3048885A1 (fr) | 2016-03-17 | 2017-09-22 | Bluestar Silicones France | Gel silicone adhesif a la peau |
EP3429643A1 (fr) | 2016-03-18 | 2019-01-23 | KCI USA, Inc. | Pansement antimicrobien |
KR101959547B1 (ko) | 2016-03-25 | 2019-03-18 | 주식회사 엘지화학 | 고흡수성 수지의 제조 방법 |
WO2017173026A1 (fr) | 2016-03-30 | 2017-10-05 | Convatec Technologies Inc. | Pansements modifiés pour plaies |
TW201800069A (zh) | 2016-03-30 | 2018-01-01 | 康華特科技有限公司 | 傷口中微生物感染檢測方法 |
US20200023102A1 (en) | 2016-04-05 | 2020-01-23 | Patrick Kenneth Powell | Wound therapy system |
GB201608099D0 (en) | 2016-05-09 | 2016-06-22 | Convatec Technologies Inc | Negative pressure wound dressing |
EP3246050A1 (fr) | 2016-05-17 | 2017-11-22 | BSN medical GmbH | Timbre transdermique ou pansement |
AU2017266861B2 (en) | 2016-05-20 | 2022-02-17 | Solventum Intellectual Properties Company | Replaceable dressing and method for viewing a tissue site |
ES2936807T3 (es) | 2016-05-31 | 2023-03-22 | Octapharma Ag | Películas a base de plasma y métodos para fabricarlas y utilizarlas |
JP2019517299A (ja) | 2016-06-01 | 2019-06-24 | 株式会社スリー・ディー・マトリックス | 自己集合性ペプチドヒドロゲルを有する止血用包帯 |
KR20190028467A (ko) | 2016-07-08 | 2019-03-18 | 컨바텍 테크놀러지스 인크 | 체액 수집 장치 |
TWI673056B (zh) | 2016-07-22 | 2019-10-01 | 大江生醫股份有限公司 | 包含細菌的水凝膠及其製備方法 |
US10076552B2 (en) | 2016-08-09 | 2018-09-18 | DATT MEDIPRODUCTS LIMITED and DATT LIFE SCIENCE PVT. LTD. | Multifunctional formulation comprised of natural ingredients and method of preparation/manufacturing thereof |
ES2833899T3 (es) | 2016-08-10 | 2021-06-16 | Adv Med Solutions Ltd | Apósito para heridas |
DE102016114819A1 (de) | 2016-08-10 | 2018-02-15 | Paul Hartmann Ag | Saugkörper zur endoluminalen Unterdrucktherapie |
WO2018031761A1 (fr) | 2016-08-10 | 2018-02-15 | Argentum Medical, Llc | Pansements antimicrobiens à base d'hydrogel |
WO2018034932A1 (fr) | 2016-08-18 | 2018-02-22 | Kci Licensing, Inc. | Outil de diagnostic en ligne pour thérapie par pression négative |
US20180056087A1 (en) | 2016-08-26 | 2018-03-01 | Adolfo Ribeiro | Wearable Micro-LED Healing Bandage |
US10590184B2 (en) | 2016-09-26 | 2020-03-17 | National Yang-Ming University | Process for a preparation of the modified porcine plasma fibronectin for enhance wound healing |
US11111362B2 (en) | 2016-09-26 | 2021-09-07 | Becton, Dickinson And Company | Breathable films with microbial barrier properties |
IT201600096247A1 (it) | 2016-09-26 | 2018-03-26 | Emodial S R L | Bendaggio a base di poliuretano e idrogel comprendente clorexidina |
US10293080B2 (en) | 2016-10-05 | 2019-05-21 | The Arizona Board Of Regents On Behalf Of Northern Arizona University | Ionic liquids that sterilize and prevent biofilm formation in skin wound healing devices |
US10940233B2 (en) | 2016-10-05 | 2021-03-09 | 3M Innovative Properties Company | Fibrinogen composition, method and wound articles |
GB2555584B (en) | 2016-10-28 | 2020-05-27 | Smith & Nephew | Multi-layered wound dressing and method of manufacture |
EP3535590B1 (fr) | 2016-11-02 | 2023-05-03 | Unilever IP Holdings B.V. | Procédé d'échantillonnage de mauvaises odeurs |
CA3042673A1 (fr) | 2016-11-02 | 2018-05-11 | Smith & Nephew Inc. | Dispositifs de fermeture de plaie |
WO2018089563A1 (fr) | 2016-11-11 | 2018-05-17 | 3M Innovative Properties Company | Pansement conformable adaptable pour plaie |
EP3538165B1 (fr) | 2016-11-11 | 2022-11-09 | Avery Dennison Corporation | Adhésifs cutanés en gel mou à base de caoutchouc |
WO2018094061A1 (fr) | 2016-11-18 | 2018-05-24 | Kci Licensing, Inc. | Système médical et pansement à utiliser sous compression |
AU2017366855B2 (en) | 2016-12-02 | 2021-03-11 | 3M Innovative Properties Company | Muscle or joint support article |
WO2018102322A1 (fr) | 2016-12-02 | 2018-06-07 | 3M Innovative Properties Company | Article de support de muscle ou d'articulation doté d'une bosse |
US10426874B2 (en) | 2016-12-02 | 2019-10-01 | Apex Medical Corp. | Wound management assembly and negative pressure wound therapy system |
US11590164B2 (en) | 2016-12-06 | 2023-02-28 | Sami Shamoon College Of Engineering (R.A.) | Topical antimicrobial formulations containing monovalent copper ions and systems for generating monovalent copper ions |
US10500104B2 (en) | 2016-12-06 | 2019-12-10 | Novomer, Inc. | Biodegradable sanitary articles with higher biobased content |
WO2018107130A1 (fr) | 2016-12-09 | 2018-06-14 | Sanvio,Inc. | Composition pour le traitement de plaies et d'autres affections dermatologiques |
WO2018108784A1 (fr) | 2016-12-12 | 2018-06-21 | Smith & Nephew Plc | Pansement pour plaies |
EP3335695B1 (fr) | 2016-12-15 | 2020-02-05 | UPM-Kymmene Corporation | Procédé de lyophilisation d'hydrogel comprenant de la cellulose nanofibrillaire, hydrogel therapeutique lyophilisé comprenant de la cellulose nanofibrillaire, et hydrogel comprenant de la cellulose nanofibrillaire |
DK3335696T3 (da) | 2016-12-15 | 2020-03-16 | Upm Kymmene Corp | Fremgangsmåde til tørring af cellefrit vævsekstrakt i en hydrogel omfattende nanofibrillær cellulose og en tørret hydrogel omfattende nanofibrillær cellulose og cellefrit vævsekstrakt |
EP3335740A1 (fr) | 2016-12-15 | 2018-06-20 | UPM-Kymmene Corporation | Hydrogel médical |
EP3338813B1 (fr) | 2016-12-20 | 2020-01-29 | BSN Medical GmbH | Produit de traitement de plaie multicouche ayant une couche de libération perforée |
JP2020513909A (ja) | 2016-12-22 | 2020-05-21 | アプライド ティシュ テクノロジーズ エルエルシーApplied Tissue Technologies Llc | 創傷治療のためのデバイスおよび方法 |
EP3401354B1 (fr) | 2016-12-22 | 2020-04-08 | LG Chem, Ltd. | Procédé de fabrication de résine super-absorbante et résine super-absorbante |
DE102016125579A1 (de) | 2016-12-23 | 2018-06-28 | Paul Hartmann Ag | Wasserhaltige Hydrogelzusammensetzung, umfassend elementare Silberpartikel |
JP2020503107A (ja) | 2016-12-23 | 2020-01-30 | カルゴン カーボン コーポレーション | 活性炭複合創傷被覆材 |
US20200114040A1 (en) | 2016-12-28 | 2020-04-16 | Kci Usa, Inc. | Antimicrobial wound dressings |
US11952455B2 (en) | 2016-12-29 | 2024-04-09 | Alcare Co., Ltd. | Foam and composition for foam |
JP2020503946A (ja) | 2017-01-09 | 2020-02-06 | ケーシーアイ ライセンシング インコーポレイテッド | 流体除去向上用の創傷ドレッシング層 |
TWI621453B (zh) | 2017-01-13 | 2018-04-21 | 廈門聖慈醫療器材有限公司 | 吸盤 |
WO2018135813A1 (fr) | 2017-01-19 | 2018-07-26 | 최성현 | Tampon pour soulager et traiter les maladies cutanées d'exsudation des protéines plasmatiques, y compris les maladies atopiques |
CA3044955A1 (fr) | 2017-01-23 | 2018-07-26 | Medela Holding Ag | Pansement poreux destine a etre utilise pour un traitement par pression negative |
US20190365948A1 (en) | 2017-01-27 | 2019-12-05 | Aziyo Biologics, Inc. | Lyophilized placental composite sheet and uses thereof |
WO2018141677A1 (fr) | 2017-02-06 | 2018-08-09 | Basf Se | Articles absorbants les fluides |
CA3049463A1 (fr) | 2017-02-14 | 2018-08-23 | Kci Licensing, Inc. | Pansement a zones de contraction variable |
JP6926239B2 (ja) | 2017-02-15 | 2021-08-25 | スミス・アンド・ネフュー・アジア・パシフィク・ピーティーイー・リミテッド | 陰圧創傷治療装置およびその使用方法 |
EP3582816A1 (fr) | 2017-02-16 | 2019-12-25 | Covestro Deutschland AG | Procédé pour la préparation d'un matériau composite pour le contact avec une plaie, exempt de substance adhésive |
WO2018156730A1 (fr) | 2017-02-22 | 2018-08-30 | Cornell University | Pansement à vide mécanique de gestion, protection et aspiration mécaniques de petites plaies incisionnelles |
US11141521B2 (en) | 2017-02-28 | 2021-10-12 | T.J.Smith And Nephew, Limited | Multiple dressing negative pressure wound therapy system |
JP2020509094A (ja) | 2017-03-03 | 2020-03-26 | ロマ リンダ ユニヴァーシティ ヘルス | 止血を促進するための組成物および方法 |
CN110582257B (zh) | 2017-03-08 | 2022-03-15 | 史密夫及内修公开有限公司 | 存在故障条件时的负压伤口治疗装置控制 |
EP3592212A1 (fr) | 2017-03-09 | 2020-01-15 | Smith & Nephew PLC | Pansement, élément de timbre et procédé de détection d'un ou plusieurs paramètres de plaie |
CN110650755A (zh) | 2017-03-09 | 2020-01-03 | 生物技术秘书部 | 用于联合的负压和流体输送系统的伤口敷料 |
EP3378450A1 (fr) | 2017-03-22 | 2018-09-26 | Mölnlycke Health Care AB | Procédé de fabrication d'un pansement et pansement |
EP3600461B1 (fr) | 2017-03-29 | 2022-08-10 | 3M Innovative Properties Company | Compositions d'hydrogel liées à des substrats polymères |
AU2018248422B2 (en) | 2017-04-04 | 2024-02-15 | Anti-Plasmin Technologies, Llc | Methods to enhance a non-surgical medical treatment |
EP3932442A1 (fr) | 2017-04-04 | 2022-01-05 | 3M Innovative Properties Co. | Appareils, systèmes et procédés de traitement d'un site tissulaire par pression négative et oxygène |
KR101852718B1 (ko) | 2017-04-04 | 2018-05-18 | 주식회사 제네웰 | 외과수술 후 절개부위 통증 감소를 위한 키트 |
GB201800057D0 (en) | 2018-01-03 | 2018-02-14 | Smith & Nephew Inc | Component Positioning And stress Relief For Sensor Enabled Wound Dressings |
CN108721677B (zh) | 2017-04-17 | 2021-11-19 | 广西美丽肤医疗器械有限公司 | 复合性材料 |
WO2018195101A1 (fr) | 2017-04-19 | 2018-10-25 | Smith & Nephew, Inc. | Cartouches pour traitement de plaies par pression négative |
DE102017003826A1 (de) | 2017-04-20 | 2018-10-25 | Lohmann & Rauscher Gmbh | Wundversorgungsanordnung für die Unterdrucktherapie |
WO2018201257A1 (fr) | 2017-05-04 | 2018-11-08 | Klox Technologies Inc. | Dispositifs biophotoniques absorbants et systèmes de cicatrisation de plaie |
CN110603061A (zh) | 2017-05-10 | 2019-12-20 | 东丽株式会社 | 医疗器械 |
ES2896175T3 (es) | 2017-05-10 | 2022-02-24 | Moelnlycke Health Care Ab | Espuma compuesta en el tratamiento de heridas |
EP3624741B1 (fr) | 2017-05-16 | 2021-11-17 | 3M Innovative Properties Company | Système de pansement absorbant à pression négative destiné à être utilisé pour des plaies mammaires post-chirurgicales |
JP2020520781A (ja) | 2017-05-17 | 2020-07-16 | ユービック インダストリー パートナーシップス インコーポレイテッドUvic Industry Partnerships Inc. | 創傷モニタリング及び治療薬剤デリバリーのための創傷被覆材 |
EP3634340A1 (fr) | 2017-05-19 | 2020-04-15 | KCI USA, Inc. | Pansements pour filtrer des fluides sortant de plaies |
WO2018217619A1 (fr) | 2017-05-22 | 2018-11-29 | Kci Usa, Inc. | Pansement chirurgical post-opératoire |
CN110785151A (zh) | 2017-05-22 | 2020-02-11 | 凯希美国公司 | 可弹性变形的伤口敷料 |
EP3630029A1 (fr) | 2017-05-22 | 2020-04-08 | KCI USA, Inc. | Pansements extensibles |
EP3409248B1 (fr) | 2017-06-01 | 2019-11-06 | Absorbest AB | Pansement de plaie |
WO2018226707A1 (fr) | 2017-06-07 | 2018-12-13 | Kci Licensing, Inc. | Pansements composites permettant une macération réduite par granulation améliorée avec traitement par pression négative |
CN110831553A (zh) | 2017-06-07 | 2020-02-21 | 凯希特许有限公司 | 用于通过负压治疗来改善肉芽生长和减少泡软的复合敷料 |
EP3634329B1 (fr) | 2017-06-07 | 2020-12-23 | 3M Innovative Properties Company | Procédés de fabrication et d'assemblage d'une interface tissulaire à deux matériaux pour une thérapie par pression négative |
US11179512B2 (en) | 2017-06-07 | 2021-11-23 | Kci Licensing, Inc. | Multi-layer wound filler for extended wear time |
EP3634339B1 (fr) | 2017-06-07 | 2022-07-27 | 3M Innovative Properties Company | Pansement à décollement et placement pour thérapie par pression négative |
US11207217B2 (en) | 2017-06-07 | 2021-12-28 | Kci Licensing, Inc. | Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy |
EP3634338B1 (fr) | 2017-06-07 | 2022-07-27 | KCI USA, Inc. | Pansement pour plaie avec absorption d'odeurs et transmission accrue de vapeur d'humidité |
EP4124324A1 (fr) | 2017-06-07 | 2023-02-01 | 3M Innovative Properties Company | Pansement à décoller et à positionner pour exsudat épais et instillation |
CN110799222B (zh) | 2017-06-07 | 2023-03-07 | 3M创新知识产权公司 | 用于减少组织向内生长的负压治疗的系统、设备以及方法 |
US20200085629A1 (en) | 2017-06-07 | 2020-03-19 | Kci Licensing, Inc. | Composite dressings with even expansion profiles for treatment of wounds using negative-pressure treatment |
RU2019139911A (ru) | 2017-06-07 | 2021-07-09 | Кейсиай ЛАЙСЕНСИНГ, ИНК. | Композитные перевязочные материалы для улучшенной грануляции и сниженной мацерации для лечения посредством отрицательного давления |
SG11201909386SA (en) | 2017-06-07 | 2019-11-28 | Kci Licensing Inc | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
RU2019139885A (ru) | 2017-06-07 | 2021-07-09 | Кейсиай ЛАЙСЕНСИНГ, ИНК. | Индивидуально изменяемые композитные перевязочные материалы для улучшенной грануляции и сниженной мацерации для лечения посредством отрицательного давления |
EP3634521A1 (fr) | 2017-06-08 | 2020-04-15 | KCI Licensing, Inc. | Thérapie par pression négative avec de l'oxygène |
EP3634327B1 (fr) | 2017-06-09 | 2023-08-30 | 3M Innovative Properties Company | Pansement de granulation pour plaies chroniques à faible exsudation |
EP3412319A1 (fr) | 2017-06-09 | 2018-12-12 | Mölnlycke Health Care AB | Mousse pour le traitement d'une plaie |
US20210161723A1 (en) | 2017-06-12 | 2021-06-03 | Kci Licensing, Inc. | Foamed and textured sintered polymer wound filler |
US11872110B2 (en) | 2017-06-13 | 2024-01-16 | Smith & Nephew Plc | Wound closure device and method of use |
CA3063859A1 (fr) | 2017-06-14 | 2018-12-20 | Smith & Nephew, Inc. | Gestion de l'elimination de liquide et maitrise de la fermeture d'une plaie dans un traitement de plaie |
EP3638173A1 (fr) | 2017-06-14 | 2020-04-22 | Smith & Nephew, Inc | Commande de fermeture de plaie et de gestion d'élimination de fluide dans le traitement de plaies |
CA3065380A1 (fr) | 2017-06-14 | 2018-12-20 | T.J.Smith & Nephew, Limited | Appareil de traitement de plaie a pression negative |
US20210145646A1 (en) | 2017-06-19 | 2021-05-20 | Kci Usa, Inc. | Wound dressing with saturation indicator |
JP7189159B2 (ja) | 2017-06-23 | 2022-12-13 | スミス アンド ネフュー ピーエルシー | センサを有効化した創傷モニタリングまたは治療のためのセンサの配置 |
EP3644916A1 (fr) | 2017-06-26 | 2020-05-06 | KCI USA, Inc. | Pansement absorbant qui incorpore un nouveau système indicateur de fluide de pansement |
US10751212B2 (en) | 2017-06-26 | 2020-08-25 | Maryam Raza | Multilayer dressing device and method for preventing and treating pressure ulcers and chronic wounds |
DE102017006025A1 (de) | 2017-06-27 | 2018-12-27 | Carl Freudenberg Kg | Hydrogel-bildende Mehrkomponentenfaser |
AU2018293063B2 (en) | 2017-06-30 | 2024-03-07 | T.J.Smith & Nephew,Limited | Negative pressure wound therapy apparatus |
EP3648810A1 (fr) | 2017-07-07 | 2020-05-13 | Smith & Nephew plc | Système de traitement de plaie et pansement pour administrer de l'oxygène à une plaie |
FR3068974B1 (fr) | 2017-07-12 | 2019-08-02 | Urgo Recherche Innovation Et Developpement | Pansement permettant la liberation controlee et prolongee d'actif |
FR3068975B1 (fr) | 2017-07-12 | 2020-07-17 | Urgo Recherche Innovation Et Developpement | Composition pour pansement interface |
GB201711179D0 (en) | 2017-07-12 | 2017-08-23 | Smith & Nephew | Wound care materials, devices and uses |
GB201711183D0 (en) | 2017-07-12 | 2017-08-23 | Smith & Nephew | Antimicrobial or wound care materials, devices and uses |
GB201711181D0 (en) | 2017-07-12 | 2017-08-23 | Smith & Nephew | Polymer foam material, device and use |
EA201992777A1 (ru) | 2017-07-21 | 2020-06-23 | Спид Кеа Минерал Гмбх | Новая раневая повязка для гемостаза |
GB201804502D0 (en) | 2018-03-21 | 2018-05-02 | Smith & Nephew | Biocompatible encapsulation and component stress relief for sensor enabled negative pressure wound therapy dressings |
WO2019022493A1 (fr) | 2017-07-26 | 2019-01-31 | (주)유레 | Pansement comprenant de l'acide hyaluronique-calcium et de la polylysine et procédé de fabrication s'y rapportant |
GB201712165D0 (en) | 2017-07-28 | 2017-09-13 | Smith & Nephew | Wound dressing and method of manufacture |
US10780201B2 (en) | 2017-07-29 | 2020-09-22 | Edward D. Lin | Control apparatus and related methods for wound therapy delivery |
US10729826B2 (en) | 2017-07-29 | 2020-08-04 | Edward D. Lin | Wound cover apparatus and related methods of use |
US11717592B2 (en) | 2017-07-31 | 2023-08-08 | Kci Licensing, Inc. | Bioresorbable dressing with structural support |
US11285048B2 (en) | 2017-08-02 | 2022-03-29 | Kci Licensing, Inc. | Multi-layer compartment dressing and negative-pressure treatment method |
CN111031956A (zh) | 2017-08-02 | 2020-04-17 | 凯希特许有限公司 | 用于伤口清创的系统和方法 |
EP3664756B1 (fr) | 2017-08-07 | 2024-01-24 | Smith & Nephew plc | Dispositif de fermeture de plaie doté d'une couche protectrice |
DE102017117828A1 (de) | 2017-08-07 | 2019-02-07 | Ivf Hartmann Ag | Binde, insbesondere Kompressionsbinde |
WO2019031477A1 (fr) | 2017-08-09 | 2019-02-14 | 東レ株式会社 | Dispositif médical et procédé de fabrication de celui-ci |
WO2019030384A2 (fr) | 2017-08-10 | 2019-02-14 | Smith & Nephew Plc | Positionnement de capteurs pour la surveillance ou le traitement des plaies activé(e) par capteurs |
US20200197580A1 (en) | 2017-08-22 | 2020-06-25 | Kci Licensing, Inc. | In-line wound fluid sampling systems and methods for use with negative pressure wound therapy |
GB201713511D0 (en) | 2017-08-23 | 2017-10-04 | Scapa Uk Ltd | Wound dressing |
WO2019040656A1 (fr) | 2017-08-23 | 2019-02-28 | Cor Medical Ventures LLC | Traitement de plaie de site chirurgical postopératoire et procédé d'enlèvement de dispositif |
EP3672655B1 (fr) | 2017-08-24 | 2022-01-19 | KCI USA, Inc. | Biomatériau et procédés de fabrication et d'utilisation dudit biomatériau |
GB2565823A (en) | 2017-08-24 | 2019-02-27 | Xiros Ltd | Psyllium based moisture absorbent material |
US11246756B2 (en) | 2017-08-24 | 2022-02-15 | The United States Of America, As Represented By The Secretary Of Agriculture | Healthcare textiles |
EP3678620B1 (fr) | 2017-09-05 | 2023-07-12 | 3M Innovative Properties Company | Systèmes et procédés permettant d'atténuer la désactivation prématurée par la lumière de champs opératoires adhésifs désactivés par la lumière |
JP2020532378A (ja) | 2017-09-05 | 2020-11-12 | ケーシーアイ ライセンシング インコーポレイテッド | フィルタリング層を使用して光不活性化接着ドレープの早期の光不活性化を軽減するシステム及び方法 |
CN111093477B (zh) | 2017-09-10 | 2023-09-12 | 史密夫及内修公开有限公司 | 用于检查装配有传感器的伤口敷料中的封装和部件的系统和方法 |
GB201718070D0 (en) | 2017-11-01 | 2017-12-13 | Smith & Nephew | Negative pressure wound treatment apparatuses and methods with integrated electronics |
SG11202001900UA (en) | 2017-09-13 | 2020-04-29 | Smith & Nephew | Negative pressure wound treatment apparatuses and methods with integrated electronics |
WO2019055176A1 (fr) | 2017-09-14 | 2019-03-21 | Kci Licensing, Inc. | Oxygénothérapie avec élimination de fluide |
CN111093721A (zh) | 2017-09-15 | 2020-05-01 | 巴德阿克塞斯系统股份有限公司 | 用于医疗装置的具有衬垫的抗菌敷料 |
US12004926B2 (en) | 2017-09-18 | 2024-06-11 | Kci Licensing, Inc. | Wound dressings and systems with remote oxygen generation for topical wound therapy and related methods |
US11547611B2 (en) | 2017-09-22 | 2023-01-10 | Kci Licensing, Inc. | Wound dressings and systems with high-flow therapeutic gas sources for topical wound therapy and related methods |
IL254636A0 (en) | 2017-09-24 | 2017-11-30 | Reddress Ltd | System and method for preparing a wound dressing |
IL254644B (en) | 2017-09-24 | 2021-06-30 | Reddress Ltd | Device for dressing a wound, system and method |
GB2566951A (en) | 2017-09-27 | 2019-04-03 | Brightwake Ltd | Compositions for wound treatment |
EP3687467B1 (fr) | 2017-09-29 | 2022-02-23 | 3M Innovative Properties Company | Pansement présentant une faible croissance interne dans le tissu et procédé de traitement par pression négative |
WO2019073326A1 (fr) | 2017-10-09 | 2019-04-18 | 3M Innovative Properties Company | Pansement de fixation à bordure conformable |
GB201716986D0 (en) | 2017-10-16 | 2017-11-29 | Matoke Holdings Ltd | Antimicrobial compositions |
AU2018352330B2 (en) | 2017-10-20 | 2021-11-18 | Safeguard Medical Technologies Limited | Composition |
WO2019083607A1 (fr) | 2017-10-23 | 2019-05-02 | Kci Licensing, Inc. | Pansement à pont évaporatif haute densité |
US20190117466A1 (en) | 2017-10-23 | 2019-04-25 | Kci Licensing, Inc. | Area management of tissue sites on articulating joints |
JP7263337B2 (ja) | 2017-10-23 | 2023-04-24 | スリーエム イノベイティブ プロパティズ カンパニー | 創傷治療用の低輪郭の分配構成要素 |
US11432967B2 (en) | 2017-10-23 | 2022-09-06 | Kci Licensing, Inc. | Fluid bridge for simultaneous application of negative pressure to multiple tissue sites |
WO2019083726A1 (fr) | 2017-10-23 | 2019-05-02 | Kci Licensing, Inc. | Pansement pour plaie à utiliser dans un traitement antibactérien |
WO2019083827A1 (fr) | 2017-10-24 | 2019-05-02 | Kci Licensing, Inc. | Pansements pour débridement et systèmes les utilisant |
WO2019083563A1 (fr) | 2017-10-26 | 2019-05-02 | Kci Licensing, Inc. | Pansement à structure élastique soudée |
EP4268775A3 (fr) | 2017-10-26 | 2023-12-27 | 3M Innovative Properties Company | Appareil de distribution |
US11466187B2 (en) | 2017-10-26 | 2022-10-11 | 3M Innovative Properties Company | Composition containing a silicone-based adhesive and cellulose nanocrystals, and methods and articles |
JP7186775B2 (ja) | 2017-10-27 | 2022-12-09 | スリーエム イノベイティブ プロパティズ カンパニー | 乳房の切開部に陰圧を与える形状の輪郭に合致したフォームドレッシング |
KR102566942B1 (ko) | 2017-10-27 | 2023-08-14 | 주식회사 엘지화학 | 고흡수성 수지의 제조 방법 |
US11400202B2 (en) | 2017-10-30 | 2022-08-02 | Kci Licensing, Inc. | Systems, apparatuses, and methods for negative-pressure treatment with pressure delivery indication |
WO2019089856A1 (fr) | 2017-10-31 | 2019-05-09 | InMEDBio, LLC | Pansement absorbant, perméable à l'air, bloquant/tuant les agents pathogènes et fabrication associée |
WO2019086332A1 (fr) | 2017-11-01 | 2019-05-09 | Smith & Nephew Plc | Appareils et procédés de traitement de plaies par pression négative avec électronique intégrée |
GB201718014D0 (en) | 2017-11-01 | 2017-12-13 | Smith & Nephew | Dressing for negative pressure wound therapy with filter |
GB201718054D0 (en) | 2017-11-01 | 2017-12-13 | Smith & Nephew | Sterilization of integrated negative pressure wound treatment apparatuses and sterilization methods |
IL255404B (en) | 2017-11-02 | 2018-10-31 | Technion Res & Dev Foundation | A zwitterionic hydrogel in the configuration of an internal multiphase emulsion |
WO2019089522A1 (fr) | 2017-11-02 | 2019-05-09 | Systagenix Wound Management, Limited | Pansement avec capteur colorimètre d'humidité |
JP7370973B2 (ja) | 2017-11-03 | 2023-10-30 | スリーエム イノベイティブ プロパティズ カンパニー | 長期装着ドレッシング |
WO2019089944A1 (fr) | 2017-11-03 | 2019-05-09 | Kci Usa, Inc. | Pansement enrichi en nutriments |
GB2568101B (en) | 2017-11-06 | 2022-09-07 | Brightwake Ltd | Antimicrobial dressing |
US20200261276A1 (en) | 2017-11-08 | 2020-08-20 | University Of Massachusetts | Post-Operative Hybrid Dressing To Optimize Skin-Grafting Procedures In Reconstructive Surgery |
WO2019094147A1 (fr) | 2017-11-09 | 2019-05-16 | Kci Licensing, Inc. | Pansement multi-module et procédés de thérapie |
WO2019094923A1 (fr) | 2017-11-13 | 2019-05-16 | Kci Licensing, Inc. | Adhésifs sensibles à la pression photosensibles pour pansements pour plaies |
CN107899061A (zh) | 2017-11-13 | 2018-04-13 | 广东泰宝医疗科技股份有限公司 | 一种藻酸盐创面修复敷料及其制备方法 |
US11559438B2 (en) | 2017-11-15 | 2023-01-24 | Smith & Nephew Plc | Integrated sensor enabled wound monitoring and/or therapy dressings and systems |
FR3074047B1 (fr) | 2017-11-30 | 2019-12-20 | Biomerieux | Dispositifs medicaux non-implantables integrant un dispositif de detection et/ou d'identification d'infections microbiologiques |
KR102649554B1 (ko) | 2017-12-06 | 2024-03-21 | 코넬 유니버시티 | 개선된 펌프 효율, 자동 압력 인디케이터 및 자동 압력 리미터를 가지는 수동 작동식 음압 상처 치료(npwt) 밴디지 |
US20200289727A1 (en) | 2017-12-06 | 2020-09-17 | Kci Licensing, Inc. | Wound dressing with negative pressure retaining valve |
WO2019113623A1 (fr) | 2017-12-11 | 2019-06-20 | Animal Ethics Pty Ltd | Pansement pour plaies |
EP3498242A1 (fr) | 2017-12-15 | 2019-06-19 | Mölnlycke Health Care AB | Pansement médical |
IL256405A (en) | 2017-12-19 | 2018-01-31 | Omrix Biopharmaceuticals Ltd | Wound bandage and method for its production |
WO2019125962A1 (fr) | 2017-12-20 | 2019-06-27 | Kci Licensing, Inc. | Pansement pour plaies pour la récolte de greffes épidermiques superficielles |
WO2019126368A1 (fr) | 2017-12-20 | 2019-06-27 | Kci Usa, Inc. | Pansement comprenant un tissu placentaire déshydraté pour la cicatrisation des plaies |
DE102017130893A1 (de) | 2017-12-21 | 2019-06-27 | Paul Hartmann Ag | pH regulierende Wundauflage |
US20200179673A1 (en) | 2018-01-08 | 2020-06-11 | Mianshui WAN | Connecting device for wound protection dressing, and wound protection dressing |
US11877912B2 (en) | 2018-01-09 | 2024-01-23 | 3M Innovative Properties Company | Systems and methods for coupling a wearable therapy system to a dressing |
US11517480B2 (en) | 2018-03-26 | 2022-12-06 | Deroyal Industries, Inc. | Multi-lumen bridge for negative pressure wound therapy system |
US20190298882A1 (en) | 2018-03-27 | 2019-10-03 | Kevin M. Nelson | Hydrogel bandage |
JP7331002B2 (ja) | 2018-03-29 | 2023-08-22 | スリーエム イノベイティブ プロパティズ カンパニー | 創傷容積の推定を伴う創傷療法システム |
US20210015677A1 (en) | 2018-03-30 | 2021-01-21 | Kci Licensing, Inc. | An absorbent dressing incorporating ph wound condition indication |
GB201805584D0 (en) | 2018-04-05 | 2018-05-23 | Smith & Nephew | Negative pressure wound treatment apparatuses and methods with integrated electronics |
GB2572642B (en) | 2018-04-06 | 2021-03-31 | Pellis Care Ltd | Treatment of diabetic foot ulcers |
US11040127B2 (en) | 2018-04-09 | 2021-06-22 | Kci Licensing, Inc. | Abdominal dressing with mechanism for fascial closure |
US20210379273A1 (en) | 2018-04-10 | 2021-12-09 | Kci Licensing, Inc. | Bridge dressing with fluid management |
BR102018007306A2 (pt) | 2018-04-11 | 2019-10-29 | Maria Cristina De Paula Mesquita | processo para fabricação de fita /placa/ curativo cicatrizante de silicone aderente com formatos específicos |
WO2019199596A1 (fr) | 2018-04-12 | 2019-10-17 | Kci Licensing, Inc. | Gabarit de coupe destiné à un champ de thérapie de plaie par pression négative |
US20210137745A1 (en) | 2018-04-13 | 2021-05-13 | Kci Licensing, Inc. | Dressing bolster with area pressure indicator |
WO2019200035A1 (fr) | 2018-04-13 | 2019-10-17 | Kci Licensing, Inc. | Système de npwt à flux d'air sélectivement contrôlable |
US11406750B2 (en) | 2018-04-13 | 2022-08-09 | Kci Licensing, Inc. | Compression strain and negative pressure delivery indicator for a wound dressing |
US11896464B2 (en) | 2018-04-13 | 2024-02-13 | Kci Licensing, Inc. | Method to dynamically measure apposition and patient limb movement in a negative pressure closed incision dressing |
EP3787705B1 (fr) | 2018-05-03 | 2023-07-19 | KCI Licensing, Inc. | Système de thérapie de plaie par pression négative avec détection de pansement absorbant complet |
EP3787580A1 (fr) | 2018-05-04 | 2021-03-10 | Dry See LLC | Article de détection de liquide et son procédé de fabrication |
US20210100925A1 (en) | 2018-05-08 | 2021-04-08 | Fidia Farmaceutici S.P.A. | Wound dressing for treatment of damaged skin |
EP3569261B1 (fr) | 2018-05-14 | 2024-04-03 | Paul Hartmann AG | Pansement fonctionnel pour plaies |
US10898606B2 (en) | 2018-05-15 | 2021-01-26 | Legacy Research and Development Group, LLC | Self-fusing low density silicone |
EP3569210B1 (fr) | 2018-05-15 | 2022-04-27 | The Procter & Gamble Company | Articles absorbants jetables |
AU2019270795B2 (en) | 2018-05-16 | 2024-04-04 | Keith R. Berend | Negative pressure wound apposition dressing system |
US20190351095A1 (en) | 2018-05-21 | 2019-11-21 | Milliken & Company | Wound care device having fluid transfer and adhesive properties |
US20190351094A1 (en) | 2018-05-21 | 2019-11-21 | Milliken & Company | Wound care device having fluid transfer and adhesive properties |
FR3082123B1 (fr) | 2018-06-07 | 2020-10-16 | Urgo Rech Innovation Et Developpement | Pansement cellularise et son procede de fabrication |
NL2021186B1 (en) | 2018-06-26 | 2020-01-06 | Icap Holding B V | Intelligent cap for skin tissue treatment |
US11701264B2 (en) | 2018-06-27 | 2023-07-18 | Kci Licensing, Inc. | Wound therapy system with wound volume estimation using geometric approximation |
TWI693929B (zh) | 2018-06-27 | 2020-05-21 | 南六企業股份有限公司 | 抗菌創傷敷料 |
WO2020005536A1 (fr) | 2018-06-27 | 2020-01-02 | Kci Licensing, Inc. | Pansement pour estimation de volume de plaie |
EP3813750B1 (fr) | 2018-06-28 | 2022-03-02 | KCI Licensing, Inc. | Doublure détachable dotée d'une protection de bord |
US20200000643A1 (en) | 2018-06-28 | 2020-01-02 | Kci Licensing, Inc. | Long-Duration, Deep Wound Filler With Means To Prevent Granulation In-Growth |
EP3813747A1 (fr) | 2018-06-28 | 2021-05-05 | KCI Licensing, Inc. | Pansement pour plaie hautement conformable |
US20200000642A1 (en) | 2018-06-28 | 2020-01-02 | Systagenix Wound Management, Limited | Multilayer absorbent dressing construction |
WO2020005577A1 (fr) | 2018-06-28 | 2020-01-02 | Kci Licensing, Inc. | Système de thérapie de plaie à pression négative distribuée incorporant un pansement absorbant et une pompe piézoélectrique |
US20200000640A1 (en) | 2018-06-29 | 2020-01-02 | Milliken & Company | Multi-Layer Wound Care Device Having Absorption and Fluid Transfer Properties |
US20210178012A1 (en) | 2018-07-04 | 2021-06-17 | Coloplast A/S | Foam wound dressing comprising an antiseptic |
GB201811449D0 (en) | 2018-07-12 | 2018-08-29 | Smith & Nephew | Apparatuses and methods for negative pressure wound therapy |
WO2020014178A1 (fr) | 2018-07-12 | 2020-01-16 | Kci Licensing, Inc. | Pansement abdominal pourvu d'une sélection par l'utilisateur d'un profil de force de fermeture fasciale |
WO2020014310A1 (fr) | 2018-07-13 | 2020-01-16 | Kci Licensing, Inc. | Pansement avancé ayant une compression et une manipulation de fluide totale accrue |
WO2020018300A1 (fr) | 2018-07-16 | 2020-01-23 | Kci Licensing, Inc. | Appareil d'instillation de fluide destiné à être utilisé avec un système à pression négative incorporant une surveillance de thérapie sans fil |
WO2020018538A1 (fr) | 2018-07-18 | 2020-01-23 | Kci Licensing, Inc. | Pansement laissant voir la plaie et kit de personnalisation |
EP3829505A1 (fr) | 2018-07-30 | 2021-06-09 | 3M Innovative Properties Company | Articles en mousse antimicrobiens et procédé de fabrication correspondant |
WO2020040863A2 (fr) | 2018-07-31 | 2020-02-27 | Kci Licensing, Inc. | Dispositifs et procédés pour empêcher des points de pression localisés dans des composants de distribution pour thérapie tissulaire |
US20200038252A1 (en) | 2018-07-31 | 2020-02-06 | Joseph Spiro | Tri-layered wound dressing and method therefor |
WO2020026144A1 (fr) | 2018-08-01 | 2020-02-06 | Systagenix Wound Management, Limited | Conditionnement de pansement à hydratation commandée de pansement activé par liquide |
EP3829515A1 (fr) | 2018-08-01 | 2021-06-09 | KCI Licensing, Inc. | Traitement de tissu mou au moyen de pression négative |
CN112423800B (zh) | 2018-08-03 | 2024-05-17 | 3M创新知识产权公司 | 具有伤口体积估计的伤口治疗系统 |
US20200038251A1 (en) | 2018-08-03 | 2020-02-06 | Kci Licensing, Inc. | Flexible and conformable wound dressing with enhanced fluid absorption capability |
US20210161725A1 (en) | 2018-08-10 | 2021-06-03 | Kci Licensing, Inc. | Wound dressing system for management of fluids in a wound and methods for manufacturing same |
US20200046876A1 (en) | 2018-08-13 | 2020-02-13 | Chuang Sheng Medicine Equipment Co. Ltd. | Hydrogel surgical dressing product having a multi-dimensional flexible hydrophilic structure-linkage composite |
EP3836872A1 (fr) | 2018-08-13 | 2021-06-23 | KCI Licensing, Inc. | Pansement à effet de dislocation destiné à être utilisé en pression négative et avec instillation de fluide |
US11938236B2 (en) | 2018-08-17 | 2024-03-26 | Seoul Viosys Co., Ltd. | Medical dressing |
US20210308318A1 (en) | 2018-08-17 | 2021-10-07 | 3M Innovative Properties Company | Wound dressing system |
EP4302790A3 (fr) | 2018-08-21 | 2024-03-27 | Solventum Intellectual Properties Company | Système d'utilisation d'une diminution de pression pour déterminer la capacité de fluide disponible dans un pansement à pression négative |
WO2020040917A1 (fr) | 2018-08-21 | 2020-02-27 | Kci Licensing, Inc. | Pansement et système à manipulation de fluide totale améliorée |
US11395918B2 (en) | 2018-08-24 | 2022-07-26 | United States Government As Represented By The Department Of Veterans Affairs | Devices, and systems for remotely monitoring and treating wounds or wound infections |
WO2020040960A1 (fr) | 2018-08-24 | 2020-02-27 | Kci Licensing, Inc. | Procédés de gestion d'humidité lors de l'utilisation d'un conduit de raccordement de plaie extra-plat |
WO2020043665A1 (fr) | 2018-08-27 | 2020-03-05 | Claudia Eder | Gel antiseptique |
AU2019331721B2 (en) | 2018-08-27 | 2022-04-21 | Advamedica Inc. | Composite dressings, manufacturing methods and applications thereof |
US11007083B2 (en) | 2018-08-28 | 2021-05-18 | Aatru Medical, LLC | Dressing |
EP3843678B1 (fr) | 2018-08-28 | 2023-07-26 | KCI Licensing, Inc. | Pansements destinés à une interpénétration tissulaire réduite |
WO2020046589A1 (fr) | 2018-08-30 | 2020-03-05 | Kci Licensing, Inc. | Pompe électro-mécanique pour le traitement par pression négative |
WO2020047255A1 (fr) | 2018-08-31 | 2020-03-05 | Kci Licensing, Inc. | Pansement de refroidissement pour un confort amélioré |
DE202019105913U1 (de) | 2018-09-04 | 2019-11-20 | Lohmann & Rauscher Gmbh | Wundreinigungseinrichtung |
WO2020051089A1 (fr) | 2018-09-04 | 2020-03-12 | Kci Licensing, Inc. | Dispositif et kit de thérapie des plaies |
WO2020051273A1 (fr) | 2018-09-05 | 2020-03-12 | Kci Licensing, Inc. | Systèmes et procédés de planification et de commande d'une thérapie sur des plaies |
US11471335B2 (en) | 2018-09-05 | 2022-10-18 | University Of South Carolina | Gel-within-gel wound dressing |
EP3849626A1 (fr) | 2018-09-12 | 2021-07-21 | KCI Licensing, Inc. | Système de thérapie de plaie avec thérapie d'instillation et contrôle dynamique de pression |
US20220111138A1 (en) | 2018-09-12 | 2022-04-14 | Kci Licensing, Inc. | Systems, apparatuses, and methods for negative-pressure treatment with reduced tissue in-growth |
WO2020055945A1 (fr) | 2018-09-12 | 2020-03-19 | Kci Licensing, Inc. | Systèmes de thérapie de plaie par pression négative et procédés d'indication de manipulation de liquide totale |
US20220040400A1 (en) | 2018-09-14 | 2022-02-10 | Kci Licensing, Inc. | Differential Collapse Wound Dressings |
WO2020060918A1 (fr) | 2018-09-17 | 2020-03-26 | Kci Licensing, Inc. | Pansement absorbant à pression négative |
US11806466B2 (en) | 2018-09-17 | 2023-11-07 | Kci Licensing, Inc. | Fluid ingress protection for NPWT device |
US11305050B2 (en) | 2018-09-19 | 2022-04-19 | Deroyal Industries, Inc. | Connector with valve for negative pressure wound therapy system |
EP3852705A1 (fr) | 2018-09-20 | 2021-07-28 | KCI Licensing, Inc. | Pansement de plaie avancé, superabsorbant, à faible traumatisme |
WO2020065531A1 (fr) | 2018-09-25 | 2020-04-02 | Systagenix Wound Management, Limited | Compositions de pansement et utilisations correspondantes |
EP3643328A1 (fr) | 2018-10-24 | 2020-04-29 | Paul Hartmann AG | Pansement de plaie de diagnostic à déclenchement par ph |
EP3643331A1 (fr) | 2018-10-24 | 2020-04-29 | Paul Hartmann AG | Pansement thérapeutique déclenché par ph |
US20220370705A1 (en) | 2019-07-24 | 2022-11-24 | Kci Licensing, Inc. | System For Treating A Tissue Site |
WO2021019461A1 (fr) | 2019-08-01 | 2021-02-04 | Kci Licensing, Inc. | Pansement ayant une caractéristique d'épithélialisation et de réduction de cicatrice |
EP4007552A1 (fr) | 2019-08-01 | 2022-06-08 | KCI Licensing, Inc. | Pansement pour main destiné à être utilisé lors d'une thérapie de plaies par pression négative |
US20220265477A1 (en) | 2019-08-06 | 2022-08-25 | Kci Licensing, Inc. | Hand Dressing For Use With Negative Pressure Wound Therapy, Negative Pressure Wound Therapy System Comprising The Same, Method For Controlling A Pump Coupled To Said Dressing |
US20220079509A1 (en) | 2020-09-11 | 2022-03-17 | Cardiac Assist Holdings | Vacuum dressing with control feedback |
-
2017
- 2017-03-30 EP EP17723752.6A patent/EP3436820A2/fr active Pending
- 2017-03-30 CN CN201780034018.5A patent/CN109416355A/zh active Pending
- 2017-03-30 CA CA3019445A patent/CA3019445A1/fr active Pending
- 2017-03-30 US US16/090,091 patent/US20230213525A1/en active Pending
- 2017-03-30 KR KR1020187031451A patent/KR20190015210A/ko not_active Application Discontinuation
- 2017-03-30 EP EP17787245.4A patent/EP3436821A2/fr active Pending
- 2017-03-30 BR BR112018070238A patent/BR112018070238A2/pt unknown
- 2017-03-30 CA CA3019436A patent/CA3019436A1/fr active Pending
- 2017-03-30 AU AU2017278022A patent/AU2017278022B2/en active Active
- 2017-03-30 CN CN201780034020.2A patent/CN109564213B/zh active Active
- 2017-03-30 WO PCT/IB2017/000442 patent/WO2017168249A2/fr active Application Filing
- 2017-03-30 SG SG11201808598UA patent/SG11201808598UA/en unknown
- 2017-03-30 BR BR112018070244A patent/BR112018070244A2/pt unknown
- 2017-03-30 WO PCT/IB2017/001182 patent/WO2017212345A2/fr active Application Filing
- 2017-03-30 JP JP2019502284A patent/JP2019512556A/ja active Pending
- 2017-03-30 JP JP2019502283A patent/JP2019513238A/ja active Pending
- 2017-03-30 US US16/090,075 patent/US11740241B2/en active Active
- 2017-03-30 AU AU2017243601A patent/AU2017243601A1/en not_active Abandoned
- 2017-03-30 KR KR1020187031448A patent/KR20190008199A/ko not_active Application Discontinuation
-
2018
- 2018-09-28 IL IL262024A patent/IL262024A/en unknown
- 2018-09-28 CL CL2018002774A patent/CL2018002774A1/es unknown
- 2018-09-28 CL CL2018002776A patent/CL2018002776A1/es unknown
- 2018-09-28 IL IL262023A patent/IL262023A/en unknown
- 2018-10-29 CO CONC2018/0011706A patent/CO2018011706A2/es unknown
- 2018-10-29 CO CONC2018/0011704A patent/CO2018011704A2/es unknown
- 2018-10-30 EC ECSENADI201881945A patent/ECSP18081945A/es unknown
- 2018-10-30 EC ECSENADI201881954A patent/ECSP18081954A/es unknown
-
2022
- 2022-05-06 AU AU2022203055A patent/AU2022203055A1/en active Pending
- 2022-10-20 JP JP2022168175A patent/JP2023017787A/ja active Pending
-
2023
- 2023-05-04 US US18/312,017 patent/US20240027454A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100178203A1 (en) * | 2009-01-15 | 2010-07-15 | Polestar Technologies, Inc. | Non-Invasive Colorimetric-Based Infection Detector And Infection Detecting Bandage |
US20110158917A1 (en) * | 2009-12-31 | 2011-06-30 | Macdonald John Gavin | Anti-viral tissue product with visual efficacy indicator |
Non-Patent Citations (2)
Title |
---|
Dai, T. et al "Chitosan preparation for wounds and burns ..." Exp. Rev., vol 9, no 7, pp 857-879. (Year: 2011) * |
Guerry, A. et al "Aniline-catalyzed reductive amination ..." Bioconj. Chem., vol 24, pp 544-549. (Year: 2013) * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230213525A1 (en) | Detecting microbial infection in wounds | |
US11865192B2 (en) | Modified wound dressings | |
Hasmann et al. | Novel peptidoglycan-based diagnostic devices for detection of wound infection | |
AU2003212897B2 (en) | Method for detecting microorganisms | |
TW201800753A (zh) | 傷口微生物感染之檢測 | |
US20200393384A1 (en) | pH RESPONSIVE MATERIALS FOR OPTICAL MONITORING OF WOUND STATUS | |
TW201741331A (zh) | 傷口中微生物感染檢測方法 | |
Lucena | Point of care early infection diagnosis: Infection sensitive biomarker immobilization onto chitosan films | |
JP2024511762A (ja) | 感染のインビトロ診断法 | |
Chibba | Substrates and Inhibitors of Enzymes Involved in Exopolysaccharide Dependent Biofilms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |